

EXHIBIT B

**UNITED STATES DISTRICT COURT
DISTRICT OF NEW JERSEY**

ALLISON SIMPSON,

Plaintiff,

V.

Case No.: 2:15-cv-06072-SDW-LDW

**BAYER HEALTHCARE
PHARMACEUTICALS, INC.,
BAYER PHARMA AG, and
BAYER OY,**

Defendants.

EXPERT REPORT OF DAVID W. FEIGAL, JR., M.D., M.P.H.

Expert Report of Dr. David W. Feigal, Jr., M.D., M.P.H.
In Re: Mirena IUD Products Liability Litigation

Contents

I. Qualifications.....	1
II. FDA Requirements and Review Practices.....	4
A. FDA's Regulatory Role.....	4
B. The New Drug Approval Process.....	5
1. Investigational New Drugs – The Phases of Drug Development	5
2. New Drug Application Review – Evaluating Safety, Effectiveness and Benefit / Risk ...	6
C. Marketed Products: Phase 4 and Postmarketing Safety Surveillance	8
1. Spontaneous Adverse Event Reports.....	8
2. Phase 4 studies and controlled trials for new indications.....	9
3. Additional sources of information.....	10
4. Medical Literature.....	10
5. Clinical Trials, Epidemiology and the Hierarchy of Evidence	11
6. Spontaneous Case Reports.....	13
7. Role of FDA in the Postmarketing Period	15
D. Product Labeling.....	16
1. Organization of the safety information in a Product Label	17
2. Changing Labels.....	18
III. Mirena (Levonorgestrel-Releasing Intrauterine System)	19
A. IND and NDA Approval	21
1. Population Council IND	21
2. NDA Review and Approval.....	21
IV. Idiopathic Intracranial Hypertension.....	24
A. The Norplant IIH Warning	25
1. The Norplant Medical Literature and Spontaneous Reports.....	26
B. Other Levonorgestrel Containing Drugs and IIH Labeling.....	29
C. The Adequacy of the Mirena Label with Respect to IIH	29

1. Initial Mirena Prescribing Information29

2. Postmarketing Safety Information and Pharmacovigilance31

D. Epidemiology Studies of Mirena and IHH.....35

1. Martinez (2010).....36

2. Etminan (2015).....36

3. Rai (2015).....38

V. Dr. David Ross’s Report [80]39

A. Norplant Labeling Is Not an Appropriate Source for Mirena Labeling.....40

B. The Criticisms of the Bayer Signal Assessments Are Unfounded42

C. The Epidemiology Evidence Does Not Support a Casual Association Between Mirena and IHH.....44

VI. Dr. Mayhar Etminan’s Report [78].....45

A. Disproportionality Analyses45

B. Meta-Analyses47


C. Reanalysis of the Rai Abstract.....48

D. Dr. Etminan’s Bradford Hill Analysis48

VII. Dr. Frederick Fraunfelder’s Report [79]50

VIII. Principle Conclusions51

IX. References Cited53



I have been asked as an expert in drug labeling and FDA regulation to provide opinions, based on my training, experience and expertise, with respect to Food and Drug Administration (FDA) regulation of the development, approval, and marketing of pharmaceutical products in the United States, as well as FDA requirements for preclinical and clinical studies, Investigational New Drug applications, New Drug Applications, labeling, post-marketing surveillance, pharmacovigilance, and monitoring of adverse event reports. I have also been asked as an expert in clinical epidemiology to provide opinions regarding the epidemiologic evidence regarding hormonal contraceptives and idiopathic intracranial hypertension.

I. Qualifications

I serve as an expert consultant on regulatory matters under the jurisdiction of the United States Food and Drug Administration (FDA), as an expert clinical epidemiologist, and on matters related to pharmaceutical products, the pharmaceutical industry, and other areas within my expertise, as described below.

I am board certified in Internal Medicine and have a Master's Degree in Public Health in the fields of epidemiology and biostatistics. I graduated from Stanford University Medical School in 1976; completed my internship and residency at the University of California, Davis in 1979; and earned an M.P.H. from the University of California, Berkeley in 1983. I was an Andrew Mellon Scholar in Clinical Epidemiology at the University of California, San Francisco from 1982-1984.

From 1982-1989, I held several positions at the University of California, San Francisco, including Associate Director of the Clinical Epidemiology program and Assistant Professor of Medicine with joint appointments in Epidemiology and Biostatistics, and was a member of the Pharmacology faculty. I was also Director of the Data Center at the AIDS Clinical Research Center. From 1989 to 1991, I was a Clinical Associate Professor of Clinical Medicine at the University of California, San Diego.

During my career, I have practiced medicine as a general internist in faculty practices at the University of California, as well as taught medical students, interns, residents, and fellows, and cared for patients on the in-patient services at several university hospitals. As an internist-epidemiologist, I conducted original research on risk factors for disease, including case-control and cohort studies, and designed and conducted clinical trials. My responsibilities for clinical trials included monitoring and reporting adverse drug reactions to FDA and to the trials' data

safety and monitoring boards, as well as to Institutional Review Boards (IRBs). Clinical trials that I designed and conducted led to the approval of new drugs and devices. I presented to and served on FDA Advisory Committees, as well as National Institutes of Health and Public Health Service Consensus Task Forces on disease prevention and treatment that included evaluation of the quality of evidence from epidemiology and clinical trials.

From 1992 to 2004, I held a number of senior positions at FDA. From 1992-1997, I held positions in FDA's Center for Drug Evaluation and Research (CDER). This Center has the responsibility for the review and approval of all new drugs, and the ongoing assessment of the quality, safety and effectiveness of marketed drugs. It has the authority to take actions through its compliance programs to assure that drugs meet standards defined in law. At CDER, I held the positions of Director of the Division of Anti-Viral Drug Products and Acting Director of the Anti-Infective Drug Products, and in addition from 1994 to 1997, I was Director of the Office of Drug Evaluation IV. When I was Director of the Anti-Viral Drug Products Division, I was responsible for drugs to treat such conditions as AIDS, herpes, hepatitis, influenza, serious fungal diseases, and tuberculosis. While I was the Acting Director of the Anti-Infective Division, I was responsible for drugs to treat bacterial infections, such as urinary tract infections, pneumonia, skin infections, and others.

I had the direct authority to approve investigational studies of new drugs for these indications, to halt such studies for safety reasons, to approve new indications for approved drugs in these areas, and to approve the manufacturing methods and take compliance actions through the CDER Office of Compliance and FDA field staff. My responsibilities included the review and approval of product labeling, in particular, indications and safety warnings for hundreds of labeling changes. Safety reviews included evaluation of animal studies, clinical trials, signal detection systems such as MedWatch, case-control studies and registries. As an Office Director, I supervised the directors of these two Divisions and was one of five people at FDA with the authority for the initial approval of new drugs. I also shared responsibility for policy development including drafting FDA Guidance documents.

From 1997-1999, I served as the Medical Deputy Director of the Center for Biologics Evaluation and Research (CBER). In this position, I was responsible for medical issues arising with blood, vaccines, and therapeutic proteins, such as interferon or erythropoietin. I directly supervised the Biostatistics and Epidemiology Division, among others, as well as the Advisory Committee Staff and served as the Center Ombudsman.

From 1999-2004, I served as Director of the Center for Devices and Radiological Health (CDRH). This Center is responsible for medical devices ranging from x-ray equipment, surgical

equipment, implants, pacemakers, orthopedic products, as well as consumer products, such as microwave ovens and cell phones. The Offices that were responsible for approval of new devices, safety surveillance, and compliance were among those that reported to me. I was directly involved in evaluating significant new potential safety problems that could result in changes in product labeling, risk management plan or product withdrawal. Like CDER and CBER, this Center has the authority to require labeling changes and other actions when products have safety problems or do not meet standards of manufacturing quality.

My career has included extensive experience in the evaluation of safety and effectiveness of pharmaceuticals, as well as other therapeutic modalities. At FDA, I was responsible for the evaluation of safety and efficacy of new drugs, including the approval process and continuing oversight of the safety and effectiveness of those drugs after approval. This involved extensive interactions with sponsors about their study design and product development programs, evaluating the results of those programs and product labeling. As a Division Director and Office Director, I had direct responsibility for evaluating the adequacy of the preclinical and clinical studies that were the basis for New Drug Applications (NDAs), and I had direct sign-off authority, known as "signatory authority," for their approval. In addition to direct review of applications, I participated in policy and guidance efforts at FDA to develop standards for review of drug safety, including drafting the current FDA Guidance for reviewers on how to review the safety section of an NDA. I presented safety evaluations to the Committee of the Institute of Medicine, in congressional testimony, and published invited commentaries on product safety. I understand fully the process and criteria utilized by FDA in assessing safety and efficacy, pharmaceutical product labeling and pharmaceutical manufacturing quality, and I participated directly in that process for years.

Since leaving FDA, I have taught and participated in research grants at Arizona State University (ASU), where I am currently an Adjunct Professor in the School of Law; I have taught a course on Food and Drug Law for the last eight years. In the research area, I have assisted my colleagues in the Biodesign Institute at ASU in developing a scientifically sound regulatory path for products ranging from diagnostic tests to detect radiation exposure, as part of federally funded counter-terrorism efforts, to artificial limbs with sensors that would allow a prosthetic hand or foot to "feel" what it touches and communicate that wirelessly to peripheral nerves. I have also assisted start-up medical product companies develop research plans that will comply with the high FDA standards.

I have also held two senior positions in two biotech-pharmaceutical companies. At Élan Pharmaceuticals, I was the Senior Vice President for Global Regulatory, Global Safety and Biostatistics. Our research and development team successfully obtained approval from FDA for

a new drug to treat Crohn's Disease during that time period. At Amgen, as the Vice President for Global Regulatory, product labeling was a nearly daily part of my job.

As a consultant in legal cases over the last eleven years, I have provided expert review for both defense and plaintiffs' attorneys. This consulting has usually involved expert review of topics, including assessment of company and FDA processes in the development of new drugs, the detection of signals of potential new adverse events, the adequacy of product safety labeling, the process of revising and keeping product labeling up to date, manufacturing quality requirements for new drug approval, the regulatory basis for market approval for drugs and devices, off-label use, FDA enforcement activities and the scientific basis for regulatory decisions by FDA, the explanation and application of principles and concepts of epidemiology and biostatistics, and other topics.

A copy of my curriculum vitae, including a list of publications that I have authored, and a list of documents I have reviewed in preparing this statement are attached as Exhibits A and B. My previous testimony in trials and depositions, in the last four years is attached as Exhibit C.

I am being compensated in this case at the rate of \$600/hour.

In forming my opinions, I have relied on my knowledge of FDA regulations, policies, review procedures, and practices, as well as my training and experience as a physician and an epidemiologist. All of the opinions stated in this report are expressed to a reasonable degree of scientific and medical certainty.

II. FDA Requirements and Review Practices

A. FDA's Regulatory Role

The FDA is a 100-year-old consumer protection agency with enforceable legal authority to assure that drugs are safe and effective, properly manufactured, and that the drug's benefits outweigh its risks for intended use. Congress vested FDA with the sole authority to approve drugs for commercial use and to withdraw that approval, if appropriate. The FDA requirements are specified in law by the Food Drug & Cosmetic Act (FDCA) passed by the U.S. Congress. The requirements of the law are described in detail in the Code of Federal Regulations. The Agency regulates and monitors the study, manufacturing, labeling, distribution, and postmarket surveillance of all prescription drugs within the United States. FDA primarily performs these tasks through the Center for Drug Evaluation and Research (CDER), one of the world's largest

drug regulatory agencies. CDER is organized into Offices, which are divided into Divisions, which specialize in drug development areas, such as manufacturing, development of new drugs, and postmarket surveillance.

Regulations have the same binding force as the law itself and failure of a product to meet these standards is a violation of the law with specified penalties. FDA also provides non-binding advice through Guidance documents. These public documents provide FDA's perspective on the whole range of issues that FDA regulates from study design to manufacturing. The recommendations are neither binding nor a guarantee of success, but represent FDA's current thinking on a given topic.

B. The New Drug Approval Process

1. Investigational New Drugs – The Phases of Drug Development

Prior to introducing a new pharmaceutical compound to the U.S. market, FDA requires every pharmaceutical company to first submit an Investigational New Drug application (IND) to the Agency. This application provides FDA with data on the manufacture of the drug, animal studies demonstrating its safety, *in vitro* studies, and protocols for future studies on human participants. If FDA accepts the IND application based on these studies, the product then undergoes clinical trials to establish safety and effectiveness in humans. In the IND phase of development, FDA has the authority to place a hold on further development of a drug product if the safety of the drug is in question. The foremost consideration for FDA during clinical investigations is drug safety. Patients in the clinical trials done under an IND are monitored to detect adverse effects. Because not all adverse effects can be anticipated, the tests are designed to assess drug effects on many different body systems. FDA meets regularly with sponsors throughout the IND process. Topics commonly discussed include dose, duration, endpoints, patient populations, comparator drugs and trial design for testing in humans.

It takes many clinical trials to provide the evidence that a drug is safe and effective for an intended use for a specific patient population. FDA regulations describe these trials in three phases, from the first small trials in normal volunteers, to the larger trials in specific patient populations, to the still larger adequate and well-controlled trials that confirm that a drug is safe and effective. Phase 1 trials are small closely monitored studies, usually in normal volunteers, to learn how a drug is absorbed and eliminated from the body and to determine safe doses for further testing. Typically, fewer than 100 subjects participate in Phase 1. Phase 2 trials are the first trials to evaluate the effectiveness of the drug for patients with a particular condition. These studies often involve several hundred patients. They are used to learn enough

about the drug to plan the larger trials in Phase 3 that will study the safety and effectiveness of the drug for one or more indications. All of these trials provide the basis for a New Drug Application (NDA) and may involve several thousand study participants. The phases frequently overlap. The process of studying a new drug is iterative as new information is learned about safety and effectiveness on an ongoing basis. Lack of effectiveness or safety problems are common and fewer than 15% of all drugs which start in Phase 1 testing complete the clinical trial process and are approved for marketing.

2. New Drug Application Review – Evaluating Safety, Effectiveness and Benefit / Risk

a. The Review Process

Following the IND phase, the drug product's sponsor submits to FDA an NDA containing data it has gathered on the product's safety and effectiveness. Generally, the NDA contains the following information: (i) reports of preclinical and clinical studies; (ii) a summary of all safety data; (iii) pharmacological data on the drug's composition; (iv) methods and facilities used in the drug's manufacturing; (v) samples of the product; and (vi) proposed labeling. These requirements are set out in detail in the regulations found at 21 CFR § 314.50.

When an NDA is received, FDA will decide if the application will be reviewed as a priority review or standard review. Even before the User Fee Act was passed by Congress in 1992, FDA assigned target review decision dates for priority review products at six months rather than the twelve month standard targets. To accomplish the faster review with the same degree of rigor, FDA expands the size of the team reviewing the product, and schedules Advisory Committee Meetings and manufacturing inspections at an earlier time point. Review decision dates are not targets for making a final decision. Rather, they are the time when a manufacturer can expect a "complete review" of the application, and while the application may be approved after a complete review, it is more common for FDA to identify additional information, called application "deficiencies," that must be addressed before a final decision is made.

FDA employs a number of resources in reviewing the NDA data, including a team of physicians and other scientists, who are experts in their respective fields. This team prepares detailed reports in their area of expertise based on their findings. These reviews and reports may contain conclusions and recommendations of the individual reviewers at the time they are written, but do not necessarily represent the final FDA position. During the review process, FDA has complete access to all of the data from the studies in the NDA, either as submitted at the time of filing or per FDA's request to the NDA applicant.

Typically, FDA and the applicant have many communications back-and-forth during FDA's review so the sponsor has an opportunity to address questions and issues identified by FDA during its review. FDA determines whether the information submitted in the NDA is sufficient to establish that the drug meets FDA's effectiveness and safety requirements. FDA will request specific information and analyses during the review that it deems necessary. When the drug passes this rigorous review, FDA will issue a letter to the drug sponsor approving the NDA. However, if FDA concludes that the application is incomplete or if questions remain to be answered, FDA will issue a letter outlining any deficiencies or faults in the application. Until 2006, the letter indicated whether FDA concluded that the application was "approvable" with the additional information, or whether it found that the application was currently "nonapprovable" because of more significant issues.¹

The ultimate purpose of the review of the preclinical and clinical data within the NDA is for FDA to review and ultimately approve the product with a label that provides adequate instructions for the safe and effective use of the drug for the purposes indicated. The format, content, and organization of the product label are specified by FDA in the regulations in order to assure uniformity and clarity. While the contents of the label are initially the result of discussion between the sponsor and FDA, FDA makes the final determination. Even following the drug's approval and release on the market, the labeling is continually reviewed by FDA for possible revisions based on postmarketing safety data and other information provided by the company and other sources available to FDA. The current labeling regulations were promulgated in 1975 and reiterated in 2006.

FDA recognizes that advances in medical knowledge precede labeling revisions by manufacturers and formal FDA labeling approval. As FDA has noted, in addition to labeling, other sources of information are essential to proper use of drugs:

Physicians clearly have access to new information on drugs through the medical literature, scientific meetings, postgraduate courses, and professional contacts with colleagues. The package insert is not intended under the law to serve as a totally current repository of all such information. It is intended instead to be an authoritative document which contains only those indications and usages based upon substantial evidence of safety and effectiveness. [3]

¹ FDA's current practice is to call letters "Complete Response" letters, which list the application's deficiencies, or "Approval Actions."

b. FDA NDA Decisions

When FDA makes a final determination that the sponsor's drug is safe and effective and has appropriate labeling, it will approve the NDA. The NDA approval means that FDA determined that, for the intended use, the sponsored product's benefits outweigh any known risks that may occur when the product is used in accordance with the approved labeling. This risk-benefit assessment is conducted with every FDA-approved drug on the market and is a crucial element of the drug approval process. This process of risk-benefit assessment occurs throughout the life of the drug, including each time FDA approves a change in the product for a new indication or approves a modification of a safety section of the product label. As part of the approval process, FDA drafts reviews documenting the evidence it considered and the reason for its decision. At the time of approval, as described in FDA approval letters, postmarketing commitments and requirements are described, many times to add additional evidence to the safety information available at the time of approval and to overcome the limitations of postmarketing surveillance, described below.

C. Marketed Products: Phase 4 and Postmarketing Safety Surveillance

Following a new drug approval, the manufacturer begins the next phase of drug development, the postmarketing period or Phase 4, when the drug is available for prescription use. To describe safety in the initial labeling, FDA rigorously compares the detailed safety information from the premarket clinical trials participants to the trials' control groups, allowing the comparison of adverse effects in patients who took the drug to those who did not. Once the drug is on the market, the number of patients who take the drug expands from the few hundreds or thousands of patients in the clinical trials, to tens of thousands or even millions of patients who are prescribed the drug by their physicians. The manufacturer of the drug reports the findings from the marketed experience to FDA in several ways, as described below.

1. Spontaneous Adverse Event Reports

Premarket safety studies will not detect all of the adverse effects related to the drug because the testing is conducted in a limited number of patients and because the types of patients are more diverse in marketed experience than in clinical trials. For these reasons, manufacturers are required to continue to collect and report adverse experience information after approval. [18] This postmarketing surveillance includes spontaneous reports of individual cases from healthcare practitioners, patients, and others, foreign adverse experience reports, new clinical trials, and information from the medical literature.

Spontaneous postmarketing adverse event reports must identify, at least: 1) the adverse event(s); 2) possible suspect drug(s); 3) a specific patient; and 4) the source of the report. There are limitations to spontaneous reports which must be taken into account. For example, patients may have multiple medical problems, they may have taken many different medications, and the reports often have incomplete information and lack follow-up information.

FDA specifies in its regulations when and how to report adverse events, with a particular focus on reporting "serious" and "unexpected" events, terms defined by FDA regulations. [18] These events are to be reported to FDA within 15 days of receipt by the manufacturer. Manufacturers submit other reports in periodic and annual reports. The regulations specify that periodic reporting does not apply to the medical literature or to foreign reports that are not subject to 15-day reporting requirements. [18]

The manufacturers, as well as two groups within FDA, analyze spontaneous adverse event reports as they are received. The physicians, epidemiologists and other scientists in the Office of Surveillance of Epidemiology code, process, and evaluate spontaneous reports.² At the same time, the multidisciplinary review team within the New Drug division which has overall responsibility for the drug and its labeling, independently evaluates safety information, and, with respect to labeling, focuses on the 15-day spontaneous adverse event reports.

During the first several years of marketing, periodic safety report summaries are required every three months. Serious and unexpected spontaneous reports must be filed with FDA within 15 days. In particular, FDA closely follows new drugs to identify potential adverse events that had not previously been recognized, or to gather additional information about potential issues which had been identified in the premarket period.

The purpose of spontaneous reporting systems is to detect a "signal" of a previously unknown potential association between an adverse effect and a drug. Beyond examining individual spontaneous reports, signal evaluation may include epidemiological studies, research on the pathophysiology of the adverse reaction, and, where feasible, clinical trials.

2. Phase 4 studies and controlled trials for new indications

Another important source of safety information comes from clinical trials and other studies conducted after the initial market approval. Some of these studies, referred to as "Phase 4

² The FDA adverse event report database, FAERS (formerly AERS and before that SRS) is available to the public. The coded sections of the reports are available quarterly for download; the narrative portion of the report is available by Freedom of Information Act (FOIA) request.

Postmarketing Commitments," are studies that the company agrees to conduct after marketing to provide additional information about specific issues that were identified in the NDA review, but were not thought to be necessary to conduct prior to NDA approval. FDA also has the authority to require safety studies in the postmarketing period.³

It is common to study new formulations or new uses of the drug after initial approval. These new uses require new Phase 2 and Phase 3 controlled trials and often add substantially to the safety database. The results of these studies are submitted to FDA as Supplemental NDAs, ("Efficacy Supplements" or "Safety Labeling Supplements"). These supplements are reviewed with the same rigorous standards as the original NDA by FDA staff to assure that the risk-benefit assessment for the drug indicates that the drug is safe and effective for the newly proposed and existing intended uses. Through this process FDA assures that the label remains accurate and up to date.

3. Additional sources of information

It is important to note that FDA has sources of information not available to any single manufacturer. In addition to spontaneous reports sent directly to FDA, drug development programs of one manufacturer may contain detailed studies of another manufacturer's drug used as a control group.

4. Medical Literature

Once a new drug is available on the market, additional studies will often be conducted by independent investigators. In addition to clinical trials, there are also publications of individual patients or a series of patients thought to have had adverse experiences from a drug or from related drugs. Independent investigations are also published describing drug interactions or reports of the experience using the drug in special populations, such as children, the elderly, patients with unapproved indications, or in patient groups who were not included in pre-approval studies due to the application of inclusion or exclusion criteria. The FDA staff and the product's manufacturers monitor the literature databases for new information, in particular about safety. It is well-known and understood that additional information about the benefits and risks of medicines will become available after they are approved, and that evaluation of that information is an ongoing process.

³ FDCA 505(o)(3).

5. Clinical Trials, Epidemiology and the Hierarchy of Evidence

As scientific evidence of safety is of varying degrees of reliability, accuracy, and validity, there is a recognized hierarchy of evidence for scientific evidence relevant to the assessment of drug safety, as described in the table below.

Among the important features of drug safety evidence to consider are: 1) whether the evidence was collected prospectively or retrospectively;⁴ 2) whether the spectrum of the adverse events observed are representative; 3) the background rate of the adverse event not associated with drug use; 4) the background rate of use of the drug in the relevant population; 5) whether there are relevant control groups; and 6) whether the study execution was thorough and unbiased.

Adverse reactions that occur in at least 0.5% of patients are usually detected in the clinical trials and described in the product labeling at product approval. Infrequent and rare adverse reactions are often described initially by individual case reports, either reported to the company or FDA, or published in the medical literature as a case series after the product enters the market. When performed properly, case-control studies are the best method to determine whether there is an increased risk of infrequent adverse events associated with a drug. When both the drug use is infrequent and the adverse event is rare, the very large pharmacoepidemiology databases⁵ may be the only practical method to assess risk.

⁴ I.e., did the study start when a drug is started with follow-up to detect adverse effects, or did the study start with the adverse effect and then look back to see what drugs had been taken.

⁵ Through the 1990s, databases of insurance records for payment for prescriptions and diagnosis codes for healthcare were available for populations of several hundred thousand patients. Now, country-wide databases from Europe, Medicare databases in the U.S., and large insurance databases provide the ability to study as many as 100 million patients.

Hierarchy of Study Design and Evidence for Drug-Associated Adverse Effects				
Hierarchy of Designs (Strongest to Weakest)	Adverse Effects assessed prospectively before adverse event?	Controls for Selection Bias / and Ascertainment Bias?	Can estimate relative risk or hazard compared to control group?	Can study rare events?
Randomized Controlled Trials (enroll patients who are randomized into groups and who take a new drug or placebo or other control)	Yes	Yes	Yes	No
Controlled Cohort Studies (enroll patients starting a new drug and compare to similar patients not taking the drug)	Yes	No / Maybe	Yes	Maybe
Registries and other uncontrolled cohort studies (e.g., pregnancy registries)	Yes	No / Maybe	No ⁶	No
Case – Control Studies (enroll patients who have already had an adverse effect and compare to similar patients without the adverse effect and look	No	Maybe / Maybe	Yes	Yes

⁶ When events, such as certain birth defects, are known to occur at certain rates, a birth defect registry can estimate whether there is likely to be an increased risk.

back to see drug use)				
Pharmacoepidemiology Studies (cohort or case-control designs conducted with insurance databases)	Yes / No	Maybe / Maybe	Yes	Yes
Case Series (a collection of patients with an adverse event)	No	Maybe / No	No	Yes
Individual Case Reports (report of a single patients with an adverse event associated with a drug)	No	No / No	No	Yes

6. Spontaneous Case Reports

An individual spontaneous case report is the observation of an adverse event associated with a drug. These reports may be useful in some cases to detect signals of a potential association between outcomes and medical treatments. The FDA and product manufacturers use spontaneous reports to detect new potential safety issues. These reports, even when aggregated, cannot provide estimates of incidence rates or prevalence for the product, let alone provide comparative rates between products. [33]⁷

As FDA has recognized in a Guidance document on pharmacovigilance, it is “rarely possible to know with a high level of certainty” whether an event reported in an individual case report was caused by the product. Only in extraordinary circumstances can a single spontaneous report result in a labeling change, usually for adverse events which do not occur in the absence of drug exposure. According to FDA, “Rigorous pharmacoepidemiologic studies, such as case-control studies and cohort studies with appropriate follow-up, are usually employed to further examine the potential association between a product and an adverse event.” [33] FDA has made clear that

FAERS data do have limitations. First, there is no certainty that the reported (adverse event or medication error) event was actually due to the product. FDA does not require that a causal relationship between a product and event be

⁷ At best, the number of spontaneous reports can be compared to market share or total sales, but since many factors, including publicity, stimulate reporting, these estimates may not be reliable.

proven, and reports do not always contain enough detail to properly evaluate an event. Further, FDA does not receive reports for every adverse event or medication error that occur with a product. Many factors can influence whether or not an event will be reported, such as the time a product has been marketed and publicity about an event. Therefore, FAERS data cannot be used to calculate the incidence of an adverse event or medication error in the U.S. population. [58]

Reporting of adverse events by physicians and patients is both voluntary and spontaneous. Recent data suggest that reporting rates can vary widely based on a number of factors, including publicity surrounding a drug adverse event, litigation, or a recall, extent of use in the population, and marketing of a drug. There has been an increase in adverse event reporting rates over recent years. [45]

Data Mining: Beginning in the late 1990's, FDA and others have studied statistical techniques to identify events reported more frequently in association with specific drugs. [28, 30, 34, 36, 68, 77] Szarfman, A., et al. [28], estimated in 2002 that there were greater than 40,000 "signals" identified, even with a method that adjusts for drug-event pairs with a small number of reports. With these methods, any given drug-event report out of the 10.4 million drug-event associations had a 23% chance of being a signal. Szarfman, went on to comment:

The validation of data mining in an absolute sense is an unreachable goal. There is no true gold standard for every adverse drug event against which the data mining systematic results can be linked and compared.⁸

Various methods to identify signals by detecting relatively higher reporting rates have been developed and compared. [34, 36] As a group, these methods are called disproportionality analyses, and all of them assess differences in adverse event reporting behavior that, like the individual cases that they are based upon, cannot establish a causal relationship between an event and a drug.

The most naïve approach, the Proportional Reporting Rate (PRR) and the related statistic the Proportional Odds Ratio, is to compare the proportion of reports for a single drug-event association to all reported drug-event associations. Without stratification, or comparison between drugs with similar use, it assumes that the patient population for the single drug-event pair is the same for the use of all drugs. Such methods will spuriously detect signals for diseases of the elderly when a drug-event association used in the elderly is compared to all drug-event pairs used across all ages.

⁸ See page 387.

A more fundamental problem with the PRR⁹ is signal exaggeration for drug event pairs with a small number of events. Levine, J.G., et al. [36] points out that using the AERS database, the PRR classifies more than half of all drug-event association pairs as a signal for 90% of all drugs in the first year they are on the market, “regardless of the clinical plausibility.”¹⁰ FDA has been a proponent of methodology that adjusts for this effect, with methods that both take into account the distributional properties of rare events (the Poisson distribution) and model the likelihood of reports for a given pair empirically from the reporting characteristics of other pairs to adjust the probability (Bayesian methods). The most widely used method by FDA authors is the Multi-item Gamma Poisson Shrinker (MGPS) [26], but as FDA points out even this method only identifies differences in reporting rates and

To further study the adverse-event risk, the signals generated by MGPS can be evaluated by individual case review and compared with various analyses from other sources (e.g. clinical trials, general practice databases, literature reports).¹¹

7. Role of FDA in the Postmarketing Period

FDA remains vigilant about drug safety throughout the lifecycle of a drug. The FDA postmarketing surveillance standards are robust: FDA requires manufacturers to have organized systems to detect, assess, and follow-up safety issues and FDA inspects and audits company clinical trials and postmarketing surveillance systems to assure the integrity of the process. When FDA scientists raise questions about a specific issue, they will ask manufacturers to provide additional information about that issue, and may require modification of the product’s labeling and take other actions to communicate the new information to prescribing healthcare professionals. While a manufacturer only has access to its own data, FDA has access to data from all manufacturers relating to the drug, which can often provide important adverse event information.

In parallel to FDA field inspectors examining on-site study records from clinical trials, FDA regularly inspects manufacturers’ pharmacovigilance operations, verifying the accuracy and timeliness of the systems in place to collect, analyze, and report spontaneous adverse events. Most of the inspections are unannounced and routine, but when there is an important new safety issue, it is not uncommon for FDA to conduct a pharmacovigilance inspection or to visit

⁹ Whether the comparison is of relative proportions or relative odds (odds ratios).

¹⁰ See page 106. The authors go on to comment: “Even in the cases when the event appears in the product labeling, many factors other than a true causal relationship between a drug and an event may influence the labeling, such as some class effects, litigation and publicity.”

¹¹ See page 7.

clinical sites where there are a number of reports. As with all inspections, FDA presents a list of potential violations to the company at the end of the inspection, a 483 form, and after review of those observations, FDA will write up an Establishment Inspection Report (EIR), which will lead to a finding that no actions are needed or that voluntary or mandatory actions are required. When FDA identifies serious findings of potential violations, it may issue a Warning Letter.

D. Product Labeling

Professional product labeling is a highly regulated monograph that, for a given product, describes in detail FDA-approved indications for use, the clinical pharmacology and efficacy determined from adequate and well controlled studies, and safety from multiple sources, including controlled studies and postmarketing surveillance. Labeling is the key source of information to assure safe use.

A label provides physicians with a clear and concise summary of the information necessary for the safe and effective use of the drug. As such, prescription drug labeling is directed to healthcare professionals and not to consumers. An FDA-approved label is a summary of the essential scientific information, providing an evidence-based assessment of risk and benefit for specific indications, to assist a prescriber making decisions for individual patients. Accordingly, the label is not intended to be an encyclopedia of all possible information and theories about benefits and risks, or to provide a text book of medicine about the disease treated or particular adverse reactions. In addition, the label directly affects what may lawfully be included in drug promotion and advertising.

FDA has clearly communicated that labels are to be based on evidence, commenting that “theoretical hazards not well-grounded in scientific evidence can cause meaningful risk information to ‘lose its significance.’” [37]¹² FDA recognizes that over-warning about potential risks can have a negative effect on patient safety and public health. In the 2006 update on labeling requirements, FDA stated:

[R]equirements for the disclosure of risk information are not necessarily more protective of patients. Instead, they can erode and disrupt the careful and truthful representation of benefits and risks that prescribers need to make appropriate judgments about drug use. Exaggeration of risk could discourage appropriate use of a beneficial drug. [37]¹³

¹² quoting [4].

¹³ See page 3935.

1. Organization of the safety information in a Product Label

FDA carefully controls the content of prescription drug labeling. Labeling is FDA's principal tool for educating healthcare practitioners about the risks and benefits of approved products to help ensure safe and effective use. [37]

The organization of a drug label is specified by regulation,¹⁴ and has evolved over time. FDA determines whether the information provided is in the proper sections of the label, and assures that an approved label is balanced and accurate. Prior to 2006, warning information was organized in the safety section of the label as: a) Contraindications, b) Warnings, c) Precautions, and d) Adverse Reactions.¹⁵

"Warnings" describe serious adverse reactions and potential safety hazards, limitations in use imposed by them, and steps that should be taken if adverse reactions occur. In 2006, FDA clarified the distinction between the Adverse Reactions section and Warnings and Precautions sections to better define FDA labeling requirements. [37] As FDA stated, this was not a change in its position. Adverse Reactions require "some basis to believe there is a causal relationship."¹⁶ Warnings and Precautions are required when there is "reasonable evidence of a causal association" although causation need not be proven.¹⁷

Warnings may be given extra emphasis by placing them in a "box" with a black line around the warning, or emphasized through the use of bold type. FDA has the sole authority to add a boxed warning and over its contents: "To ensure the significance of boxed warnings in drug labeling, they are permitted in labeling only when specifically required by the FDA." [4] FDA limits the use of these warnings to avoid overuse, which would ultimately dilute the warning's impact. FDA carefully reviews serious and fatal adverse effects of drugs and makes determinations when a boxed warning is necessary. Only those adverse events which are considered to be reasonably associated with the drug are to be included in the "Adverse Reactions" section of the labeling.

¹⁴ 21 CFR 201.57 and 21 CFR 201.80 enumerate labeling requirements for prescription drugs and spell out what must be included in each section of the labeling.

¹⁵ In 2006, FDA eliminated the distinction between the Warning and Precautions section of the label to create a single section. FDA commented that based on physician surveys "the distinction between warnings and precautions is not meaningful to practitioners who use labeling." [37] Current labels may also describe safety determined from clinical trials in a "Clinical Trials" section, clinically relevant animal toxicity information in a "Nonclinical Toxicology" section, and spontaneous reports in a "Post-marketing" section. Transition to a reorganized labeling format began in 2006.

¹⁶ 21 CFR 201.57(c)(7).

¹⁷ 21 CFR 201.57(c)(6).

Although as a prescription product, the Mirena labeling is written in technical language for healthcare professionals, the prescribing information labeling also contains information for patients. One section of the Precautions section, entitled "Patient Counseling" describes information about risks and benefits for a healthcare provider to discuss with a patient. Additionally, in the FDA approved prescribing information, Mirena contains a "Patient Information" section, written in lay language to facilitate discussion between prescriber and patient.

In my experience at FDA, the process of changing safety labeling is usually initiated by the NDA sponsor, but FDA will also initiate safety labeling changes. The FDA review staff will conduct its own independent analysis of warnings and make determinations based on that analysis.

2. Changing Labels

FDA has the sole authority to approve products and their labels and the sole authority to remove such approval. While companies must submit labeling applications to FDA, and are responsible for labeling content, the New Drug divisions have the final word on labeling changes. Since passage of the Food Drug and Cosmetic Act in 1938, manufacturers are not permitted to sell a product when FDA determines that the labeling is "false and misleading" or that the drug lacks "adequate instructions for use."¹⁸ To remain on the market, FDA requires such labels be changed to comply with the labeling regulations. Additionally, since 2007, FDA is required to notify holders of approved NDAs of new safety information it believes should be in the labeling and can order the NDA holder to implement necessary safety labeling changes.¹⁹

The regulations provide for two types of labeling change applications: those which require FDA's prior approval (Prior Approval Supplements, or PAS); or those which may be implemented immediately,²⁰ while the application is still pending (Changes Being Effected supplements, or CBE). Both PAS and CBE applications are subject to review and approval by

¹⁸ Whether a drug's labeling is "false and misleading" requires consideration of, among other things, the totality of information provided in the labeling and available about the drug in general. Prescription drugs are exempt from "adequate instructions for use," which refers to nonprescription products, if the product complies with the FDA labeling regulations found at 21 CFR 201.57 and elsewhere.

¹⁹ FDCA 505(o)(4).

²⁰ In the case of some moderate changes in manufacturing, the changes can be implemented 30 days after submission.

FDA. FDA's authority over boxed warnings, set forth in the regulations, makes clear that changes to boxed warnings cannot be made by CBE applications.²¹

Unless there is evidence of a causal association that satisfies the standard for inclusion in a label, the FDA will reject a CBE supplement implemented by a sponsor.²² If FDA ultimately does not approve a CBE which has been implemented, the manufacturer must cease use of the CBE labeling and modify the labeling content to comply with FDA-approved language.

Manufacturers are not permitted to sell products without approved labeling, and to do so may result in a finding that they are misbranded, subjecting the manufacturer to possible seizure of the product, substantial fines, criminal penalties, and/or NDA withdrawal.

In my experience, FDA expects prior approval review for substantive labeling changes, in particular, when the labeling change involves a safety issue already under review by FDA. For significant changes, it is helpful for companies and FDA to review together the scientific evidence that each brings to the understanding of a safety issue. A PAS provides an opportunity for such interaction. In some cases, when FDA is considering similar potential safety issues with multiple drugs, FDA may require that all of the products incorporate identically worded safety information.

III. Mirena (Levonorgestrel-Releasing Intrauterine System)

The importance of safe and reliable contraception is beyond question. Prevention of unintended pregnancies has significant health benefits. Even today, pregnancy complications include a not-insignificant risk of thromboembolism, cardiovascular disease, stroke, hemorrhage, infection and death. [69] Several major categories of contraceptives are widely available. Reversible drug and device contraception includes barrier methods, systemic hormonal products, and intrauterine devices (IUDs). [74]

The earliest IUDs for contraception were developed in the 1920's and were made out of silver, gold, silk, stainless steel and other materials, however, wide-scale use would await better acceptance of contraception following World War II and the introduction of plastic IUDs such as the Lippes Loop in 1962. [19]²³ The complications associated with these IUDs included

²¹ See 21 CFR 201.80(e).

²² 21 CFR 314.70(c)(7).

²³ See also

https://medicine.buffalo.edu/research/research_highlights_host.html/content/shared/smb/research_highlights/lippes-loop.detail.html.

increased menstrual bleeding, pain, expulsion, and less commonly, infection, ectopic pregnancy, embedment in the uterine wall, and perforation of the uterus.

Clinical acceptance of IUDs suffered a severe set-back in the 1970's, due to reports of serious infections associated with the Dalkon Shield, which used a unique braided string that allowed bacteria to ascend into the uterine cavity. Copper containing IUDs were first marketed in the late 1960's followed by development of progesterone eluting devices in 1976 that led to the design of Mirena. Historically, IUDs, including Mirena, have been more widely used outside of the United States and, as a result, applications for marketing approval in the U.S. have included reviews of both investigational and postmarketing studies, as well as pharmacovigilance results from other countries.

In actual use, IUDs are among the most effective forms of contraception, and one that avoids many of the adverse effects, some very serious, of systemic hormone contraception. In a 2009 policy report, the American College of Obstetricians and Gynecologists (ACOG) [48] recommended the use of IUDs as first-line contraception when a long-acting reversible form of contraception is indicated. IUDs are also recommended as first-line contraception for most women by the Centers for Disease Control and Prevention [51], World Health Organization [50], American Academy of Pediatrics [67], and ACOG [54]. ACOG specifically recommends Mirena for use in obese women, and the CDC recommends Mirena without restriction in this population. [40, 51] The Mayo Clinic's Department of Obstetrics & Gynecology similarly notes that (1) progestogen-only or non-hormonal contraceptives are "preferred methods of contraception for women who are obese," (2) that intrauterine devices are effective at preventing unintended pregnancies regardless of BMI, and (3) that intrauterine devices "may be the ideal first option" for women with elevated BMIs. [61]

Mirena's contraceptive benefit derives in part from Levonorgestrel (LNG). Levonorgestrel is the levo enantiomer of the progesterone norgestrel. It was first synthesized in the 1960's and has been used in contraceptives since the 1980's as an oral contraceptive, either alone or in combination with ethinylestradiol. LNG has also been used in contraceptive implant systems and in several IUDs. [20] Levonorgestrel is an active ingredient in 54 NDAs and ANDAs and is available over the counter for post-coital "emergency" contraception.²⁴ All of these dosage forms are included in the World Health Organization's list of essential medications. [75]

²⁴ The FDA Labeling database lists 75 separate product labels where levonorgestrel is an active ingredient. See <https://rmm2.scinet.fda.gov/druglabel/#lblsums-1>.

As a contraceptive, the benefit of Mirena in preventing unwanted pregnancies is considered against the adverse medical effects of pregnancy itself, which will be prevented by contraception. Pregnancy continues to be associated with significant, sometimes life-threatening complications, including thromboembolism, hypertension, gestational diabetes, hemorrhage, and infection. [62]

A. IND and NDA Approval

1. Population Council IND

On August 17, 1983, an IND was submitted²⁵ to FDA's Division of Metabolic and Endocrine Products Division by the Population Council, an international nonprofit organization headquartered in New York City that has conducted contraceptive research and developed a number of contraceptive products, including the copper T, Norplant, and Mirena. On December 12, 1983, FDA found that the safety and dose in the proposed clinical trial was supported by the IND and agreed that the trial could proceed.²⁶ Development of Mirena continued in world-wide trials, and Mirena was first approved for marketing in Finland in 1990. On November 12, 1997, the IND was transferred to Berlex Laboratories, who filed an NDA on January 21, 2000, based on the U.S. and world-wide experience with Mirena.

2. NDA Review and Approval

On January 21, 2000, Berlex Laboratories, Inc. submitted an NDA for Mirena. FDA approved the application on December 6, 2000, after a very interactive review that included 41 supplemental submissions.

The purpose of the NDA review is to determine if FDA can conclude that adequate information has been presented to demonstrate that the drug product is safe and effective for use as recommended in the approved prescription labeling.²⁷ With each NDA supplement, FDA again reviews the evidence to this standard.

At the time of the NDA submission, Mirena had been approved and marketed in 28 countries, beginning in the early 1990's. In addition to containing more than 20 investigational trials and

²⁵ See MIR_INDND_290033 to MIR_INDND_290974.

²⁶ See MIR_INDND_289748 to 9752.

²⁷ MIR_INDND_00010719 at 00010720.

the relevant medical literature, the U.S. NDA included the global marketing experience with Mirena. This data contributed years of postmarketing surveillance safety information.

Plaintiff's expert Dr. Ross criticizes the use of studies performed outside the U.S. to support the Mirena NDA and questions the adequacy of the sponsor's showing that foreign study results were applicable to the U.S. population and practice of medicine. Review of the basis for Mirena approval demonstrates that the studies included a subset that met the FDA clinical trial requirements for approval of a contraceptive product in the United States. Moreover, Dr. Ross offers no evidence that the populations studied were not susceptible to IHH. Ultimately, based on the fact that the FDA approved the NDA, the FDA reviewers must have concluded that these studies met the regulatory requirements.²⁸ I see no indication that they did not.

a. Effectiveness

The Integrated Summary of Efficacy (ISE) [21], provided adequate and well-controlled study evidence of effectiveness from 17 clinical trials, begun in 1981, with 1,594 women from qualified sites.²⁹ The studies randomized participants to the levonorgestrel-releasing intrauterine system, copper-containing IUDs, or oral contraceptives. Six hundred thirty-three women completed five years of study. In the pivotal trial, the Pearl Indices³⁰ at 5 years were 0.08 for levonorgestrel-releasing intrauterine systems and 1.26 for the copper IUD. As the NDA ISE reported: "At 5 years, the cumulative discontinuation rates/100 women for all sites were as follows: PID (1.6), expulsion (5.2), bleeding (10.7), pain (4.9), hormone related (11.2), amenorrhea (5.8), other medical (9.2), planning pregnancy (14.2), other personal (10.7), and other discontinuation (1.0)."³¹

b. Safety

The NDA's Integrated Summary of Safety (ISS) [22] included safety information from 3,021 women in 20 clinical trials, including 2,899 women from contraceptive studies, with the remainder from studies of menorrhagia and endometrial protection. The total safety database included the experience of 7,688 woman-years total exposure. The adverse events leading to discontinuation are described above, most commonly involving menstrual disorders. Five

²⁸ See 21 CFR 314.106(b); MIR_HC_238038 at 238045.

²⁹ Site qualification was determined by adherence to specified good clinical practice requirements. There were 745 women studied in nonqualified sites which were not relied upon to determine efficacy.

³⁰ The Pearl Index is a statistical estimation of the number of unintended pregnancies in 100 woman-years of exposure.

³¹ MIR_INDND_00127646 at 128220.

ectopic pregnancies occurred, with a Pearl Index of 0.07 at five years. No cases of IHH were reported.

FDA medical reviewer Dr. Furlong included in her analysis an examination of known adverse reactions of other levonorgestrel containing contraceptives. As she noted:

Unlike other contraceptive methods containing levonorgestrel, the effectiveness of Mirena appears to depend more on the local than the serum concentration of levonorgestrel. In fact, the serum concentration of levonorgestrel produced by Mirena is lower than the serum concentration produced by any currently marketed levonorgestrel-containing contraceptive in the USA (e.g., approximately one tenth the serum concentration produced by an oral contraceptive containing 0.1 mg levonorgestrel and about half that produced by the Norplant System).
[24]³²

She further commented: *“Recommended warnings include the warnings that are currently on the U.S. labels for the other two USA-approved IUDs.* These include warnings about pelvic infection, ectopic pregnancy, congenital anomalies, septic abortion, perforation, embedment, and breast cancer.”[24]³³ (emphasis added). Although Bayer included the 1997 Norplant label as part of its Mirena NDA submission, Dr. Furlong did not conclude that the Mirena label should include Norplant’s warnings, nor those of any of the oral contraceptive products containing levonorgestrel.³⁴

The science supports Dr. Furlong’s comment about the differences between Mirena and other LNG-containing contraceptives then on the market. Norplant releases approximately three to four times more LNG on a daily basis than does Mirena, and this LNG is released systemically.³⁵ Given its systemic effects, Norplant users have been found to have mean LNG blood concentrations almost double those of Mirena users.³⁶ The NDA review documents and subsequent labeling reviews show that FDA and Berlex Laboratories considered some safety labeling to be appropriate for all IUDs. FDA, however, did not take the same approach with

³² See page 7.

³³ See page 6.

³⁴ MIR_INDND_53366 at 55897.

³⁵ Norplant releases “85 mcg/day followed by a decline to about 50 mcg/day by 9 months and to about 35 mcg/day by 18 months with a further decline thereafter to about 30 mcg/day.” [17] Compare this to Mirena, which releases “approximately 20 mcg/[day] over the first 3 months tested (day 0 to day 90). It is reduced to approximately 18 mcg/day after 1 year and then decreases progressively to approximately 10 mcg/day after 5 years.” [65]

³⁶ Among Norplant patients, LNG levels are 327 ± 119 pg/mL at 12 months, and 258 ± 119 pg/mL at 60 months. [17] For Mirena patients, mean concentrations are 180 ± 66 pg/mL at 12 months and 159 ± 59 pg/mL at 60 months. [65] Since the daily dose of LNG decreases over time, Table 1 of Dr. Etminan’s report, which compares the mean blood LNG level for Norplant users after one year to the mean blood LNG level for Mirena users between one and six months, is an inapt comparison.

Norplant. FDA did not require Mirena, a locally-acting LNG IUD product, to contain the same warnings as Norplant, a subcutaneous implant which releases approximately four times as much LNG directly into systemic circulation than Mirena.

IV. Idiopathic Intracranial Hypertension

Idiopathic intracranial hypertension³⁷ (IIH) refers to elevated intracranial pressure in the absence of an intracranial structural abnormality that could cause the increased pressure, and with normal cerebrospinal fluid (CSF). IIH most often presents in young women who are overweight or obese, although it is occasionally seen in children, men, and older adults as well. [52] Signs and symptoms include papilledema, headache, pulsatile noises, and visual disturbances.

Apart from IIH, other sources of elevated intracranial pressure include brain tumor or trauma, intra-cerebral hemorrhage, infection, venous thrombosis, hydrocephalus, and post-operative effects. Because these and other causes of elevated pressure must first be ruled out, IIH is a diagnosis of exclusion. The Clinical diagnosis is based on the modified Dandy criteria: [1, 57]

- Elevated intracranial pressure, but with normal CSF composition [46]³⁸;
- Neuroimaging showing no etiology for intracranial hypertension;
- No other cause of intracranial hypertension apparent [71];
- No other neurologic abnormalities or impaired level of consciousness;
- Signs and symptoms of increased intracranial pressure (headache, transient visual obscurations, pulse synchronous tinnitus, papilledema, and/or visual loss).

IIH is a relatively rare condition, although it is significantly more common in several distinct population groups. In the general population, the incidence rate of IIH has been estimated at approximately 1 per 100,000 person-years. [7] Due to increases in obesity since those data were generated several decades ago, and because obesity dramatically increases the risk for IIH, the incidence rate is likely higher today. Among women of childbearing age,

³⁷ Idiopathic intracranial hypertension is also known as “pseudotumor cerebri” and “benign intracranial hypertension.”

³⁸ Intracranial pressure between 20-30 mm Hg signals mild intracranial hypertension, levels between 20 and 25 mm Hg require treatment in most circumstances, and sustained pressures above 40 mm Hg indicate severe elevation. [46]

however, there is an estimated incidence rate of approximately 3.5 per 100,000 woman-years. [7] IIH is most common in a subset of these women: overweight and obese women of childbearing age. Among women of childbearing age, those who are overweight or obese develop IIH at a rate between approximately 14.85 per 100,000 woman-years (for women 10% or more over ideal body weight) and 19.3 per 100,000 woman-years (for women 20% or more over ideal body weight). [7] Women who have recently gained weight are also at increased risk of developing IIH. [39] Studies examining the body habitus of IIH patients have found that upwards of 94% of those patients were overweight or obese, and controlled studies consistently determine that excess weight and recent weight gain are independent risk factors for developing IIH. [7, 8, 10, 12, 31, 39, 42, 53, 55, 71] It is worth noting that obese women tend to have lower progesterone levels compared to non-obese women. [60]

With many patients, IIH either resolves spontaneously or resolves after the patient receives a lumbar puncture. [59] Lumbar puncture is a diagnostic tool which tests the pressure and composition of CSF, but it often provides symptom relief by removing fluid and reducing pressure. Apart from lumbar puncture, common treatments include acetazolamide, a diuretic which decreases CSF production, and recommending weight loss. [71] Acetazolamide and weight loss have each been shown to improve symptoms of IIH. [59, 64]

Other systemic diseases have been reported in association with IIH, as have certain vitamin deficiencies and excesses, but no causal relationship between IIH and these factors has been demonstrated. [42] Although IIH has also been reported in patients using the Norplant contraceptive system, as discussed below, these reports and the medical literature do not provide reasonable evidence of an association between Norplant and IIH, let alone reasonable evidence of a causal association between them.

A. The Norplant IIH Warning

Based on a small number of case reports, the following IIH warning was added to Norplant:³⁹

Idiopathic intracranial Hypertension

Idiopathic intracranial hypertension (pseudotumor cerebri, benign intracranial hypertension) is a disorder of unknown etiology which is seen most commonly in obese females of reproductive age. There have been reports of idiopathic

³⁹ November 16, 1992 letter from Victoria to Sobel (response to FOIA #2015-8544) (confirming that Wyeth “would be submitting proposed labeling for Norplant to address spontaneous reports of Idiopathic intracranial hypertension which had been received for users of the Norplant System.”); Record of November 10, 1992 Rarick conversation and November 15, 1992 letter (indicating the same).

intracranial hypertension in NORPLANT SYSTEM users. A cardinal sign of idiopathic intracranial hypertension is papilledema; early symptoms may include headache (associated with a change in frequency, pattern, severity, or persistence; of particular importance are those headaches that are unremitting in nature) and visual disturbances. Patients with these symptoms, particularly obese patients or those with recent weight gain, should be screened for papilledema and, if present, the patient should be referred to a neurologist for further diagnosis and care.

NORPLANT SYSTEM should be removed from patients experiencing this disorder. [17]

Norplant was also contraindicated in women with IIH.

I have seen no evidence that the Norplant IIH warning was based on anything more than spontaneous reports of IIH in Norplant users. Spontaneous adverse event reports can be useful in identifying potential signals for further investigation, but they also suffer from a number of deficiencies. As addressed in greater depth earlier in this report, adverse event reports cannot be used to calculate incidence rates or prove causal associations. Adding warnings based on spontaneous adverse event reports alone runs the risk of over-warning. Over time, FDA has become more acutely aware of the risk of over-warning. Labeling that conformed to the 1979 labeling standards [4] often included many warnings based on postmarketing reports that were no longer included in the labels for the same drugs after converting to the Physician's Labeling Rule (PLR) standard, first proposed in 2000 and in effect as of 2006. [25] In part, this related to an increased attention by FDA to over-warning, and importantly, an emphasis on the need for "reasonable evidence of a causal association" for a labeling Warning. [37] Norplant was withdrawn from the market prior to the PLR's passage. However, it is my opinion that the available evidence fails to provide reasonable evidence of an association between IIH and Norplant (i.e., evidence that IIH occurs more often in Norplant users that would be expected by chance alone).

1. The Norplant Medical Literature and Spontaneous Reports

The scant literature discussing IIH in Norplant users does not provide reasonable evidence of an association between Norplant and IIH.

In 1993, Sunku, A.J., et al. [11], reported two patients who developed IIH after having Norplant implanted. The authors discussed that the relationship between Norplant and IIH could have been "coincidental," and the publication lacks information about excess weight or recent weight gain, both of which are known risk factors for IIH. Such case reports provide no reasonable evidence of an association between Norplant and IIH.

In 1995, in a letter to the editor Alder, J.B., et al. [14], described two additional Norplant patients who developed IIH. Neither patient was obese, although the authors do not state whether the patients were overweight or had recent weight gain. Alder did not report whether the patients had Norplant removed but did report three recurrences of IIH in one patient. Alder also searched adverse event reports from three databases and identified 56 cases of “intracranial hypertension or disk edema” associated with Norplant. However, this is a broader group of disorders than IIH alone, as there are many causes of intracranial hypertension and disk edema, and Alder did not specify how many had IIH, or if clinical narratives were available for the cases from the databases. The authors commented: “Levonorgestrel may have contributed to the onset of intracranial hypertension, or it may have had nothing to do with it.”

Wyeth-Ayerst responded to Alder’s letter, presenting details about the company’s 70 spontaneous reports. [15] Three-quarters of the IIH patients for whom weight information was available were obese, raising the issue of whether Norplant or obesity was associated with IIH. As Wyeth observed: “In 24 of the 44 reports in which information on follow-up was available, idiopathic intracranial hypertension did not abate after the implant was removed. This further confounds the issue of a causal relation.” Overall, even assuming a conservative 20% discontinuation rate, Wyeth calculated an observed reporting rate of 4.1 per 100,000 woman-years. This is nearly five times less than the expected rate among obese women, who accounted for a substantial majority of the reports, and it is in line with the incidence rate among reproductive-age women generally.

With respect to Norplant-associated visual disturbances, a report by the National Academy of Sciences’ Institute of Medicine commenting on the provisional final results from the International Collaborative Postmarketing Surveillance led by the World Health Organization in 1998 found no association between Norplant and visual disturbance. Although 15 of 19 cases of visual disturbance in this study were among Norplant users, closer scrutiny revealed no causal relationship between Norplant and visual disturbance. Six cases proved to be disorders of refraction, requiring eyeglasses; five cases were various diagnoses including borderline glaucoma, an intraocular foreign body, thyroiditis, cestode infection, and keratitis; and 8 cases (7 in Norplant users) were 1- to 3-month complaints associated with headache or fatigue, all reversible. [20]⁴⁰

⁴⁰ See page. 62.

In 1995, Wysowski, D.K., and L. Green [13] evaluated serious adverse reports in Norplant users from all sources available to FDA,⁴¹ including 39 cases of IIH. In 21 cases no body weight information was available, but all patients whose weight was reported had recent weight gain (8 cases) and/or were obese (16 cases) or overweight (2 cases). Four patients continued using Norplant and the IIH resolved, as did 16 patients who had Norplant removed. Eight patients had Norplant removed but symptoms continued. The interpretation of dechallenge cases is made difficult by the concurrent treatment with lumbar puncture and acetazolamide.[59, 64] The authors estimated that the reporting rate was approximately 5.5 per 100,000 woman-years, which did not exceed the expected background rate for IIH. The authors concluded that it was not possible to determine whether Norplant or body habitus were related to the development of IIH.

Irvin Sivin of the Population Counsel responded to Wysowski and Green's calculation. [16] He pointed out that the authors had underestimated the years of experience American women had with Norplant, resulting in an over-estimate of the reporting rate by 34% to 50%. Using corrected data, Sivin determined that the IIH reporting rate was actually between 2.8 and 3.7 per 100,000 woman years. This rate was well within the background rate for women of childbearing age (approximately 3.5 per 100,000) and markedly below that for overweight or obese women (approximately 19.3 per 100,000). Sivin concluded that "the incidence of serious adverse events during Norplant use does not raise the 'suspicion of a causal association with Norplant.'" I agree with Sivin's conclusion.

I also note that when attempting to understand adverse event under-reporting and its impact on estimating incidence rates, it is not correct to assert that the extent of under-reporting is known, and that incidence can be arrived at by multiplying the known reports by some number, such as 10.

Studies have demonstrated that the extent of underreporting for adverse events varies widely by medication and even within a class of medications. One reference [35], cited by Dr. Ross, estimates that 15% of serious conditions are reported. Another well-documented study found a reporting rate of 35%. [45] There is no single under-reporting rate that applies to all drugs and all adverse reactions in all clinical settings. Reporting rates are influenced by factors including publicity received by a medicine, the background rate of the adverse event in the general population, and the time the product has been on the market. [45] As Hazell, L., and Shakir, S. A. [35] conclude "[i]t would be inappropriate to apply a standard 'correction factor' based on

⁴¹ Wysowski and Green reviewed spontaneous reports from manufacturers, consumers, and health care professionals; clinical trials; and the medical literature.

the results of this study, since there is inevitably considerable variation in under-reporting for different drugs and types of ADRs, in different populations and at different points in time.”

B. Other Levonorgestrel Containing Drugs and IIH Labeling

No LNG-containing product currently marketed in the United States carries an IIH warning. Neither the LNG-containing oral contraceptives nor the other LNG-containing IUDs marketed in the U.S. (Skyla and Liletta), which FDA approved after Bayer had shared the results of its signal assessments for IIH (discussed below), contain an IIH warning.⁴² Also, Nexplanon, a progestin-containing implant approved in 2006, does not have an IIH warning.⁴³

Although not marketed in the U.S., FDA did approve the Jadelle implant, which was the successor product to Norplant. The Jadelle prescribing information was also based on Norplant,⁴⁴ using the pre-PLR labeling standard that Norplant followed. As discussed above, the evidence did not support an association between Norplant and IIH, let alone a causal association, and I have seen no evidence that Jadelle is any different. In my opinion, the fact that Jadelle carries an IIH warning⁴⁵ does not justify including such a warning in the Mirena label.

C. The Adequacy of the Mirena Label with Respect to IIH

1. Initial Mirena Prescribing Information

At the time of Mirena’s launch, clinical trial and post-marketing data did not support the inclusion of an IIH warning in the Mirena label. As described above, Berlex Laboratories’ proposed labeling was based on a concise summary of the scientific evidence obtained from adequate and well controlled trials, the safety experience with Mirena, postmarketing surveillance, and the medical literature. [23] In my opinion the approved Warning labeling concisely summarized the known risks of Mirena so that a healthcare professional could consider the risks and benefits for individual patients. Those risks did not, and still do not include IIH.

⁴² <https://dailymed.nlm.nih.gov/dailymed>, 2013 Skyla Label, 2015 Liletta Label.

⁴³ 2006 Nexplanon Label, 2015 Nexplanon Label.

⁴⁴ Nov. 13–14, 2015 Dep. Tr. of Juliane Schoendorf, at 44:14–44:20, 79:6–79:10, 114:8–114:11, 148:11–148:15, 170:11–170:14.

⁴⁵ 2002 Jadelle Label.

By 2000, no clinical trial participants had been diagnosed with IIH during a Mirena trial. Bayer did report a single potential IIH case in the August 2000 PSUR,⁴⁶ before Mirena's initial U.S. label was finalized. However, this case did not provide adequate evidence of an association between Mirena and IIH. The patient had a history of IIH predating her Mirena usage, and the case report addressed the patient's worsened headache after receiving acetazolamide (a medication for which she had a known toxicity), but not symptoms while she was using Mirena.⁴⁷ The case report does not indicate that the patient's IIH recurred or worsened as a result of Mirena use. Although Dr. Ross criticizes Bayer for its handling of this IIH report, the FDA received the report months before issuing preliminary labeling comments in November 2000.⁴⁸ If FDA had believed that this case report was reasonable evidence of an association between Mirena and IIH, it was fully within FDA's authority to require an IIH warning prior to Mirena approval. The FDA did not require such a warning.

In my opinion, FDA's approach was reasonable. Although FDA's 2005 Guidance for Industry: Good Pharmacovigilance Practices and Pharmacoeconomic Assessment [33] states that "single well-documented case report" can create a signal "particularly if the report describes a positive rechallenge or if the event is extremely rare in the absence of drug use," that standard has not been met here. First, this case is not "well-documented," as the report lacks critical information (e.g., the patient's body habitus). Second, the report does not "describe[] a positive rechallenge." Third, although IIH is rare, it is not "extremely rare" without the use of Mirena.⁴⁹ There is a known background rate of IIH in women of childbearing age, and a significantly higher background rate among those with excess weight, or those with recent weight gain. Most importantly, the function of a signal is to highlight a potential safety concern for further evaluation, not to prompt an immediate change in labeling. Therefore, even if this case report were the type that could create a signal, it would not have triggered an obligation to add an IIH warning to Mirena's label without further investigation.

The November 2001 PSUR, which reported three additional cases of IIH among Mirena users, also did not justify the addition of an IIH warning to the label.⁵⁰ First, FDA received this PSUR and could have required action from Bayer if it believed action to be necessary. Second, it is notable that there had been just 4 spontaneous reports of IIH after use of Mirena by more than 2

⁴⁶ PSUR's are the European periodic safety reports that FDA accepts in place of the U.S. PADER-format safety reports.

⁴⁷ MIR_INDND_00032125 at 32610.

⁴⁸ MIR_INDND_00010880.

⁴⁹ The example that FDA has historically given is agranulocytosis with thiouracil to treat hyperthyroidism, a extremely rare drug-event combination and an event unreported in association with thyroid disease.

⁵⁰ MIR_AC_00174527.

million women. Even accepting underreporting, this reporting rate is just a fraction of the expected incidence rate of IIH in women of childbearing age. Thus, it was reasonable for Bayer not to further investigate the link between Mirena and IIH or to seek FDA permission to modify its label.

Evidence suggests that by the time the Mirena label was being negotiated, FDA had become more alert to preventing over-warning than it had been earlier in the 1990s when Norplant added its IIH warning. For example, during Mirena label discussions, FDA struck Bayer's proposed warning about venous thromboembolism (VTE) that indicated based on epidemiologic studies of progestin-only pills that there may be a slight, non-statistically significant increase in risk of VTE.⁵¹ This is an example that when FDA finds insufficient scientific justification to conclude that there is reasonable evidence of an association, FDA will not accept a Warning.

2. Postmarketing Safety Information and Pharmacovigilance

At all times since Mirena's approval in 2000, Bayer has maintained strong pharmacovigilance practices that provide accurate and timely evaluation and reporting of postmarketing safety data. Collecting and analyzing spontaneous postmarketing adverse event data is an important task, however, these reports cannot be used to assess causality. The FDA makes this clear on its website, which states that "[s]ubmission of a safety report does not constitute an admission that [a] . . . product caused or contributed to an event."⁵² Instead, a positive signal suggests deeper investigation into the association between a medicine and an event is needed.

Three times since Mirena's approval – in 2008, 2014, and 2015 – Bayer has conducted signal assessments to determine whether the updated Mirena data warranted further investigation into the relationship between Mirena and IIH. These investigations occurred after the issuance of the PLR, under which a medication label must warn of an adverse event when there is "reasonable evidence of a *causal* association" between the medication and the event.⁵³ The FDA's 2005 Guidance [33] suggests considering the following factors when determining whether a causal relationship exists:

⁵¹ MIR_CCDS_00000742, MIR_INDND_00010880, MIR_JR_00095903, MIR_INDND_00044480.

⁵² openFDA, *About*, FDA.gov (updated 3/10/16) ("Submission of a safety report does not constitute an admission that medical . . . product caused or contributed to the event. The information in these reports has not been scientifically or otherwise verified as to a cause and effect relationship and cannot be used to estimate the incidence of these events.").

⁵³ 21 CFR 314.125.

1. Occurrence of the adverse event in the expected time;
2. Absence of symptoms related to prior exposure;
3. Evidence of positive dechallenge or positive rechallenge;
4. Consistency of the event with the established pharmacological effects of the product;
5. Consistency of the event with the known effects of other products in the class;
6. Existence of other supporting evidence from preclinical studies, clinical trials, and/or pharmacoepidemiologic studies; and,
7. Absence of alternative explanations for the event – such as confounders.

As discussed in detail below, each of Bayer's three assessments appropriately concluded that there was not reasonable evidence of a causal association between Mirena and IIH, and that no further investigation was necessary. These assessments were shared with the FDA, which had the explicit authority to require the addition of safety language to product labels. FDA did not conclude from the signal assessments that there was reasonable evidence of a causal association between Mirena and IIH, thus did not require an IIH warning.

a. 2008 Signal Assessment

In 2008, because of several spontaneous adverse event reports of IIH among Mirena users, the British health authority, the MHRA, requested that Bayer conduct an investigation of IIH reports. Dr. Juliane Schoendorf of Global Pharmacovigilance led the investigation, and findings were reported in the 2008 PSUR.⁵⁴

Bayer found no confirmed cases of IIH in clinical trials and no articles discussing IIH in Mirena patients. A database search for three terms – benign intracranial hypertension, intracranial pressure increased, and papilledema⁵⁵ – located 24 cases of diagnosed or suspected IIH. At this point, the estimated post-marketing experience with Mirena exceeded 33 million woman-years, with an estimated 12.76 million units sold. This resulted in a reporting frequency of 0.07 cases per 100,000 woman-years, based on a 10% annual discontinuation rate.⁵⁶ More than 80% of patients whose weight was reported were overweight or obese, which suggests that that weight,

⁵⁴ MIR_AC-R_00178489-00178493.

⁵⁵ While it is reasonable to identify potential cases with broader terms such as papilledema, review of the narrative, usually not available from pharmacoepidemiology studies or most spontaneous report databases, is necessary to identify suspected IIH cases. Bayer reviewed the case reports and excluded from further consideration those that did not represent IIH.

⁵⁶ Recent studies of Mirena use have reported annual discontinuation rates of 11-12%. Moreau C. Frequency of discontinuation of contraceptive use: results from a French population-based cohort. *Hum Reprod.* 2009; 24(6):1387-1392; Peipert JF. Continuation and Satisfaction of Reversible Contraception. *Obstet. Gynecol.* 2011; 117(5):1105-1113.

the primary risk factor for IIH, played a role. Apart from weight, there were no discernible patterns in the relevant data. Some patients reported IIH symptoms prior to receiving Mirena, and in 3 of 8 cases where information was available, symptoms did not resolve after the Mirena was removed. There was no clear case of positive dechallenge, as those patients whose Mirenas were removed also generally underwent lumbar puncture as part of the diagnosis, as well as receiving other IIH treatments.

Given the incidence rate for IIH among women of childbearing age, a finding of 0.07 cases per 100,000 woman-years is extremely low, even assuming underreporting. Given the population that uses Mirena, and especially given the ACOG recommendation that Mirena be a preferred contraceptive option among obese women, one would expect to see *more* IIH among Mirena users than we do.

Overall, data from the 2008 signal assessment did not indicate that Mirena presented an increased risk of developing IIH. MHRA concurred with Bayer's assessment that there was "insufficient evidence of an association between Mirena and BIH,"⁵⁷ and agreed that Bayer was not obligated to undertake observational studies or add an IIH warning to Mirena's label. Bayer did agree to continue monitoring IIH adverse event reports.

b. 2014 Signal Assessment

Following the 2008 signal assessment, Bayer continued monitoring adverse event reports of IIH. In 2014 Bayer undertook another signal assessment after identifying an increase in IIH reporting resulting from reports generated from legal cases.⁵⁸

Bayer's review of the epidemiology and medical literature confirmed that there was still no support in the studies for a connection between IIH and Mirena. An updated review of clinical trial data found three cases of potential IIH, none of which appeared to have been caused by Mirena:

- A patient with pre-existing IIH received Skyla, another LNG IUD. During her time with Skyla, "no worsening of the pseudotumor occurred."⁵⁹ Bayer appropriately concluded this was not a case of IIH related to Mirena or Skyla.
- A patient developed diplopia shortly after her Mirena insertion, although it was unclear whether she had IIH, and a lumbar puncture was never performed. Symptoms resolved

⁵⁷ MIR_JSEU_00780138.

⁵⁸ MIR_PKEU_00699321-00699335.

⁵⁹ MIR-JSEU_01446069.

without Mirena removal.⁶⁰ Bayer appropriately determined that the patient's symptoms were not related to her Mirena usage.

- An obese 37-year-old woman (BMI 31) had a second Mirena placed after 5 years with her first Mirena. Ten months later, after 5 years and 10 months of consecutive Mirena use, she developed IIH. The patient recovered without removing Mirena.⁶¹ The investigator appropriately concluded that IIH was not related to Mirena, and Bayer concurred.

An updated review of adverse event reports found 66 reports of IIH, with a cumulative postmarketing experience of approximately 99.4 million woman-years. This resulted in a steady reporting rate of 0.07 per 100,000 woman-years, despite the surge in reports coming from legal claims, and demonstrates no increased risk of developing IIH among Mirena users.

A deeper look at the 66 cases reveals the same themes that have consistently appeared in analyses of IIH patients. There was no clear temporal pattern between insertion and development of IIH symptoms, with almost one-third of cases reporting symptom onset between years 2 and 11 of Mirena use, when LNG release levels would have decreased, and the other cases dispersed fairly equally over time. Where information was available, 81% of patients had excess weight or had experienced recent weight gain, the major risk factors for IIH.

Finally, there was no clear relationship between the presence of Mirena and IIH symptoms, as some patients recovered with Mirena still in place, there were no positive dechallenges, and some patients' symptoms did not improve after Mirena removal. Of those who did recover after Mirena removal and treatment for IIH, some did not experience improvement until several years after removal. This timeline demonstrates that an ongoing source of LNG did not cause the patients' IIH symptoms.

c. 2015 Signal Assessment

In 2015 Bayer conducted another signal assessment,⁶² this time in response to a new publication by Etminan [76] which included a FAERS analysis suggesting a small increase in the risk of

⁶⁰ MIR-JSEU_01057343.

⁶¹ MIR_BSR_36776; MIR_ISEU_268963.

⁶² MIR_KCOPLEY_JSEU_00000046 to 00000067.

developing IIH with the use of Mirena.⁶³ Bayer studied the Etminan publication and another publication, a meeting abstract by Rai [72], and again queried its database for IIH reports.

Bayer was unable to recreate Etminan's disproportionality scores from his FAERS analysis. Instead, Bayer's search of the FAERS and WHO databases for IIH in Mirena users compared to all other female patients ages 17-45 found no disproportionate reporting of IIH among Mirena users. Having reviewed this analysis and the Etminan and Rai papers, I agree with Bayer's critical assessment of them. I will discuss the shortcomings of these papers in more detail in a later section of this report.

Finally, Bayer found 114 IIH cases reported for Mirena and 1 for Skyla (Jaydess), with a total postmarketing exposure of approximately 120 million woman-years. This resulted in an estimated reporting rate of 0.09 cases per 100,000 woman-years, a small increase over the 2014 findings. This is not surprising, given that 46 of the 114 reports stemmed from litigation. Again, even accounting for Dr. Ross's hypothesized reporting rate, this reporting rate is significantly lower than what would be expected from women of childbearing age, let alone an overweight or obese population. As has consistently been the case, the vast majority of women for whom body habitus data were available had excess weight, or had experienced recent weight gain. Additionally, there was no consistent period between Mirena insertion and symptom onset, and there were no clear cases of positive dechallenge. Nor were there any cases of rechallenge.

In sum, Bayer's signal analyses demonstrate that there is not reasonable evidence of an association, let alone a causal association, between IIH and Mirena. This is consistent with results from numerous studies finding no statistically significant relationship between the use of oral contraceptives and IIH. [6-9, 12]

D. Epidemiology Studies of Mirena and IIH

The medical literature regarding Mirena and IIH consists entirely of a single case report and two epidemiologic studies. Due to their flaws and inherent limitations, none of these sources provide any evidence of a causal association between Mirena and IIH.

⁶³ Etminan also conducted a retrospective cohort study which found no statistically significant difference in IIH risk between Mirena users and the users of two combined oral contraceptives.

1. Martinez (2010)

In 2010, H. Martinez reported a “very atypical case” of IIH in a woman who used an unspecified LNG IUD. [49] Although the case report indicates that the woman was not obese, it provides no information about whether the patient was overweight or had recent weight gain, both of which are independent risk factors for IIH. Nor does it indicate when IIH developed vis-à-vis insertion of the IUD. Although the patient’s doctors recommended removal of her IUD, the case report does not indicate whether the IUD was ultimately removed. Even assuming that the IUD was removed, the patient was treated with acetazolamide, precluding any assessment about whether removal contributed to improvement in the patient’s symptoms. [64] In short, this single case report provides no evidence of a causal association between Mirena and IIH.

2. Etminan (2015)

In 2015 Etminan, M., et al. [76] published a reporting disproportionality analysis of IIH and Mirena using the FAERS database and a retrospective cohort study. A closer review of this article reveals that Etminan’s reported results have serious methodological flaws that limit the validity of the authors’ conclusions.

First, with respect to both studies, Etminan uses incorrect search terms. Etminan searches the FAERS database for “benign intracranial hypertension, idiopathic intracranial hypertension, cerebral edema, intracranial hypertension, papilledema and papilledema [sic].” For the retrospective cohort study, Etminan searches for “obstructive hydrocephalus[,] idiopathic normal pressure hydrocephalus, benign intracranial hypertension, cerebral edema and papilledema.” Cerebral edema (accumulation of excessive fluid within the brain tissue), idiopathic normal pressure hydrocephalus (enlargement of cerebral ventricles without evidence of chronic increased intracranial pressure), and obstructive hydrocephalus (blockage of the flow of cerebrospinal fluid out of the brain’s ventricles), would each preclude a diagnosis of IIH under the modified Dandy criteria. [1, 57] Intracranial hypertension (high pressure inside the skull) is a general condition that can reflect numerous conditions other than *idiopathic* intracranial hypertension. Papilledema (swelling of the optic nerve due to increased intracranial pressure) can be present in any disorder that increases intracranial pressure.

Second, Etminan does not report any effort to verify the diagnoses coded in the FAERS database or in the IMS LifeLink database that was used for the retrospective cohort study. This important step is essential for interpretable pharmacoepidemiology studies. FDA generally recommends that sponsors of pharmacoepidemiologic studies “validate diagnostic findings through a detailed review of at least a sample of medical records.” [33] Etminan’s failure to do so here is

particularly troubling, given that the ICD-9 code for IIH has only a 55% positive predictive value. [66]

Third, neither the disproportionality analysis of reporting behavior, nor the retrospective cohort study contained any covariate information about the well-established risk factors of excess weight or recent weight gain, which is particularly important given the ACOG recommendations [40] discussed above regarding IUD contraception for obese women. This creates confounding by indication.

Fourth, although Etminan's disproportionality analysis purports to quantify the odds of reported cases of intracranial hypertension among Mirena users, Etminan does not report restricting his database search to women of reproductive age. Because incidence rates of IIH are substantially lower in men, children, and non-reproductive age women, including those populations in the comparison biases the results toward a higher odds ratio for Mirena use, which is of course a product only used by women of reproductive age.

Fifth, while Etminan purports to conduct Bayesian sensitivity analyses for both studies to estimate the effect of an unknown prior, the assumptions underlying these analyses are invalid, and the way he reports the results is misleading. With respect to his FAERS disproportionality analysis, Etminan adjusted the odds ratio "according to estimates in the medical literature" for the relationship between intracranial hypertension and Mirena (but not for the relationship between intracranial hypertension and weight). Yet Etminan cites no literature that would support using a prior of 1.5 to 2.5, which presupposes that there is a relationship between Mirena and IIH. I am not aware of any literature that would support such an assumption.

For the retrospective cohort study, Etminan adjusted the ratio according to estimates of the relationship (1) between excess weight and Mirena use, and (2) between excess weight and intracranial hypertension. Etminan selected symmetrical priors, which (1) assume that it is equally likely that overweight and obese women are attracted toward use of combined oral contraceptives as it is that they are attracted toward Mirena use, and (2) assume that obesity is just as likely to increase the risk for intracranial hypertension as it is that obesity decreases the risk for intracranial hypertension. Given that Mirena is recommended for obese women over combined oral contraceptives [40], and given that obesity is a known risk factor for IIH – facts that the publication even acknowledges, it is not valid to select symmetrical hypothesized odds ratios for these relationships. The "risk" of use of Mirena by obese women and the risk of obesity for IIH should both be greater than 1. By reporting the average effect of his symmetrical

priors Etminan has misleadingly showed that his Bayesian analysis will have no effect on his odds ratios.⁶⁴

Sixth, in a 2016 letter to the editor, Friedman reports that Etminan had been retained as a medical expert for Plaintiffs in this litigation prior to publication of the article. [82] In his response, Etminan did not deny Friedman's allegations, instead insisting that the study was "independent" in spite of his "involvement as an expert in any litigation." [81] Etminan's failure to disclose this conflict of interest — Etminan went so far as to explicitly "declare no conflict of interest in preparing this article" — is of concern.

Despite the flawed methodology which would bias the results against Mirena, it is noteworthy that Etminan's retrospective cohort study reports no statistically significant difference in the risk of ICH between Mirena and either of two oral contraceptives (EE-norgestimate and EE-norethindrone). Etminan's assertions in the publication that "EE-norethindrone is protective for ICH" as compared to Mirena, and that there is a "higher risk of ICH for Mirena compared with EE-norgestimate," both of which are contradicted by the results of the cohort study, further reveal the biases of the authors.

3. Rai (2015)

In 2015, a meeting presentation abstract by Rai, R., et al. [72], was published with a half-page description of a purported case-control study. The methodology is flawed in numerous respects, rendering meaningless the reported results.

In selecting the case group, 473 patients with "ICD-9 codes for pseudotumor cerebri" were screened according to the study's inclusion criteria. Out of the 176 patients that met those criteria, 59 completed telephone birth control histories, and 8 reported having used Mirena for contraception at the time of ICH symptom onset. This methodology is problematic in several respects. First, while Rai reports using "ICD-9 codes for pseudotumor cerebri," Rai does not report which codes he used. Given that there is only one ICD-9 code for pseudotumor cerebri — "benign intracranial hypertension" — to the extent that Rai used multiple codes, he must have used codes that were over-inclusive or incorrect.⁶⁵ Second, the small percentage of patients who completed Rai's telephone interview raises concerns about selection and response bias. Third, Rai reports no effort to confirm the diagnosis of ICH in any of the patients in the case group,

⁶⁴ See Table 1.

⁶⁵ See ICD-9-CM Diagnosis and Procedure Codes, available at <https://www.cms.gov/medicare/coding/ICD9providerdiagnosticcodes/codes.html>.

despite the fact that the ICD-9 code for IIH has been shown to have only a 55% positive predictive value for identifying patients. [66]

To select the control group, Rai queried CPT codes in a health claims database for LNG IUD insertion in 220,904 women without "ICD-9 codes for PTC" who were aged 18-55 and had at least one clinical encounter from 2008-2013. Rai identified 4,408 Mirena users (approximately 2.0% of women in the database). Again, methodology of the selection of controls is problematic. No telephone interviews were performed to verify whether or not any patients used Mirena. Given that IUD usage in the United States from 2008-2013 fluctuated between 3.8% and 7.2% of all reproductive-age women [70], it is likely that Rai underestimated the number of Mirena users in the control group, which would have the effect of overestimating the odds ratio. As Rai fails to identify the health claims database used to select the control subjects, it is difficult to analyze the control group further. Third, the fact that Rai selected cases and controls using distinct methodologies presents a serious risk of ascertainment bias. Fourth, Rai reports no attempt to match cases with controls beyond female gender and age.

The Rai abstract suffers from another major flaw: Excess weight and recent weight gain are strongly associated with an increased risk of IIH, yet Rai fails to control for those confounders. Although Rai reports that "[t]here were no significant differences between LNG-IUS users and non-users in terms of . . . body mass index [or] recent weight gain," this does not indicate that Rai controlled for excess weight or recent weight gain when calculating the presented odds ratio. Rather, this statement about BMI and weight gain is simply a comparison between the IIH patients who did use Mirena and the IIH patients who did not use Mirena. It is not a comparison between the IIH patients who did use Mirena and the non-IIH controls. Moreover, the Valenzuela abstract, which presents data from the same case-control study, reports that twice as many cases had recent weight gain than the control group. [73]

Given the numerous flaws in the Rai abstract, the reported odds ratio of 7.7 cannot be taken at face value. Indeed, the authors themselves recognize that the evidence is "preliminary," that the connection between Mirena and IIH is merely a "possib[ility]," and that removal of Mirena in a patient who develops IIH is generally not warranted.

V. Dr. David Ross's Report [80]

I disagree with Dr. Ross's assessment of the evidence for a relationship between Mirena and IIH and his conclusions about the need for a warning for IIH in the Mirena prescribing information

labeling. Dr. Ross asserts that the Mirena label is inadequate because it does not contain an IIH warning. Dr. Ross supports this argument in two major ways:

First, he focuses on the label for Norplant, a subcutaneous LNG implant withdrawn from the market more than a decade ago. Dr. Ross argues that Norplant's label, which contained language regarding IIH, should have guided development of the Mirena label, regardless of whether there was sufficient evidence of an association to support the language in Norplant's label and regardless of whether Mirena's own clinical trials and post-marketing data suggested an association between Mirena and IIH.

Second, he argues that Mirena's post-marketing data constituted reasonable evidence of a causal association between Mirena and IIH, and should have compelled the company to introduce an IIH warning. Neither claim is supported by the record.

A. Norplant Labeling Is Not an Appropriate Source for Mirena Labeling

Dr. Ross's claim that Mirena's launch label should have included an IIH warning drawn from Norplant's label is without support and contrary to the FDA's conclusion regarding the adequacy of Mirena's label at the time of FDA approval.

First, I disagree with Dr. Ross's conclusion that "the Norplant warning automatically created an association" between Mirena and IIH. FDA can — and does — impose common warnings on drugs in a pharmacological Class when FDA concludes that there is likely a Class effect. There is no indication in the Mirena FDA review documents, or in the labels that FDA approved, that FDA considered the Norplant labeling to be class labeling for all levonorgestrel products. In fact, to the contrary, FDA medical reviewer Dr. Furlong noted that "[u]nlike other contraceptive methods containing levonorgestrel, the effectiveness of Mirena appears to depend more on the local than the serum concentration of levonorgestrel" and ultimately recommended that Mirena *"include the warnings that are currently on the U.S. labels for the other two USA-approved IUDs"* [24]⁶⁶ (emphasis added). These warnings did not include an IIH warning. [24]⁶⁷ Internal communications demonstrate that the Mirena launch label was developed using FDA's suggested approach, ultimately modeling the Mirena label primarily on the labels for other IUDs, with the contents of the Norplant label being included only where there was scientific

⁶⁶ See page 7, and MIR_INDNDA_53366 at 55897.

⁶⁷ See page 6.

support for doing so.⁶⁸ Employing other IUD labels when drafting the Mirena label was a sensible approach, given (1) all three products are IUDs which work by affecting the uterine environment, and (2) the differences between Mirena and Norplant.

Second, Bayer faced no obligation to adopt the Norplant label language simply because the two systems each employed LNG. Dr. Ross cites no authority for his claim, and indeed manufacturers generally need not employ warnings from other medications. Bayer reasonably and appropriately decided that the Norplant label should be used only on a case-by-case basis when scientific evidence demonstrated its applicability to Mirena.⁶⁹ For example, the Norplant label included a precaution about autoimmune diseases related to silicone use. Bayer considered this precaution but determined that “[f]rom a medical/toxicological perspective there is no reason to assume that the silicone tubing of Mirena might induce autoimmune disease.”⁷⁰ As a result, Bayer’s proposed Mirena label did not include similar language about risks of silicone.

Third, Dr. Ross cites no authority for his claim that in the absence of clinical trial data disproving the hypothesis that Mirena causes IIH, Bayer was obligated to include an IIH warning in its label. Nor does he provide support for his claim that Bayer was obligated to conduct pivotal studies that were sufficiently powered to establish the safety of Mirena with respect to IIH. Given how rare IIH is in the population, it would have been impossible to design and execute a clinical trial large enough to study the issue.⁷¹ The FDA acknowledges that clinical trials are “impractical in almost all cases when the event rates of concern are less common than 1:2000-3000,” [33] and IIH is significantly less common than that, even among obese women, who are at the highest risk. I am unaware of any sponsor ever being obligated to do a study of adverse events expected to occur just once in every 33,000 person-years. Rather, the whole purpose of pharmacovigilance is to detect signals of potential adverse events occurring too infrequently to be observed during clinical trials. [33] Indeed, plaintiffs’ expert Dr. Fraunfelder states: “[T]he study population required in order to detect a single case of PTC among potential Mirena users would be at least 90,910. Obviously, this is an impractical number of subjects for a pre-marketing study.” Perhaps more importantly, Dr. Ross’s proposed warning

⁶⁸ MIR_JR_00186051, MIR_JR_00186066, MIR_JR_00186596, MIR_JR_00186491, MIR_JR_00186518, MIR_JR_442929, MIR_PSEU_00530579.

⁶⁹ MIR_JR_00186491.

⁷⁰ MIR_JR_442929.

⁷¹ Dr. Ross inaccurately states: “Reliable detection of a single case of IIH would require a safety database of 10,000 patients or more” [80], yet he cites a background rate of IIH as 3.3 per 100,000. A study of at least 90,000 patients would be required to have a 95% chance of detecting a single case. [43, 47]. This is just one of many errors and miscalculations in his report.

standard — inclusion of all theoretical adverse events in a label absent evidence disproving an association — would result in widespread over-warning, which presents two distinct risks. First, a label that contains numerous warnings not supported by medical evidence could dilute the importance of well-supported warnings.⁷² Second, patients and their physicians may be deterred from using a highly efficacious and safe product if faced with a long list of warnings and precautions that are not based on rigorous scientific assessment.⁷³

Fourth, Dr. Ross's criticism of Bayer for not having a procedure to evaluate headaches among clinical trial patients to see whether they were indicative of papilledema or other signs or symptoms of IIH is entirely unsupported. Headaches not only have a high background rate in the general population, but are also an extremely common and non-specific adverse event for many medications. It would be untenable to design a program that would include a diagnostic evaluation for IIH with each reported headache.

B. The Criticisms of the Bayer Signal Assessments Are Unfounded

Dr. Ross offers a host of minor and unfounded criticisms of the 2014 signal assessment with which I disagree:

- Dr. Ross concludes that Bayer failed to “address whether the risk of weight gain in Mirena users . . . could lead to obesity and thereby raise the risk of IIH.” This criticism is without merit, as there is no evidence that Mirena causes significant weight gain. To the contrary, prospective studies have demonstrated minimal weight gain with Mirena use. [63]
- Dr. Ross claims that Bayer applied a “nonexistent regulatory standard” in concluding that “confirmed evidence for a causal association of levonorgestrel implant use and intracranial hypertension is lacking.” He ignores Bayer's statement in the same

⁷² See [4] (“The Commissioner believes that including theoretical hazards as contraindications in drug labeling would cause that very important section of the labeling to lose its significance.”), [37] (“Overwarning, just like underwarning, can . . . have a negative effect on patient safety and public health. . . . FDA believes that including relative or hypothetical hazards diminishes the usefulness of the [contraindications] section.”), [44] (“[I]nclusion of speculative or hypothetical risks, could . . . decrease the usefulness and accessibility of important information by diluting or obscuring it. As FDA has stated, labeling that includes theoretical hazards not well-grounded in scientific evidence can cause meaningful risk information to lose its significance.”).

⁷³ See [44] (“[I]nclusion of speculative or hypothetical risks, could discourage appropriate use of a beneficial drug, biologic, or medical device . . .”).

paragraph that “available data for Mirena do currently not indicate that Mirena use would be associated with an increased risk for developing IIH.”⁷⁴

- Dr. Ross claims that Bayer focused “primarily on the potential alternative explanation of obesity as the cause for these cases,” and, as a result, that Bayer’s analysis “was directed at excluding a relationship between Mirena and IIH, rather than an objective exploration of the data.” This criticism is unwarranted. Bayer examined whether there was a causal relationship between Mirena and IIH by looking for features that would suggest a causal relationship (e.g., common duration of onset, positive dechallenge, and the absence of alternative explanations), just as recommended by FDA’s 2005 Guidance (sponsors should “look for features that may suggest a causal relationship between the use of a product and the adverse events”). [33]⁷⁵
- Dr. Ross claims that Bayer’s Standard Operating Procedures for signal detection failed to require Bayer to submit its findings to FDA, but he ignores the fact that Bayer submitted each of its signal assessments to FDA as part of its PSURs.⁷⁶ Additionally, the FDA “will make its own assessment of the potential safety risk posed by the signal in question, taking into account all the information provided by the sponsor and any additional relevant information known to FDA (e.g., information on other products in the same class).” [33]⁷⁷ FDA received Bayer’s signal assessments and, having approved an IIH warning in the Norplant label years before, did not ask Bayer to add an IIH warning to the Mirena label. Nor was Bayer obligated to take additional steps after completing its signal analyses and finding no signal, apart from ongoing monitoring for future signals. FDA’s 2005 Guidance clearly states that “risk management is an iterative process and steps to further investigate a potential safety risk, assess the product’s benefit-risk balance, and implement risk minimization tools would best occur in a logical sequence, not simultaneously. Not all steps may be recommended, depending on the results of earlier steps.” [33]⁷⁸

⁷⁴ MIR_PKEU_00699321 at 00699334.

⁷⁵ See page 6.

⁷⁶ MIR_INDNDA_00246210, MIR_INDNDA_00340337.

⁷⁷ See page 18.

⁷⁸ Id.

C. The Epidemiology Evidence Does Not Support a Casual Association Between Mirena and IIH

Dr. Ross conducts his own disproportionality analysis of the U.S. adverse event data and suggests that Bayer should have compared reported adverse events for Mirena patients with IIH (22, by his count) against those reported for ParaGard (0) and other IUDs on the market (1). I fundamentally disagree with this approach, as FDA's 2005 Guidance notes that comparison between two or more reporting rates must be made with "extreme caution." [33] Additionally, when Dr. Ross conducted his review of the adverse event reports compiled in OpenVigil 2.0, he gathered the data incorrectly. Dr. Ross reported 22 unique reports of IIH in U.S. patients exposed to Mirena, when in fact there are only 14 unique cases of IIH.⁷⁹ In effect, Dr. Ross double-counted some patients, for whom multiple reports were submitted, and thereby overstated the number of cases of IIH observed in Mirena users by more than 50%. It is also notable that, where reported, the mean patient weight among the 14 patients was approximately 218 pounds (median 195.1 pounds), meaning that most of the patients were overweight or obese.

Moreover, the method Dr. Ross cites for his disproportionality analysis [27], the PRR, is not a method that FDA recommends for use with FAERS data when, as here, the total number of events is less than 20. [33]⁸⁰ Dr. Ross even misinterprets the meaning of the PRR statistic when he comments that "the magnitude of this increase [in the PRR] indicat[es] that Mirena is likely related to IIH by accepted criteria." The PRR only shows differences in reporting rates and is not used to indicate that a drug and an event are "related."

Dr. Ross also attempts to compare Mirena IIH reporting to Skyla, Liletta, and ParaGard. Even when "extreme caution" is exercised, comparisons to other products can only be done if there is an adequate marketing period for products to generate results, which is not the case for the recently marketed Skyla (2013) and Liletta (2015). OpenFDA contains no adverse event reports associated with Liletta and just 1,430 adverse event reports associated with Skyla (compared to 73,330 adverse event reports associated with Mirena).⁸¹ It is also not appropriate to draw conclusions from comparisons to older products such ParaGard, which was approved in 1984,

⁷⁹ An Individual Safety Report (ISR) code is assigned to each unique report. A case ID is assigned to each unique patient. Where multiple reports are submitted for the same patient, multiple ISRs will be generated, but all of them will have the same case ID. There are only 14 unique case IDs associated with IIH among Mirena users in OpenVigil 2.0. See <http://www.is.informatik.uni-kiel.de/pvt/OpenVigil/search/>.

⁸⁰ See page 9.

⁸¹ See <http://www.researchae.com/>.

well before the implementation of the MedWatch program in 1992. While postmarketing reporting did occur before 1992, the number of reports submitted was just a fraction of the number of reports seen in more recent times. [45] Products that have long been on the market also tend to have very low reporting rates. Consequently, openFDA contains just 2,266 adverse event reports associated with ParaGard. Even more importantly, analyses of reporting rates in FAERS cannot provide information about incidence or prevalence of drug-associated adverse events. Such estimates must come from other sources, such as epidemiology studies for rare events.

Finally, Dr. Ross misquotes a sponsor's requirements. In FDA's 2005 Guidance, FDA explicitly does not require the use of data mining signal detection activities. [33]⁸² The cornerstone of pharmacovigilance systems is the case-by-case evaluation of individual reports and the submission of those reports in either 15-day or periodic reports.

Dr. Ross uncritically accepts the 2015 Rai abstract as evidence of "patients exposed to Mirena being 7.7 times more likely to develop IIH than non-users." Because the abstract has not been turned into a full-length article, the only information available about the study's methodology is what appears in half a page.

Dr. Ross uncritically accepts Etminan 2015 as evidence that "independent of potential confounders such as obesity, Mirena use increases the risk of IIH," a conclusion that even Dr. Etminan fails to draw from his own study in his own report.

VI. Dr. Mayhar Etminan's Report [78]

Dr. Etminan has offered an expert report in this litigation, and I take this opportunity to address several of his points.

A. Disproportionality Analyses

In Tables 2 and 3 of his report, Dr. Etminan lists the results of flawed disproportionality analyses using the FAERS and WHO databases. In Table 2, Dr. Etminan searched the FAERS database using OpenVigil 2.1 for cases of papilledema and IIH. In Table 3, he searched the WHO database for papilledema and "Hypertension intracranial."⁸³ Dr. Etminan's

⁸² See page 9.

⁸³ "Who Analysis.xls"

disproportionality analyses for papilledema are irrelevant to whether there is a signal for IIH, as papilledema is not unique to IIH. And although “Hypertension intracranial” is the WHO Adverse Reaction Terminology (WHO-ART) term for IIH, it is also the WHO-ART term for fontanelle bulging and any other source of increased intracranial pressure.⁸⁴ Dr. Etminan did not review the case reports in an effort to discern how many cases of “Hypertension intracranial” represent IIH specifically.

With respect to Dr. Etminan’s disproportionality analyses, Dr. Etminan purports to calculate reporting odds ratios from the FAERS and WHO databases for “common intrauterine contraceptives.” Table 2 presents the FAERS results for Cu-7, Mirena, Depo-Provera, and all drugs containing levonorgestrel. Table 3 presents the WHO results for those same drugs, as well as ParaGard and Norplant. Dr. Etminan’s comparator products are inappropriate. Cu-7, a copper IUD, was removed from the market in 1986.⁸⁵ Since the FAERS database includes data only from January 1, 2004 through June 30, 2014, one would not expect to see any reports of IIH in users of Cu-7. In fact, there are only 3 total adverse event reports for Cu-7 in the entire FAERS database.⁸⁶ Dr. Etminan also provides no explanation for why his search of “common intrauterine contraceptives” includes Depo-Provera (which is not an IUD, and which involves a different progestin than Mirena), Norplant (which is not an IUD), or all levonorgestrel-based products (which includes oral contraceptives). Depo-Provera is also uninformative due to the fact that there are only 4,734 total adverse event reports associated with it in OpenVigil 2.1 (compared to 68,150 reports associated with Mirena). These figures indicate that Depo-Provera is not a valid comparator product for Mirena, particularly for low frequency events like IIH.

Nonetheless, I attempted to reproduce Dr. Etminan’s FAERS disproportionality analysis using OpenVigil 2.1, and the results that Dr. Etminan reports are incorrect. Dr. Etminan claims that there were 58 “Reported Cases” of IIH in Mirena users. While 58 unique reports were submitted (as evidenced by 58 unique ICR codes), multiple reports were submitted for several patients, such that only 40 unique cases are present in the database (as evidenced by 40 unique case IDs). Twenty-four of those cases occurred in the United States. Moreover, analysis of the individual case reports is inconsistent with a causal relationship between Mirena and IIH. Information on weight was available for 9 patients, with a mean weight of 206.5 pounds (median 198.4 pounds). The fact that weight information was not available for 31 patients further highlights the limitations of drawing conclusions from FAERS searches. There was also no common duration

⁸⁴ See <http://bioportal.bioontology.org/ontologies/WHO-ART?p=classes&conceptid=http%3A%2F%2Fpurl.bioontology.org%2Fontology%2FWHO%2F0115>.

⁸⁵ Lewin T, Searle, assailing lawsuits, halts U.S. sales of intrauterine devices. NY Times. 1986.

⁸⁶ See <http://www.is.informatik.uni-kiel.de/pvt/OpenVigil2.1/search>.

between insertion of Mirena and onset of IIH. One patient's IIH reportedly pre-dated Mirena insertion by 13 days, one patient reportedly developed IIH on the same date as Mirena insertion, and the remaining 15 patients for whom information was available developed IIH between 5 days and 11 years after Mirena insertion, with no discernible pattern.

The biggest problem with Tables 2 and 3 is Dr. Etminan's conclusion that the results of his disproportionality analysis "allude to a causal link with LNG contraceptives, including Mirena, and IIH." Disproportionality assessments are merely measures of reporting behavior and do not assess risk or causality. The proper use of disproportionality measures is to identify signals of potential associations between drugs and adverse events that merit further study with reliable epidemiologic methods. As FDA's 2005 Guidance states, "[d]ata mining is not a tool for establishing causal attributions between products and adverse events," and measures of disproportionality "are inherently exploratory or hypothesis generating." [33] I do not find Dr. Etminan's disproportionality methods reliable or compelling.

B. Meta-Analyses

Dr. Etminan's Table 4, which reports a pooled odds ratio for IIH from four studies, is also incorrect. Dr. Etminan's meta-analysis pools the results of three oral contraceptive studies with the odds ratio reported by the Rai abstract. [72] None of the three oral contraceptive studies reported a statistically significant odds ratio. [8, 9, 12] In other words, the statistical significance of the pooled odds ratio is driven *entirely* by the odds ratio reported by Rai, which is flawed for the numerous reasons that I discuss above. Dr. Etminan provides no rationale for estimating the risk of Mirena by pooling the Rai odds ratio with odds ratios from studies of oral contraceptives.

Moreover, Dr. Etminan calculated the results of his meta-analysis using a fixed-effects model, rather than a random-effects model. A fixed-effects model assumes that the true effect size for all studies is identical, and that the only reason for variation between the studies is sampling error. By contrast, under the random-effects model, the goal is to estimate the mean of a distribution of different effects. Consequently, a random-effects model produces a similar pooled odds ratio but results in wider confidence intervals. Here, Dr. Etminan pools the results from studies that have different designs and that assess different contraceptive forms (oral contraceptives vs. IUDs). Dr. Etminan's choice of a fixed-effects model is not appropriate, as there is no scientific basis to assume that these very different hormonal products would have the same risk as Mirena. Simple inspection of the data shows three oral contraceptive studies that have an average risk very close to the null, and a single study of a different product, Mirena, with a different risk estimate. In my opinion, there is no basis for including these four

studies together in a meta-analysis, and certainly no basis for assuming that they all model the same effect and differ only due to chance. Dr. Etminan also calculated the pooled odds ratio using a random-effects model (although he did not disclose the results in his initial report), and the result was an odds ratio that was not statistically significant (OR 2.08 (0.72-5.99)).⁸⁷

Finally, Table 4 uses the wrong odds ratio from the Ireland study. Dr. Etminan uses the odds ratio for oral contraceptive use at least 12 months prior to diagnosis of IIH (2.50). Ireland separately reported the odds ratio for oral contraceptive use immediately prior to diagnosis (1.80). [8] Dr. Etminan should have used the latter odds ratio, which more accurately measures whether IIH was caused by oral contraceptive use. Had he done so, the pooled odds ratio would have decreased accordingly.

C. Reanalysis of the Rai Abstract

Acknowledging that the Rai abstract did not control for BMI or recent weight gain, Dr. Etminan purports in Table 5 to test the robustness of Rai's odds ratio using "hypothetical BMI values." However, the assumptions underlying this calculation are inaccurate. First, Dr. Etminan assumes, without justification, an odds ratio of 2 to 4 for the degree of confounding between BMI and IIH. Yet Daniels reported odds ratios of 6.5 for women with BMIs between 25 and 29, 19.5 for women with BMIs between 30 and 35, and 26.0 for women with BMIs above 35. [42] In other words, Dr. Etminan markedly underestimates the degree of confounding between BMI and IIH. Second, Dr. Etminan assumes that no more than 50% of Mirena users who developed IIH in the Rai study were overweight or obese. Given that excess weight has been shown to be present in much higher percentages among patients who developed IIH [12, 29, 31, 32, 73], this assumption cannot be justified. Thus, Table 5 does not adequately correct for the Rai abstract's failure to control for BMI or recent weight gain. In any event, modeling results based on such a small number of events cannot produce reliable results.

D. Dr. Etminan's Bradford Hill Analysis

Dr. Etminan concludes that there is a causal link between Mirena and IIH by misapplying the criteria introduced by Sir Austin Bradford Hill in 1965. [2] At the outset, it bears emphasizing that Bradford Hill envisioned applying his framework only *after* an "association between two variables" was "perfectly clear-cut and beyond what we would care to attribute to the play of chance." For the reasons that I discuss above, such an association between IIH and Mirena has

⁸⁷ "Response to Queries.pdf"

never existed. Therefore, it is inappropriate to even apply Bradford Hill's framework here. Even if it were appropriate to apply Bradford Hill, there is nothing about Bradford Hill that will salvage low quality evidence. In fact, what evidence there is struggles to meet the criteria for a signal, let alone provide evidence of a causal association.

Nonetheless, Dr. Etminan claims that a temporal relationship is present because "all women who experienced IHH or PE [sic] with Mirena mentioned in this litigation, the case report and the two epidemiologic studies [of] IHH and PPE were reported after a woman was exposed to Mirena." Yet among the criteria for inclusion in Dr. Etminan's study was use of "a study drug for at least six months before experiencing an event." [81] Similarly, Rai conducted telephone interviews of those patients with ICD-9 codes for IHH to obtain "birth control histories of the 3 month timeframe *preceding* IHH onset" and found 8 cases of IHH. [72] In other words, the designs of the studies excluded any cases without a temporal relationship. More importantly, this criterion asks more than the simple question of whether use of a drug preceded onset of an event. Rather, it asks whether the passage of time between use of a drug and onset of an event is consistent across cases. As Bayer's signal assessments have shown, and as my search of the FAERS database has confirmed, such consistency is lacking here. The only indisputable observation is that a few plaintiffs and reporters have concluded that a drug taken before an adverse event caused that adverse event.

Dr. Etminan states that the strength and consistency of the association have been shown by the disproportionality analyses from Tables 2 and 3, and the odds ratio reported by Rai. As discussed above, methodological flaws preclude reliance on any of these sources.

Dr. Etminan also asserts that the criterion of a dose-response relationship is irrelevant here because Mirena "comes as a fixed dose." Not so. For one, the amount of LNG released by a Mirena IUD decreases over time. [65] Dr. Etminan could have measured, but did not, whether IHH onset is more common shortly after insertion than toward the end of the five-year period. Moreover, since Mirena, Skyla, Liletta, and the various oral contraceptives that contain LNG are all associated with different mean serum blood concentrations of LNG, Dr. Etminan could have measured, but did not, whether incidence rates of IHH are higher among users of drugs associated with higher mean serum blood levels.

Dr. Etminan states that there is coherence and biological plausibility because contraceptive hormones "increase blood pressure and clotting." His theories are not supported by the literature. ACOG specifically states that Mirena is an "appropriate option in women with hypertension" because progestin has not been shown to significantly impact blood pressure.

[40] Moreover, a recent meta-analysis of eight observational studies calculated an odds ratio for venous thromboembolism (clots in the veins) among Mirena users of 0.61 (0.24 to 1.53). [56]

Dr. Etminan maintains that an analogy exists in that progestins other than LNG have been linked to IHH. Specifically, Dr. Etminan cites two case reports among users of medroxyprogesterone (MPA). [5, 41] In at least one case, the patient was overweight (BMI 28). [41] Regardless, two reports of IHH among MPA users are insufficient to establish an association.

Dr. Etminan acknowledges that specificity does not exist in this case but claims, without explanation, that this criterion “does not apply to this question.” Although diseases can be caused by more than one mechanism, the absence of specificity nonetheless factors against a finding of causation.

Dr. Etminan asserts that there is experimental evidence of an increased risk of IHH with Mirena, based on “case-reports, disproportional analysis and epidemiologic studies.” None of these are sources of experimental evidence.

Finally, Dr. Etminan states that there is dechallenge, which is not a Bradford Hill criterion, because (1) a single woman using MPA allegedly experienced resolution of IHH upon stopping use of the drug; (2) some women allegedly saw resolution of symptoms upon removal of Norplant; and (3) there is one “possible case [of dechallenge] with an intrauterine device similar to Mirena.” However, MPA is an entirely different progestin than LNG. An unspecified number of the Norplant users who experienced resolution of symptoms were treated with lumbar punctures and/or acetazolamide [13], precluding any conclusion about whether Norplant removal or these therapies was the cause of their improvements.[59, 64] And as for the “possible case [of dechallenge] with an intrauterine device similar to Mirena,” the author states that removal of the IUD was recommended by the patient’s doctors, but does not indicate whether the patient followed that advice. [49] The patient was also treated with acetazolamide.

VII. Dr. Frederick Fraunfelder’s Report [79]

Lastly, I briefly address the expert report that Dr. Fraunfelder submitted in connection with this litigation.

Dr. Fraunfelder opines that the cohort analysis performed in the 2015 Etminan article [76] “could suggest a possible class effect” because “the risk of PTC was similar to norgestimate, while norethindrone had a lower risk associated with use.” The Etminan cohort analysis cannot be read as evidence of a class effect. For one, it is incorrect to state that norethindrone was

associated with a lower risk for IIH than Mirena, since the results of the cohort analysis were not statistically significant (OR 0.31 (0.04-2.29)). Moreover, given that every study that has assessed the risk of IIH among combined oral contraceptive users has found no increased risk [5, 6, 7, 8, 11], the fact that the risk of IIH among Mirena users was comparable to the risk among users of two combined oral contraceptives is evidence that Mirena does not cause IIH.

Dr. Fraunfelder also asserts that there are 105 reports in the National Registry of Drug-Induced Ocular Side Effects of “Benign intracranial hypertension, Papilledema, Intracranial pressure increased, and Optic nerve disorder.” Out of those search terms, only “Benign intracranial hypertension” is specific to IIH. Because Dr. Fraunfelder has yet to provide the adverse event reports contained in the registry, I have been unable to determine how many of the reports are specific to IIH or to further analyze them (e.g., to determine how many of the women were overweight or obese). I note, however, that the registry collects adverse event reports from the WHO and FAERS databases, so many of the reports are likely duplicate entries for reports contained elsewhere. Dr. Fraunfelder notes that 5 out of 12 patients for whom dechallenge data was provided saw no resolution of symptoms upon removal of Mirena, which suggests that Mirena was not the cause of their IIH.

Finally, Dr. Fraunfelder recently added Exhibit A to his expert report, which contains the results of a search of the WHO database that is not referenced in his report.⁸⁸ While the search revealed 63 cases of various eye disorders among Mirena users, only 16 cases of IIH were located. Fourteen of those cases came from the United States. Since the WHO database includes adverse events reported to FAERS, only two new cases of IIH were located. The WHO database does not maintain data on weight, precluding an assessment of the number of women who were overweight or obese. No instances of positive dechallenge were located, and time between insertion of Mirena and development of IIH ranged from 5 to 1065 days, with no discernible pattern, making a causal relationship unlikely.

VIII. Principle Conclusions

In addition to the opinions expressed in the above report and based on the evidence presented, I conclude that:

- 1.) There has never been a confirmed safety signal related to IIH among Mirena users;

⁸⁸ “Fraunfelder-A(1) - WHO Data.pdf”; “Fraunfelder-A(2) - 5.30.2013 WHO Data SS.xlsx”

- 2.) Bayer's extensive pharmacovigilance efforts have carefully assessed clinical trial safety data, spontaneous adverse event reports, literature case reports, and published literature and have properly concluded that there is no reasonable evidence of an association between Mirena and IIH;
- 3.) The evidence for an association between Norplant and IIH is lacking, but in any case the Norplant warning is not an appropriate basis to warn about IIH in the Mirena labeling;
- 4.) Disproportionality studies do not show a statistically significant relationship between Mirena and IIH, but in any case are only evidence of a signal, not evidence of a causal association; and
- 5.) The Mirena label has always been adequate with respect to IIH. There has never been reasonable evidence of an association, causal or otherwise, between Mirena and IIH.

I reserve the right to supplement this report as new facts come to light, as the state of the science may change, or in response to the reports or testimony of other experts in this case.


David William Feigal, Jr. MD MPH

March 24, 2016

IX. References Cited

1. Dandy, W.E., *Intracranial Pressure without Brain Tumor: Diagnosis and Treatment*. Ann Surg, 1937. **106**(4): 492-513.
2. Hill, A.B., *The Environment and Disease: Association or Causation?* Proc R Soc Med, 1965. **58**: 295-300.
3. Department of Health and Human Services, *Proposed Rule: Labeling for Prescription Drugs used in Man*. Federal Register, 1975. **40**(67): 15392 to 15399.
4. Department of Health and Human Services and Food and Drug Administration, *Labeling and Prescription Drug Advertising; Content and format for labeling human prescription drugs*. June 26. Federal Register, 1979. **44** (124): pp. 37434 to 37467.
5. Bahemuka, M., *Benign intracranial hypertension associated with the use of depo-provera (depot medroxyprogesterone): a case report*. East Afr Med J, 1981. **58**(2): 140-1.
6. Digre, K.B., M.W. Varner and J.J. Corbett, *Pseudotumor cerebri and pregnancy*. Neurology, 1984. **34**(6): 721-9.
7. Durcan, F.J., J.J. Corbett and M. Wall, *The incidence of pseudotumor cerebri. Population studies in Iowa and Louisiana*. Arch Neurol, 1988. **45**(8): 875-7.
8. Ireland, B., J.J. Corbett and R.B. Wallace, *The search for causes of idiopathic intracranial hypertension. A preliminary case-control study*. Arch Neurol, 1990. **47**(3): 315-20.
9. Giuseffi, V., et al., *Symptoms and disease associations in idiopathic intracranial hypertension (pseudotumor cerebri): a case-control study*. Neurology, 1991. **41**(2 (Pt 1)): 239-44.
10. Wall, M. and D. George, *Idiopathic intracranial hypertension. A prospective study of 50 patients*. Brain, 1991. **114** (Pt 1A): 155-80.
11. Sunku, A.J., A.E. O'Duffy and J.W. Swanson, *Benign Intracranial Hypertension Associated with Levonorgestrel Implants. P2 18. Program and Abstracts*,. American Neurological Association, 1993. **34**: 299.
12. Radhakrishnan, K., et al., *Epidemiology of idiopathic intracranial hypertension: a prospective and case-control study*. J Neurol Sci, 1993. **116**(1): 18-28.
13. Wysowski, D.K. and L. Green, *Serious adverse events in Norplant users reported to the Food and Drug Administration's MedWatch Spontaneous Reporting System*. Obstet Gynecol, 1995. **85**(4): 538-42.

14. Alder, J.B., F.T. Fraunfelder and R. Edwards, *Levonorgestrel implants and intracranial hypertension*. N Engl J Med, 1995. **332**(25): 1720-1.
15. Weber, M.E., H.E. Rofsky and M.W. Dietch, *Levonorgestrel implants and intracranial hypertension: Spokespersons for Wyeth-Ayerst Laboratories reply*. NEJM, 1995. **332**(25): 1721.
16. Sivin, I., *Serious adverse events in Norplant users reported to the Food and Drug Administration's MedWatch Spontaneous Reporting System*. Obstet Gynecol, 1995. **86**(2): 318-20.
17. Wyeth-Ayerst Laboratories, *Physician's Desk Reference. Norplant Systems (levonorgestrel Implants) Prescribing Information Labeling*. 1996: Pages 2759 to 2764.
18. Food and Drug Administration, *21 CFR Part 202.1 Prescription Drug Advertising*, 1996.
19. Thiery, M., *Pioneers of the intrauterine device*. Eur J Contracept Reprod Health Care, 1997. **2**(1): 15-23.
20. Insitute of Medicine, *Committee on Contraceptive Research and Development, Division of Health Sciences Policy. Contraceptive Research, Introduction, and Use: Lessons From Norplant*. 1998. 128 pages.
21. Berlex Laboratories Inc., *NDA 21-225. Mirena (LNG-Releasing Intrauterine System). Integrated Summary of Efficacy, January 31, 2000*. Bates MIR_INDNDA_00127646 at MIR_INDNDA_00128214 to 8462.
22. Berlex Laboratories Inc., *NDA 21-225. Mirena (LNG-Releasing Intrauterine System). Integrated Summary of Safety, January 31, 2000*. Bates MIR_INDNDA_00127646 at MIR_INDNDA_00129476-00127646, MIR_INDNDA_00130432-00133348, and MIR_INDNDA_00133349-00135205.
23. Jo-Ann Ruane; Berlex Laboratories, *Belrex Laboratories Inc. Re: NDA 21-225 Mirena (levonorgestrel-releasing intrauterine system), General Correspondence: Desk Copies of NDA Volume 2.1 and 2.2, Draft Prescribing Information labeling. February 18, 2000*. Bates MIR_INDNDA_00010441 to 10516.
24. Furlong, L., *Division of Reproductive and Urological Drug Products. CDER. FDA. NDA 21-255 Mirena. Medical Review. December 5, 2000*. Bates MIR_JR_00855811 to 5860.
25. Food and Drug Administration, *Requirements on Content and Format of Labeling for Human Prescription Drugs and Biologics; Requirements for Prescription Drug Product Labels. Proposed rule. December 22. Federal Register,, 2000. 65*(247): 81082 to 81131.
26. DuMouchel, W. and D. Pregibon, *Empirical bayes screening for multi-item associations. Proceedings of the conference on knowledge discovery and data. Aug 26-29, 2001. ACM Press. p 67- 76*.

27. Evans, S.J., P.C. Waller and S. Davis, *Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports*. *Pharmacoepidemiol Drug Saf*, 2001. **10**(6): 483-6.
28. Szarfman, A., S.G. Machado and R.T. O'Neill, *Use of screening algorithms and computer systems to efficiently signal higher-than-expected combinations of drugs and events in the US FDA's spontaneous reports database*. *Drug Saf*, 2002. **25**(6): 381-92.
29. Galvin, J.A. and G.P. Van Stavern, *Clinical characterization of idiopathic intracranial hypertension at the Detroit Medical Center*. *J Neurol Sci*, 2004. **223**(2): 157-60.
30. Szarfman, A., J.M. Tonning and P.M. Doraiswamy, *Pharmacovigilance in the 21st century: new systematic tools for an old problem*. *Pharmacotherapy*, 2004. **24**(9): 1099-104.
31. Kesler, A., et al., *Idiopathic intracranial hypertension: risk of recurrences*. *Neurology*, 2004. **63**(9): 1737-9.
32. Glueck, C.J., et al., *Idiopathic intracranial hypertension, polycystic-ovary syndrome, and thrombophilia*. *J Lab Clin Med*, 2005. **145**(2): 72-82.
33. Food and Drug Administration, *Guidance for Industry: Good pharmacovigilance practices and phamacoepidemiologic assessment*. March, 2005. 23 pages. Available from: <http://www.fda.gov/downloads/RegulatoryInformation/Guidances/UCM126834.pdf>.
34. Almenoff, J., et al., *Perspectives on the use of data mining in pharmaco-vigilance*. *Drug Saf*, 2005. **28**(11): 981-1007.
35. Hazell, L. and S.A. Shakir, *Under-reporting of adverse drug reactions : a systematic review*. *Drug Saf*, 2006. **29**(5): 385-96.
36. Levine, J.G., J.M. Tonning and A. Szarfman, *Reply: The evaluation of data mining methods for the simultaneous and systematic detection of safety signals in large databases: lessons to be learned*. *Br J Clin Pharmacol*, 2006. **61**(1): 105-13; author reply 115-7.
37. Food and Drug Administration, *Final Rule. 21 CFR Parts 201, 314, and 601. Requirements on Content and Format of Labeling for Human Prescription Drug and Biological Products*. January 24. *Federal Register*, 2006. **71**(15): pp. 3922 to 3997.
38. ACOG Committee on Practice Bulletins--Gynecology, *ACOG Practice Bulletin. Clinical management guidelines for obstetrician-gynecologists, Number 72, May 2006: Vaginitis*. *Obstet Gynecol*, 2006. **107**(5): 1195-1206.
39. Ball, A.K. and C.E. Clarke, *Idiopathic intracranial hypertension*. *Lancet Neurol*, 2006. **5**(5): 433-42.
40. ACOG Committee on Practice Bulletins-Gynecology, *ACOG practice bulletin. No. 73: Use of hormonal contraception in women with coexisting medical conditions*. *Obstet Gynecol*, 2006. **107**(6): 1453-72.

41. Chan, J.W., *Idiopathic intracranial hypertension associated with depot medroxyprogesterone*. Eye (Lond), 2006. **20**(12): 1396-7.
42. Daniels, A.B., et al., *Profiles of obesity, weight gain, and quality of life in idiopathic intracranial hypertension (pseudotumor cerebri)*. Am J Ophthalmol, 2007. **143**(4): 635-41.
43. Van Belle, G., *Statistical rules of thumb*. 2nd ed. Wiley series in probability and statistics. 2008, Hoboken, N.J.: Wiley. xxi, 272 p.
44. Food and Drug Administration, *Supplemental Applications Proposing Labeling Changes for Approved Drugs, Biologics, and Medical Devices, A proposed Rule*. January 16. Federal Register, 2008. **73** (2848): 2848 -2854.
45. McAdams, M., J. Staffa and G. Dal Pan, *Estimating the extent of reporting to FDA: a case study of statin-associated rhabdomyolysis*. Pharmacoepidemiol Drug Saf, 2008. **17**(3): pp. 229-39.
46. Rangel-Castilla, L., S. Gopinath and C.S. Robertson, *Management of intracranial hypertension*. Neurol Clin, 2008. **26**(2): 521-41, x.
47. Ludbrook, J. and M.J. Lew, *Estimating the risk of rare complications: is the 'rule of three' good enough?* ANZ J Surg, 2009. **79**(7-8): 565-70.
48. American College of Obstetricians and Gynecologists, *Committee on Gynecologic Practice: Long-Acting Reversible Contraception Working Group. ACOG Committee Opinion no. 450: Increasing use of contraceptive implants and intrauterine devices to reduce unintended pregnancy*. Obstet Gynecol, 2009. **114**(6): 1434-8.
49. Martinez, H.M., *Atypical Pseudotumour Cerebri*. . Abstracts of the 2010 Meeting of the International Neuro-Ophthalmology Society, Lyon, France., 2010: VIII-P 7.
50. World Health Organization. Reproductive Health and Research., *Medical eligibility criteria for contraceptive use*. 4th ed. 2010, Geneva: Department of Reproductive Health and Research, World Health Organization. 125 pages.
51. Centers for Disease, C. and Prevention, *Update to CDC's U.S. Medical Eligibility Criteria for Contraceptive Use, 2010*. MMWR Morb Mortal Wkly Rep, 2010. **59**(RR-4): 1-86.
52. Deangelis, L.M., *Tumors of the Central Nervous System and Intracranial Hypertension and Hypotension*, in *Cecil Textbook of Medicine*, L. Goldman and A.I. Schafer, Editors. 2011.
53. Ko, M.W., et al., *Weight gain and recurrence in idiopathic intracranial hypertension: a case-control study*. Neurology, 2011. **76**(18): 1564-7.
54. American College of Obstetricians and Gynecologists, *ACOG Practice Bulletin No. 121: Long-acting reversible contraception: Implants and intrauterine devices*. Obstet Gynecol, 2011. **118**(1): 184-96.
55. Raoof, N., et al., *The incidence and prevalence of idiopathic intracranial hypertension in Sheffield, UK*. Eur J Neurol, 2011. **18**(10): 1266-8.

56. Mantha, S., et al., *Assessing the risk of venous thromboembolic events in women taking progestin-only contraception: a meta-analysis*. BMJ, 2012. **345**: e4944.
57. Shaw, G.Y. and S.K. Million, *Benign intracranial hypertension: a diagnostic dilemma*. Case Rep Otolaryngol, 2012. **2012**: 814696.
58. Food and Drug Administration, *Adverse Event Reporting System (AERS) Updated April 27, 2012*. Available from: <http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Surveillance/AdverseDrugEffects/default.htm>.
59. Biousse, V., B.B. Bruce and N.J. Newman, *Update on the pathophysiology and management of idiopathic intracranial hypertension*. J Neurol Neurosurg Psychiatry, 2012. **83**(5): 488-94.
60. Yeung, E.H., et al., *Adiposity and sex hormones across the menstrual cycle: the BioCycle Study*. Int J Obes (Lond), 2013. **37**(2): 237-43.
61. Marnach, M.L., M.E. Long and P.M. Casey, *Current issues in contraception*. Mayo Clin Proc, 2013. **88**(3): 295-9.
62. Speidel, J.J., et al., *Pregnancy: not a disease but still a health risk*. Contraception, 2013. **88**(4): 481-4.
63. Vickery, Z., et al., *Weight change at 12 months in users of three progestin-only contraceptive methods*. Contraception, 2013. **88**(4): 503-8.
64. Nordic Idiopathic Intracranial Hypertension Study Group Writing Committee, et al., *Effect of acetazolamide on visual function in patients with idiopathic intracranial hypertension and mild visual loss: the idiopathic intracranial hypertension treatment trial*. JAMA, 2014. **311**(16): 1641-51.
65. Bayer Health Care, *Mirena, Prescribing Information Labeling, 2014*, 2014. 27 pages. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021225s033lbl.pdf.
66. Koerner, J.C. and D.I. Friedman, *Inpatient and emergency service utilization in patients with idiopathic intracranial hypertension*. J Neuroophthalmol, 2014. **34**(3): 229-32.
67. American Association of Pediatricians, *Committee on Adolescence, Policy Statement - Contraception for Adolescents*. Pediatrics, 2014. **134**(4): e1244-56.
68. Harpaz, R., et al., *A time-indexed reference standard of adverse drug reactions*. Sci Data, 2014. **1**: 140043.
69. Center for Disease Control, *Reproductive Health: Pregnancy Mortality Surveillance System, 2014*. Available from: <http://www.cdc.gov/reproductivehealth/MaternalInfantHealth/PMSS.html>.
70. Barnum, A.M. and J. Jones, *National Center for Health Statistics. Data Brief No. 188. Trends in Long-acting Reversible Contraception Use Among U.S. Women Aged 15–44, 2015*.

71. Lee, G.L. and M. Wall, *Idiopathic Intracranial Hypertension (Pseudotumor Cerebri): Clinical Features and Diagnosis*. . UpToDate, 2015.
72. Rai, R., et al., *The relationship between the levonorgestrel-releasing intrauterine system and idiopathic intracranial hypertension*. Annual Meeting of the Association for Research in Vision and Ophthalmology, Program Number 2228, 2015.
73. Valenzuela, R.M., *Exploratory study of the relationship between the levonorgestrel-releasing intrauterine system and idiopathic intracranial hypertension*. North American Neuro-Ophthalmology Society 41st Annual Meeting Abstracts, 2015. **Poster 102**.
74. Center for Disease Control, *Fact Sheet: Contraception*, 2015. Available from: <http://www.cdc.gov/nchs/fastats/contraceptive.htm>.
75. Organization, W.H., *19th WHO Model List of Essential Medicines*, 2015. Available from: http://www.who.int/medicines/publications/essentialmedicines/EML2015_8-May-15.pdf.
76. Etminan, M., H. Luo and P. Gustafson, *Risk of intracranial hypertension with intrauterine levonorgestrel*. Ther Adv Drug Saf, 2015. 6(3): 110-113.
77. Duggirala, H.J., et al., *Use of data mining at the food and drug administration*. J Am Med Inform Assoc, 2015.
78. Etminan, M., *Expert Report*. January 22, 2016. 72 pages.
79. Frauenfelder, F.W., *Expert Report*. January 22, 2016. 40 pages.
80. Ross, D., *Expert Report*. January 22, 2016. 112 pages.
81. Etminan, M., *Risk of intracranial hypertension with intrauterine levonorgestrel: reply*. Ther Adv Drug Saf, 2016. 7(1): 25-6.
82. Friedman, D., *Risk of intracranial hypertension with intrauterine levonorgestrel*. Ther Adv Drug Saf, 2016. 7(1): 23-4.

EXHIBIT A

Curriculum Vitae

David W. Feigal, Jr., M.D., M.P.H.

11806 Barranca Road
Santa Rosa Valley, CA 93012
+1 (301) 613 2779 (Mobile)
Feigal david@msn.com

EDUCATION

Attended	Institution & Location	Degree Granted	Degree Conferred, Title or Status	Subject
1967-71	University of Minnesota Minneapolis, MN	1971	B.A. summa cum laude	Psychology
1971-1976	Stanford University Palo Alto, CA	1976	M.D.	Medicine
1976-1979	University of California, Davis Sacramento, CA		Intern and Resident	Internal Medicine
1982-1983	University of California, Berkeley, CA	1983	M.P.H.	Epidemiology & Biostatistics
1982-1984	University of California, San Francisco, CA		A.W. Mellon Scholar in Clinical Epidemiology	Epidemiology

LICENSES, CERTIFICATIONS:

1977 -	Medical License: California (# G34473)
1979	Certified, American Board of Internal Medicine (# 71092)

EMPLOYMENT: PRINCIPAL POSITIONS HELD

1979-80	University of California, Davis	Chief Resident, Medicine
1980-82		Assistant Professor, in Residence of Medicine
1984-85	University of California, San Francisco	Adjunct Assistant Professor of Epidemiology and International Health with joint appointment in Medicine

1986-89		Assistant Professor, in Residence of Medicine with joint appointment in Epidemiology and Biostatistics
1989-91	University of California, San Diego	Associate Clinical Professor of Medicine
1992-96	Food and Drug Administration, Center for Drug Evaluation and Research (CDER)	Director, Division of Anti-Viral Drug Products
1996-97		Acting-Director, Division of Anti-Infective Drug Products
1995-97		Director, Office of Drug Evaluation-IV
1997-99	Food and Drug Administration, Center for Biologics Evaluation and Research (CBER)	Medical Deputy Center Director
1999-2004	Food and Drug Administration, Center for Devices and Radiological Health (CDRH)	Center Director
2004 -06	NDA Partners L.L.C	Partner
2006 - 08	Élan Pharmaceuticals, Inc.	Senior Vice President of Global Regulatory Affairs, Global Safety Surveillance and Biostatistics
2008 - 10	Amgen, Inc.	Vice President of Global Regulatory Affairs
2010 -	NDA Partners L.L.C	Partner

ANCILLARY POSITIONS HELD CONCURRENTLY:

1980-82	Univ. of California, Davis Department of Medicine	Residency Training Program Coordinator
1984-88	Univ. of California, San Francisco	Associate Director: AW Mellon Program in Clinical Epidemiology
1984-89		Faculty, Institute for Health Policy
1984-89		Adjunct Faculty, Clinical Pharmacology
1986-89		Director, Data Center, AIDS Clinical Research Center
1986-89		Joint Appointment in School of Dentistry
1985-89	San Francisco General Hospital	Chair of Department of Quality Assurance and Risk Management
2004 - 07	Arizona State University	Research Professor, Arizona Biodesign Institute

2005 -		Adjunct Professor, Sandra Day O'Connor School of Law
2005 - 07	University of California, San Diego	Von Liebing Fellow in Entrepreneurship, School of Engineering
2011 - 12	Topica Pharmaceuticals	Chief Medical Officer
2012 -	ExsoMed	Chief Medical Officer
2013 -14	CytoDyn Inc.	Chief Medical Officer

HONORS AND AWARDS:

1969	Phi Beta Kappa
1981	Junior Faculty Teaching Award (selected by the medical school senior class, UC Davis)
1986	'Outstanding Graduate Student Instructor' (selected by School of Public Health, UC Berkeley)
1997	FDA Award of Merit: "For providing outstanding leadership and management of Office of Review Management resources resulting in rapid delivery of safe, effective new drug products to the public."
1997	CDER Excellence in Communication Award: "For exceptional team efforts in improving communications with Industry and within FDA to facilitate the review and development of safe and effective drugs in the Office of Drug Evaluation IV".
1998	FDA Commissioner's Special Citation: "For design and implementation of the Blood Action Plan to strengthen the safety of the nation's blood supply."
1998	FDA Award of Merit: "For advancing the field of AIDS by leading the collaborative evaluation of HIV-RNA as an endpoint in clinical trials for anti-HIV drugs."
1998	FDA Commendable Service Award: "For exceptional efforts by the Guidance for Industry – Evaluating Clinical Studies of Antimicrobial Drug Products Team leading to consistency in the evaluation of anti-infective drugs."
1999	FDA Group Recognition Award: "For developing guidance for the Fast Track provision of FDAMA to speed availability of products to consumers suffering from serious and life-threatening conditions."
2002	Presidential Executive Rank Award : "For Sustained Outstanding Performance."
2005	Health and Human Service Secretary's Award for Distinguished Service for the Tissue Action Plan
2011	Regulatory Affairs Professional Society: Honorary Fellow (the first such award)

UNIVERSITY SERVICE:

UC DAVIS CAMPUS WIDE:

1980-82 Human Subjects Committee

UC DAVIS SCHOOL OF MEDICINE:

1980-82 Educational Advisory Committee

1982 Physicians Advisory Committee to the Hospital Information System

UC DAVIS DEPARTMENT OF MEDICINE:

1979-82 Third year Medicine Clerkship Committee

1979-82 Intern and Resident Selection Committee: (Chair 1980-1982)

1981-82 Residency Review Committee: (Chair)

UC SAN FRANCISCO SYSTEM-WIDE:

1985 University-wide Task Force on AIDS: Study Section

UC SAN FRANCISCO SAN FRANCISCO GENERAL HOSPITAL CAMPUS-WIDE:

1985-89 Quality Assurance Committee, (Chair)

1985-89 Utilization Review Committee

1985-89 Self-Accreditation Committee, (Co-Chair)

1985 Product Evaluation Committee

1985-89 Joint Conference Committee

1985-86 Medical Information Steering Committee

1985-86 Ad Hoc Committee on Open Heart Surgery at SFGH

1987 Ad Hoc Committee on Interdepartmental Relationships and Privileges

1988 Ad Hoc Committee on HIV Testing

1989 HIV Policy Committee

UC SAN FRANCISCO INSTITUTE FOR HEALTH POLICY

1985-9 Publications Advisory Committee

UC SAN FRANCISCO, DEPARTMENT OF MEDICINE

1985-6 SFGH Primary Care Internship Selection Committee

Arizona State University, Sandra Day O'Connor School of Law

2008 - Advisory Board member, Center for Law, Science & Innovation

TEACHING ACTIVITIES: UC Davis

Academic Years	Course	Nature of Contribution
1978-82	Physical Diagnosis	Lecture: The Problem Oriented Record; Preceptor
1979-82	Gastroenterology: Year II Medical student Core Curriculum	Lecture and Videotape (patient interview) Stress and the GI Tract
1979-82	Medicine Wards	Ward Attending
1979-82	Third Year Medicine Clerkship	Prepared and graded all written examinations
1979-82	General Medicine Clinic	Clinic Attending
1980-82	General Medicine Consult	Consult Attending
1980-82	Acting Internship in Medicine	Course Chair
1980-82	Behavioral Medicine Clinic	Clinic Attending

Lectures at UC Davis

- 1980 Medical Grand Rounds, "Stress and the GI Tract"
Family Practice Grand Rounds, "Dementia and Delirium"
Medical M&M Conference, "Fever and Abdominal Pain in an Elderly Woman"
Continuing Medical Education Conference on Preoperative Evaluation, "Anesthetic Risk"
- 1981 Second Annual Conference on Preoperative Evaluation, "Use of Blood Products"
Internal Medicine Noon Conferences, "Dementia and Delirium"
Medical M&M Conference, "Sudden Death in 27 Year Old Black Female with a Valve Replacement"
Biostatistics Review Course for faculty and fellows (12 workshop style lectures),
- 1982 Ambulatory Case Conference, "Stress & the GI Tract"
Medical M&M Conference, "Dementia in a 54 year old Woman"
- 1983 Third Annual Conference on Preoperative Evaluation, "Preoperative Assessment of the Elderly Patient"

TEACHING ACTIVITIES: UC San Francisco / UC Berkeley

Academic Years	Course	Nature of Contribution
1982-89	Ambulatory Care Clerkship	Preceptor
1982-85	A.W. Mellon Summer Student Research Design Workshop	Lecturer; Preceptor
1982-89	Research design Workshop and Advanced Epidemiology	Lecturer; Faculty Preceptor

	Seminar	
1982-89	General Medicine Clinic	Clinic Attending
1983-86	Computer Workshop: Data skills for new faculty and fellows	Course Director (5 week course)
1984-89	Medicine Wards	Ward Attending
1984-89	General Medicine Consult	Consult Attending
1984-89	Epidemiology: 1 st year medical student core curriculum	Section Leader
1985-86	UC Berkeley BEHS 160: Introduction to Public health	Faculty in charge of two 10 lecture modular sections on epidemiological methods
1985-1987	UC SF IDS 140.22: Responsibilities of Medical Practice	Lectures on Hospital Quality Assurance Programs
1987-89	Clinical Pharmacology and Therapeutics Elective	Lectures on Pharmacoepidemiology
1987	UC Berkeley: Introduction to Epidemiology	Lectures on Clinical Epidemiology
1987-89	AIDS Epidemiology Seminar	Weekly Seminar organizer

Lectures at UCSF

1984	Primary Care Grand Rounds, "Isolated Systolic Hypertension"
	Family Practice Grand Rounds, "Elevated Cholesterol and your Heart: What have we learned from recent clinical trials?"
1985	Epidemiology Grand Rounds, "Pharmacoepidemiology: How we find adverse drug reactions"
	Conference on Practical Advances in Medicine, "Computers: How to retrieve medical information in a practical way"
	Clinical Pharmacology Research Seminar, "Pharmacoepidemiology", San Francisco, CA
	Occupational Medicine Grand Rounds, "Methodology to Detect Rare Events", San Francisco, CA
	Primary Care Grand Rounds, "How are adverse drug reactions detected?"
	Primary Care Grand Rounds, "Mild Hypertension: the case for nonpharmacologic treatment"
	Clinical Pharmacology: Topics in Therapeutics, "Pharmacoepidemiology: Postmarketing drug surveillance"
	Family Practice Grand Rounds, "Mild Hypertension: the case for nonpharmacologic treatment"
1986	Medicine Noon Conference, "How to read the medical literature; Part I: observational studies; Part II: experimental studies"
	Departments of Medicine and Anesthesia Conference: Preoperative Evaluation of the Surgical Patient, "Surgery and the Elderly Patient"
	SFGH Medical Grand Rounds, "Legal Aspects of Quality Medical Care"

- Comprehensive Care of the AIDS Patient: A Workshop, "Integrating Research into the Clinical Setting"
- 1987 Conference: Legal Aspects of Medical Practice, "The Epidemiology of Malpractice"
- Departments of Medicine and Anesthesia Conference: Preoperative Evaluation of the Surgical Patient, "Surgery and the Elderly Patient"
- Occupation Health Grand Rounds, "Application of Statistical Methods to Problems in Occupational Health"
- Comprehensive Care of the AIDS Patient: A Workshop, "Integrating Research into the Clinical Setting"
- San Francisco Department of Public Health: National AIDS Conference, "Care: Acute Inpatient Hospital Quality Assurance Programs"
- APEX Program for AIDS Education, "AIDS Drug Protocols"
- Conference, "Hospital Quality Assurance Programs"
- Veteran's Administration Conference on Geriatric Care: Controversies in Geriatric Care, "Debate: Problems in the Treatment of Isolated Systolic Hypertension"
- 1988 National AIDS Conference: San Francisco Department of Public Health, "AIDS Drug Protocols and The Testing and Approval of New Drugs"
- Conference, "Hospital Quality Assurance, Utilization Review, and Risk Management Programs"
- CME Course: Comprehensive Care of the AIDS Patient, "AIDS: Cost of Care"

TEACHING ACTIVITIES: UC San Diego

Academic Years	Course	Nature of Contribution
1990-91	Logistic Regression Workshop	Course lecturer (10 week workshop)
1990-91	General Internal Medicine / Geriatrics Journal Club	Coordinator
1990-91	General Medicine Clinic	Clinic Attending
1990-91	Medicine Wards	Ward Attending
1990-91	General Medicine Consult	Consult Attending

Lectures at UC San Diego

- 1989 Physicians for AIDS Care: Update on the prevention and management of PCP, "PCP Prophylaxis", San Diego, CA
- University of California, San Diego Infectious Disease Conference, "Oral Manifestations of HIV Infection", San Diego, CA
- 1990 Medical Grand Rounds, "Prophylaxis and treatment of Pneumocystis carinii with aerosolized pentamidine", San Diego, CA
- Annual Conference on the Evaluation of the Preoperative Patient, "The Political Economy of Surgery"

TEACHING ACTIVITIES: Arizona State University

Academic Years	Course	Nature of Contribution
2005 -	Food and Drug Law	Course Director (15 week, 2 or 3 Credit, Fall Semester open to Law School students and graduate level students in the School of Engineering and Life Sciences).
2011 -2012	U.S. Consumer Protection Agencies	Instructor (15 week 3 Credit, Undergraduate course)

PREDOCTORAL STUDENTS SUPERVISED:

1983	Chris Cox	(Medical Student, UCSF)
1985	Tamara Barr, R.N.	(MPH Candidate, UC Berkeley)
1986	Constance Rainer	(Medical Student, University of Minnesota)
1986	David Kirn	(Medical Student, UCSF)
1987	Tom Tieri	(Medical Student, UCSF)
1988	Deborah Kato	(Medical Student, Cornell)
1988	Paul Cusick	(Medical Student, University of Massachusetts)
1989	Eckart V. Hirschhausen	(Medical Student, University of Heidelberg, Germany)

POSTDOCTORAL FELLOWS PRECEPTED:

1983-85	Susan Cummins, M.D.	(Epidemiology Fellow)
1984-85	Richard Glaser, M.D.	(Epidemiology Fellow)
1987-89	Robin Edison, M.D.	(Preventive Medicine Resident)
1989	David Glidden	(University of Washington, Biostatistics Ph.D. Student)
1991	Fernando Rubenstein	(Primary Care Fellow)
2005-6	Christine Meis McAuliffe	(Law School Doctoral Dissertation Committee)

GOVERNMENT SERVICE:

WORLD HEALTH ORGANIZATION:

Global Program on AIDS:

- | | |
|---------|--|
| 1993-96 | Steering Committee on Drug Clinical Trials: Member |
| 1993 | Second Meeting on the Development of Drugs and Vaccines for AIDS:
Speaker and FDA representative: Harmonization of Regulatory
Requirements for AIDS Drugs, "Accelerated Approval", Geneva,
Switzerland |
| 1993 | Workshop on the Development of Agents to Prevent Heterosexual transmission
of HIV: "Topical Microbicides, "Regulatory Requirements for Vaginal
Microbicides to Prevent HIV Infection", Geneva, Switzerland |
| 1993-97 | International Working Group on Vaginal Microbicides: chair and founding
member |
| 1994 | Global program on AIDS Consensus Panel on Prevention of perinatal
transmission of HIV: Speaker and panelist |
| 1994 | Workshop on Harmonization of Regulatory Requirements for AIDS Drug
Development: Invited participant |

INTERNATIONAL CONFERENCE ON HARMONIZATION

- | | |
|----------|---|
| 1995-96 | Efficacy Lead: Center for Drug Evaluation and research, FDA |
| 1995 | 3 rd ICH Delegate

3 rd International Conference on Harmonization, "General Considerations for
Clinical Trials", Yokohama, Japan, 1995 |
| 1995-96 | CDER Topic Lead E8: "General Considerations" |
| 1997- 99 | CBER Topic Lead: M4 "Common Technical Document, Efficacy" |
| 1998 | ICH Update, "The ICH Common Technical Document", Bethesda, MD |

GLOBAL HARMONIZATION TASK FORCE

- | | |
|-----------|---|
| 2000 – 04 | GHTF Steering Committee Member: Lead US Regulatory Delegation |
| 2000 | 8 th Global Harmonization Task Force Meeting, "DEHP Plasticizers in Medical
Devices", Quebec, Canada, 2000 |
| 2002 | 9 th Global Harmonization Task Force Meeting, "Total Product Life Cycle:
Postmarket Surveillance and Vigilance", and "New and Emerging
Technologies: Consumer Protection that Fosters Innovation", Singapore, 2002 |

EUROPEAN MEDICINES EVALUATION AGENCY (EMA)

1996 Invited Presentation: Surrogate markers, combination nucleosides and protease inhibitors

NATIONAL ACADEMIES OF SCIENCE

Institute of Medicine

Combination HIV Therapies: Considerations for Policy and Research, "Preclinical Data Requirements", Washington, DC, 1992
Changing Demographics of the AIDS Epidemic: Implications for Clinical Research, "Enhancing Diversity in Drug Development, An FDA Perspective", Washington, DC, 1993
IOM Panel to Review FIAU, "The FIAU Experience", Washington, DC, 1994
Roundtable for the Development of Drugs and Vaccines Against AIDS: Collaboration between Government and Industry, "Challenges and Opportunities for HIV Drug and Vaccine Development", Washington, DC, 1994
IOM Conference on Therapeutics of Children, "Special Considerations for Evaluating Medical Devices in Infants and Children", Washington, DC, 1999
IOM Workshop: Innovation and Invention in Medical Devices, "Innovation and Invention in Medical Devices", Washington, DC, 2000
New Approaches to Early Detection and Diagnosis of Breast Cancer: Accelerating the Flow from Concept to Clinic, "Challenges in assessing the safety and efficacy of cancer detection devices", Washington, DC, 2003
IOM Committee on Post-marketing Surveillance of Pediatric Medical Devices." Device Post-Market Surveillance in Children." Consultant to the Committee 2004 -2005
IOM Workshop on Modifications to the 510(k) Clearance Process. Invited Paper. 2010

National Academy of Engineering

Bioengineering, Materials (BEMA) Roundtable, "FDA Perspective on Medical Device Development", Washington, DC, 2000
National Academy's Biomedical Materials Roundtable Meeting, "Developing Biomaterials: An FDA Perspective", Washington, DC, 2002
BEMA – "Science-Based Assessment: Accelerating Product Development of Combination Medical Devices", Washington, DC, 2003
AIMBE Symposium: Imaging and Bioengineering, Partners for the Future, "Public Policy Issues Related to Imaging", Washington, D.C. 2004
BEMA – "Examining the Regulatory Path for Emerging Biomaterials Technologies", Woods Hole, MA, 2004

National Research Council, Board on Mathematical Sciences

National Research Council, Board on Mathematical Sciences: Science and Technology Symposium, "Surrogate Markers", Washington, DC, 1992

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES

Secretary's Advisory Committees

- 1996 – 98 HHS Panel on Clinical Practices for Treatment of HIV Infection
- 2000 – 02 Secretary's Advisory Committee on Genetic Testing,
Presentation: "FDA's Role in the Transition of In Vitro Diagnostic Devices
from Research to Routine Testing", Washington, DC, 2000
- 2001 Women's Health Dialogue, Washington, DC, 2001
- 2002 Secretary's Advisory Committee on Regulatory Reform, "FDA and CMS
Collaboration", Minneapolis, MN
- 2003 – 04 Secretary's Advisory Committee on Genetics Health and Society, FDA Liaison
Representative
Presentation: "FDA's Regulation of Genetic Tests, Washington, DC, 2003

HHS Workshops

- National AIDS Task Force on Drug Development, "Surrogate Markers: FDA proposal for
and integrated approach", Washington, DC, 1994
- Public Health Service Disability Awareness Conference, "Opening Remarks", Rockville,
MD, 1996
- Office of AIDS Policy Workshop, "Clinical Practice of HIV Treatment", Washington, DC,
1997
- HHS Consumer Roundtable, "Medical Devices and Radiological Health", Washington, DC,
2000
- White House Conference on Alternative Medicine, "Medical Devices and Alternative
Medicine", Washington, DC, 2000
- CMS – Medicare Medical Directors Workgroup, "New Technology in Medicine",
Baltimore, MD, 2001

NATIONAL INSTITUTES OF HEALTH

- 1992 – 96 AIDS Clinical Drug Development Committee
- 1992 – 97 Faculty: IDSA AIDS Fellowship Program
- 1992 – 96 Executive Committee: AIDS Clinical Trials Group

PHS Consensus Conferences

- US Public Health Service Consensus Panel on Prophylaxis against PC in HIV infected
Patients, "Evaluation of the trimethoprim-sulfamethoxazole", Bethesda, MD, 1987
- Steroid Use in Pneumocystis carinii pneumonia, "Acute mortality of PCP pneumonia: A
case series of the first 500 cases at San Francisco General Hospital 1981 – 1986", San
Diego, CA, 1990
- Consensus Conference on Steroids and PCP, "Predictors of early mortality upon hospital
admission for PCP", San Diego, CA, 1990
- NIH Workshop on the Placebo, "Use of placebos in clinical trials to test procedural
interventions", Bethesda, MD, 2000

NIH Workshops and Conferences

- NCI National Cancer Institute: Third National Forum on Biomedical Imaging in Oncology, "Cancer Imaging Products: Drug, Biologicals, and Devices", Arlington, VA, 2002
- Fourth National Forum on Biomedical Imaging in Oncology, "Regulatory Update", Bethesda, MD, 2003
- Fifth National Forum on Biomedical Imaging in Oncology, "Current Issues in Imaging Device Regulation", Bethesda, MD, 2004
- BIROW II: Biomedical Imaging Research Opportunities II, "Developing New Imaging Technology: An FDA Perspective", Bethesda, 2004
- NIAID ACTG Annual Meeting, "Women and special populations in HIV Drug Trials", Washington, DC, 1993
- 12th meeting of the acquired Immunodeficiency Syndrome Program Advisory Committee (APAC), "Accelerated Approval", Bethesda, MD, 1993
- CPCRA: Annual Meeting, "Data collection requirements and monitoring clinical trials", Alexandria, VA, 1993
- NIAID-UNAIDS Satellite Symposium on Topical Microbicides, "Topical Microbicides", Vancouver, BC, 1996
- NIDCR National Institutes of Health: NIDCR – Dental, Oral & Craniofacial Forum, "FDA and Medical product Consumer Protection", Washington, DC, 2001
- NIHCHD Contraceptive Technology Workshop, "Development of Vaginal Microbicides to Prevent HIV transmission", Bethesda, MD, 1994
- Clinical Center NIH Clinical Center: Critical Care Medicine Department Conference, "Evidence based Medicine and Device Regulation: How to Foster Innovation", Bethesda, MD, 2002
- Rounds Other NIH Cost Effective Strategies for the Diagnosis of Pulmonary Complications: Calculations of 'Cost Effectiveness', "NIH Workshop on the Pulmonary Complications of AIDS", San Francisco, CA, 1987
- Workshops NIH – FDA Symposium on AIDS Clinical Trials, "AIDS Clinical Trials: Non traditional study designs", Rockville, MD, 1990
- Fogarty Center, NIH: US-Japan Cooperative Medical Science Program: Sixth Joint Scientific Meeting of the AIDS Panels, "Scientific Research Opportunities in the Pacific: FDA Perspectives", Palm Springs, CA, 1994
- Gene Therapy Conference, "Surrogate Markers NIH," Bethesda, MD, 1997
- Research Needs for the Design and Analysis of Surrogate Endpoints in Clinical Trials, "Clinical Perspectives on Surrogate Markers", Potomac, MD, 1998
- Prenatal Gene Therapy Workshop, "Clinical Endpoints and Measurement Outcome", Bethesda, MD, 1999
- FDA/NIH Workshop on Non-Clinical Toxicological Study Design Issues for Development of AAV-Based Gene Therapies: A Platform Studies Approach, "Role of Platform Studies in Drug Evaluation", Bethesda, MD, 1999
- NIH Technology Assessment Conference on Improving Medical Implant Performance Through Retrieval Information: Opportunities and Challenges, "National Implant Data Retrieval and Analysis", Bethesda, MD, 2000
- Foundation for NIH: Imaging Database Resources Initiative, "Importance of FDA-NIH-Industry Collaboration", Bethesda, MD 2004

INVITED PAPERS, LECTURES AND PRESENTATIONS**Academic Institutions**

Applied Sciences University, Lubeck, Germany	International Seminar on Harmonization of Standards (Honoring the Retirement of Professor Horst Frankenberger), "Global Harmonization of Medical Devices", Lubeck, Germany, 2003
Arizona State University	Personalized Medicine and Molecular Diagnostics, Legal Regulatory and Ethical Perspectives, "Regulatory Issues for Personalized Medicine", 2007
Carnegie Mellon University	Materials Science Seminar Series, "Medical Devices", Pittsburgh, PA, 2001
Columbia University	FDA Workshop: Community based clinical trials, "The San Francisco Community based trials of PCP prophylaxis", New York, NY, 1989 Symposium on Quality of Life, "Drugs, Drug Companies and Quality of Life Issues: Quality of Life Measures: An FDA Perspective", New York, NY, 1993 The American Institute of Life-Threatening Illness and Loss: Regulatory Issues, Pharmacoeconomics and Quality of life Issues in the Evaluation of Therapeutic Agents: Oncologic, Cardiovascular, and other Drugs as Models, "Assessment of Drug Therapies Using Quality of Life Measures", New York, NY, 1997
Dartmouth Medical School	Device and Drug 3D1 Symposium, "Clinical Development and Commercialization: Differences: United States and Europe/United Kingdom", Woodstock, VT, 2003 Seminar, "Role of Clinician Inventor/Entrepreneur in Pre-Clinical and Clinical Development of a new Medical Device", Lebanon, NH, 2003 Medical Grand Rounds, "Innovation and Consumer Protection – FDA and New Technology", Lebanon, NH, 2004 Device and Drug 3D3 Symposium, "Conflict of Interest: Medical Device Development", Woodstock, VT, 2005 Device and Drug 3D4 Symposium, "International Harmonization of Regulatory Standards, Is it worth the trouble?", Woodstock, VT, 2006
Duke University	Device Drug Eluting Stents Conference, "The Shrinking Total Product Life Cycle: Regulatory Processes and Innovation", Washington, DC, 2002 Clinical Research Institute Roundtable, "New Technology Review", Tyson's Corner, VA, 2002 Clinical Research Institute: Genetics and Cardiovascular Disease II, "", Pentagon City, VA, 2003 Clinical Research Institute: Device Evaluation Think Tank, "", Rockville, MD, 2003
Georgetown University	Georgetown Clinical Pharmacology Conference, "Rapid Drug Development: The Protease Inhibitors", Washington, DC, 1997 Center for Drug Development Science Course: Modeling and Simulation of Clinical Trials in Drug Development and Regulation, "PK/PD Modeling in Regulatory Decisions for Effectiveness", Herndon, VA, 1997 Center for Drug Development Study Conference, "Pharmacogenomics", Washington, DC, 1999

	Center for Drug Development Study Conference: Protein Pharmacology, "Protein PK/PD: A Regulatory Perspective", Annapolis, MD, 1999
	Center for Drug Development Studies, Georgetown University: Confirmatory Evidence (to Support a Single Clinical Trail (SCT): An Exploratory Workshop, "The Nature and Source of Evidence for Effectiveness", Washington, DC, 2002
	Center for Drug Development Study Conference: Clinical Development of Oncologic Agents: Challenging the Tradition, "Predictive diagnostics, biomarkers/surrogate endpoints and how they can be used in drug development", Washington, DC, 2003
	The International Life Science Summit East, "Drug and Device Development: The Challenge of Turning Research into Reality", Washington, DC, 2003
Georgia Tech	Biomedical Engineering Seminar, "One Hundred Years of Consumer Protection", Atlanta, GA, 2001
	Medical Technology Leadership Forum Summit – Defining a Regulatory Process for Combination Product: The emergence of Tissue Engineering, "Regulatory Approaches to Tissue Engineering", Atlanta, GA, 2002
Golden Gate University	Conference, "Hospital Quality Assurance Programs", San Francisco, CA, 1987
	Conference, "Hospital Quality Assurance, Utilization Review, and Risk Management Programs", San Francisco, CA, 1988
Harvard University	Contemporary Issues in Clinical Trials Harvard School of Public Health, Department of Biostatistics, "Current and Future FDA Criteria for the Evaluation of Anti-HIV Drugs by the FDA, Boston, MA", Boston, MA, 1997
	Medical School Seminar-The Clinical Investigator Training Program, "Endpoints in Clinical Trials", Boston, MA, 1999
	Center for Innovation in Medical Technology – Harvard Medical School – Stanford Conflict of Interest Forum, "", Boston, MA, 2002
Howard University	Deadly Diseases & People of Color: Are Clinical Trials an Option?, "New Therapies for Diseases Affecting People of Color: AIDS", Washington, DC, 1996
Johns Hopkins University	Medical School Symposium, "Prophylaxis with Aerosolized Pentamidine for PCP", Baltimore, MD, 1989
Memorial Sloan Kettering	Pulmonary Grand Rounds, "Prophylaxis against P carinii pneumonia", New York, NY, 1990
New Jersey University of Medicine and Dentistry	Infectious Disease Rounds, "New agents in the treatment and prevention of PCP", Newark, NJ, 1990
San Diego State University	Regulatory Affairs Student Seminar, "Consumer Protection and Medical Devices", Rockville, MD, 2001
	Student FDA Field Visit, "Consumer Protection: Devices and Radiological Products", Rockville, MD, 2002
Scripps Clinic	Scripps Clinic Symposium: The Changing World of International Product Development, "Pharmacogenomics: A Regulatory Perspective", La Jolla, CA, 1999

	Symposium, "Drug Delivery: Problems and Possibilities", La Jolla, CA, 2001
	5th Bio Symposium, "Perspectives on the Future FDA", La Jolla, CA, 2003
Shanghai Institute of Mental Health	"Quality Assurance in Acute Care Hospitals, Peer Review of Medical Staff, Accreditation and Licensing American Hospitals, Use of Small Computers in Medical Departments (A day long seminar for Hospital Administrators)", Shanghai, China, 1988
Stanford University Law School	Program in Law Science and Technology Conference, "Genetic in vitro Diagnostics", Stanford, CA, 2000
Stanford University School of Engineering	Bioengineering Class: Innovation and Technology, "Innovation and the FDA – 100 years of Consumer Protection" 2005
Suffolk University School of Law	FDA Regulation of Medical Technologies, "Defining a Medical Device", "Device Classification", "An Inside Look at the FDA Approval Process"; Boston, MA 2004
Tufts University	PRIM&R (Public Responsibility in Medicine and Research): AIDS Clinical Research and Care: Meeting the Challenges of an Epidemic in Flux, "An Overview of the Status of AIDS Research in the '90s", Boston, MA, 1992
	Accelerated Approval of New Drugs, "Constructing a Framework for Surrogate Endpoint Selection", Boston, MA, 1994
	New Technologies, Challenges and Opportunities for the Medical Device Industry: A Collaborative Workshop Sponsored by the Tufts University Schools of Engineering & Medicine. "Innovation and Regulation.", Boston 2004
Uniformed Services University of Health Sciences	Clinical Pharmacology Seminar, "Surrogate Markers in Drug Development", Bethesda, MD, 1994
University of Arizona	The Promise of Stem Cells: Tissue Engineering And Regenerative Medicine, "Regulation of Stem Cells: Role of FDA, States and Others", Tucson, AZ 2006
University of California, Berkeley	Haas School of Business: New Economic Forum, "Biotechnology and Medical Devices", Portola Valley, VA, 2003
University of California, Davis	Conference on Practical Advances in Medicine, "Computers: How to retrieve medical information in a practical way", Sacramento, CA, 1985
	University of California Davis Conference, "The Political Economy of Surgery: Surgical practice in a changing environment", Carmel, CA, 1989
	Annual Conference on the Evaluation of the Preoperative Patient, "The Political Economy of Surgery", Carmel, CA, 1990
	Annual Conference on the Evaluation of the Preoperative Patient, "The Political Economy of Surgery", Carmel, CA, 1990

University of California, San Diego	von Liebig Forum Lecturer, the Jacobs School of Engineering, "Innovation and Consumer Protection – FDA and New Technology", San Diego, CA 2004
University of California, San Francisco	Department of Epidemiology and Biostatistics: Clinical Trials Workshop, "Interacting with the FDA", San Francisco, CA, 1995
	School of Dentistry, "Rapid Development of AIDS Drugs", San Francisco, CA, 1995
	San Francisco County Health Department, "Update on AIDS Drug Development", San Francisco, CA, 1996
	UCSF Department of Epidemiology and Biostatistics: Clinical Trials Workshop, "Interacting with the FDA", San Francisco, CA, 1996
	UCSF Department of Epidemiology and Biostatistics: Clinical Trials Workshop, "Placebo vs. Active Controlled Clinical Trials", San Francisco, CA, 1996
	8th Symposium on Clinical Trials: Design Methods and Controversies, "FDA Perspectives on Drug Development", San Francisco, CA, 2000
University of Indiana	Medical Technology Leadership Forum Technology Conference, "Medical Device Innovations Based on Information Technology", Indianapolis, IN, 2000
University of Iowa	Conference: AIDS '89, "Management and Prevention of Pneumocystis carinii Pneumonia", Ames, IA, 1989
University of Maryland	Institute of Human Virology Conference: Immune Reconstruction and Surrogate Markers in HIV/AIDS: Defining the Obstacles, "Predicting Clinical benefit from Immune Markers", Bethesda, MD, 1999
	Bioscience Research Day: CEO's Breakfast, "Academic Government Partnerships", College Park, MD, 2001
	Policy Development Seminar, "Score Cards and Strategic Planning", College Park, MD, 2003
University of Minnesota	School of Public Health Grand Rounds, "Development of Drugs for HIV Infection", Minneapolis, MN, 1996
	Medical Technology Leadership Forum - Facilitating the Continuum from Experimental to Clinical Use: Designing Alternative Models, "Medical Devices: Overcoming Regulatory Hurdles", Minneapolis, MN, 2003
University of Rhode Island	School of Pharmacy: Changing Paradigm of Blood Regulation, "CBER's Blood Action Plan", New Orleans, LA, 1999
University of Texas, San Antonio	Pulmonary Fellows Conference, "Pulmonary Complications of HIV Infection", San Antonio, TX, 1989
University of Texas, Austin	International Conference for Drug Development, "Current Issues in Biologics", 1998; "Regulatory path for emerging therapeutic technology", Barton Creek, TX 2004
University of Washington	School of Public Health: The Impact of Regulatory Programs on Medicine and Public Health, "Off-label Use of Medical Products", Seattle, WA, 2002
Vanderbilt University	Bioengineering Departmental Seminar: "Emerging Therapeutic Technology", Nashville, TN, 2004
Virginia Tech	Virginia Tech - FDA Seminar, "Center for Devices and Radiological Health", Blacksburg, VA, 2001
Yale University	Yale / Genaissance Genomics Symposium, "Drug Development, Regulation, and Genetically Guided Therapy", New Haven, CT, 2001

FDA Sponsored Presentations

Advisory Committee	<p>FDA anti-infective advisory panel meetings, "Aerosolized Pentamidine for prophylaxis against PCP in HIV infected adults", Rockville, MD, 1988</p> <p>FDA Anti-infective Advisory panel meeting, "Considerations of the Parallel Track proposal for early drug availability", Bethesda, MD, 1989</p> <p>CDER Scientific Advisory Committee New Member Orientation, "Role of Members and Perspectives from the Infectious Disease Committees", , 1996</p> <p>CDER: Orientation for CDER Advisory Committee Members, "Roles of members and Perspectives of a Former Member", Rockville, MD, 1997</p> <p>Anti-infective Drug Advisory Committee, CDER, "Evaluability Criteria for the Evaluation of Antimicrobials", Gaithersburg, MD, 1997</p> <p>FDA Workshop for Patient Representatives, "Device Advisory Committees", Rockville, MD, 2001</p>
CBER	<p>CBER / ORA Training Course: Blood Bank Inspection, "Oversight of the Blood Industry", Annapolis, MD, 1997</p> <p>Team Biologics Training, "Blood Oversight and Regulation", Potomac, MD, 1998</p>
Consumer Round Table	<p>FDA Consumer's Roundtable, "The Mammography Quality Standards Act", San Juan, PR, 2000</p>
District Meetings	<p>FDA South East District Conference, "Spotlight on Radiological Health", San Juan, PR, 2001</p> <p>FDA Dallas District Staff Seminar, "Consumer Protection: Device and Radiological Products - Center and Field", Dallas, TX, 2001, 2004</p>
FDA: Scientific Rounds	<p>Center for Drug Evaluation and Research, FDA: Scientific Rounds, "End-point Methodology in HIV infection", Rockville, MD, 1992</p> <p>FDA Scientific Rounds: Office of Clinical Pharmacology and Biopharmaceutics (OCPB), "Pharmacogenomic Data Submissions - The Path from Concept to Reality", Rockville, MD, 2003</p>
Grassroots	<p>Grassroots Meeting, "CDRH Priorities", Denver, CO, 2002, Salt Lake City 2003 Dallas TX, 2003, 2004</p>
Public Affairs Specialists	<p>The Public Affairs Specialist/Public Affairs Liaison National Training Conference "2001 - A Consumer Protection Odyssey", "Spotlight on Radiological Health", Leesburg, VA, 2001</p> <p>HHS/FDA National Public Affairs Conference: Communicating Risk, Results and Relevance to American Consumers - A dialogue on safety and security through science", "Medical Devices: Communicating Success and Risk", Nashville, TN, 2003</p>
Science Board	<p>FDA Science Board, "Programmatic Peer Review: Center for Devices & Radiological Health", Rockville, MD, 2000</p> <p>FDA Science Board, "Update: CDRH Science Review", Rockville, MD, 2001</p> <p>FDA Science Board, "Tissue Engineering and Device Regulation", Washington, DC, 2001</p> <p>FDA Science Board, "CDRH Science Review", Rockville, MD, 2001</p> <p>FDA Science Board, "Developing Biomaterials", Rockville, MD, 2002</p> <p>FDA Science Board, "Quality Teams and Regulatory Review", Rockville, MD, 2003</p>

Science Forum	FDA Science Forum, "Detecting Biological and Security Risks", Washington, DC, 2003
FDA Workshops	<p>FDA Workshop: Geriatric Drug Testing, "Adverse Reactions in the Systolic Hypertension in the Elderly Trial", Washington, DC, 1985</p> <p>CANDA Workshop, "The Computerized Rolling NDA", Rockville, MD, 1994</p> <p>FDA: Clinical Trials Workshop, "Designing Trials with Clinical End-points", Bethesda, MD, 1995</p> <p>Clinical Trials Workshop, "FDA Role and Responsibility in Clinical Trials", San Francisco, CA, 1998</p> <p>Minimizing Medical Product Errors - A Systems Approach, "CBER Perspective on Medication Errors", Bethesda, MD, 1998</p> <p>FDA and the Changing Paradigm for Blood Regulation, "CBER's Action Plan for Improving Blood Safety", New Orleans, LA, 1998</p> <p>FDA Symposium on Drugs and the Liver, "FIAU and Chronic Hepatitis B", Rockville, MD, 1999</p> <p>National Patient Safety Forum: Patient Safety - Emerging Opportunities in the Health Care System, "Building Safety In: The Essential Role of Device Users", Bethesda, MD, 2000</p> <p>FDA Workshop: Human Bone Allograft: Manipulation & Homologous Use in Spine and Other Orthopedic Reconstruction and Repair, "Medical Devices from Human Bone", Bethesda, MD, 2000</p>
FDA Workshops (continued)	<p>FDA Statistician's Meeting, "Statistical Issues in Medical Devices", Rockville, MD, 2000</p> <p>Mutual Recognition Agreement Medical Devices Annex Training, "Mutual Recognition Agreements", Gaithersburg, MD, 2001</p> <p>FDA Workshop - Home Health Care, "Home Health Care and Medical Devices", Bethesda, MD, 2002</p> <p>CDRH Clinical Trials Methodology Course, "Surrogate Markers", Gaithersburg, MD, 2003</p> <p>CDRH Staff College: Total Product Life Cycle 101 Training Course, "Total Product Life Cycle", Gaithersburg, MD, 2003, 2004</p> <p>FDA Workshop on the Development of Novel Drug Delivery Devices, "Opening Remarks", Rockville, MD, 2003</p> <p>CDRH Workshop on the Development of SARS Diagnostics, "Rapid Development of Diagnostic Devices for New Infectious Disease Threats", Rockville, MD, 2003</p> <p>First Annual MDUFMA Stakeholders' Meeting, "Medical Device User Fees: The First Year", Gaithersburg, MD, 2003</p>

Other Regulatory Body Presentations

MDA / NAPSE	The Medical Devices Agency (UK) 2nd Annual Conference: Protecting Patients - Improving Safety, "Regulatory Issues in the United States", London, England, 2002
MHRA	MHRA (UK) Staff Seminar: Beyond "Pre-market and Post-market" : Regulation and the total product life cycle, 2006
SFDA	State FDA (China) with the Beijing University International MBA Program: 14 Lecture Short Course on US FDA Regulation of Pharmaceutical Medicine, Beijing, 2005

Professional Organizations and Societies

AAAS	American Association for the Advancement of Science, Annual Meeting, "The Evolving Genome in Clinical Development and policy", Denver, CO, 2003
AAMC	American Association of Medical Colleges Council of Deans, "Institutional Review Boards: Current Challenges", Rio Grande, PR, 2000
AAMI	10th Annual Association for the Advancement of Medical Instrumentation/FDA International Standards Conference, "Global Standards – Global Quality", McLean, VA, 2000 - 2003
AAOS	American Academy of Orthopedic Surgeons/Orthopedic Surgical Manufacturers Association Device Forum, "CDRH External Science Review Recommendations", Gaithersburg, MD, 2002
AAPS	AAPS Western Regional Meeting, "Accelerated Drug Development and Approval", San Francisco, CA, 1997 American Association of Pharmaceutical Scientists Annual Meeting, "The Treatment of AIDS- A Revolutionary Paradigm in Drug Discovery, Development and Approval", Boston, MA, 1997 AAPS Symposium on Clinical Pharmacology: Optimizing the Science of Drug Development, "Role of Clinical Pharmacology in Accelerated Approval of Antivirals", Crystal City, VA, 1998 AAPS Annual Meeting, "FDA Perspectives for Accelerated Approval of AIDS Drugs", San Francisco, CA, 1998 AAPS Annual Meeting, "drug/disease modeling to increase the efficiency of drug development", Baltimore, MD 2004
ABA	Arizona Biotech Association: "FDA and CLIA: Trends in Medical Diagnostic Commercialization", 2006
ABRA	American Blood Resources Association Plasma Forum, "The Blood Action Plan", Washington, DC, 1998
ACC	American College of Cardiology Course, "International Trends in Cardiovascular Disease Mortality: Possible explanations", San Francisco, CA, 1987 American College of Cardiology, "Sharing a Commitment to Improve Cardiovascular Disease", Bethesda, MD, 2001 American College of Cardiology Industry Forum, "Cardiovascular Devices: Regulation and Consumer Protection", Bethesda, MD, 2002
ACCP	American College of Clinical Pharmacology: Annual Meeting, "Keynote Address: Genetically Guided Therapy: The Genome, biomarkers and pharmacology", Tampa Bay, FL, 2003
ACLA	American Clinical Laboratories Association, Annual Meeting, "Regulation of Genetic Tests", Washington, DC, 2002
ACOG	American College of Obstetrics and Gynecology: Preventing perinatal transmission of HIV infection, "ACTG 076 - The FDA Review Process", Washington, DC, 1994
ACP	American College of Physicians: Preparing for Surgery: Medical Evaluation of the Preoperative Patient, "Improving Patient Risks: Assessing new technologies", Carmel, CA., 1992
AFCR	American Federation for Clinical Research/ASCI/AAP: Surrogate End Points, New Drug Development and the Clinical Investigator, "Surrogate Endpoints", Washington, DC, 1993
AmFAR	American Foundation for AIDS Research, NIH: Annual Meeting: Community Based Trials Clinical Trials Network, "AIDS Treatment: What do we know and how did we learn it?", Alexandria, VA, 1993 AmFAR: Off-Label Drug Use in HIV Disease, "Issues and Concerns of the FDA

- Regarding Off-Label Drug Use", Washington, DC, 1994
- AmFAR: Update on HIV Treatment, "New AIDS Drugs: Guide to early access for the primary care physician", New York, NY, 1995
- APA 5th Annual American Pharmaceutical Association End-of-Summer Science Symposium: The Yellow Brick Road Gets Longer: Social, Economic and Technological Issues Shaping Clinical Design in the '90s, "Impact of Innovation in the Clinical Study Design on AIDS Drug Approval", Washington, DC, 1992
- ASAI0 American Society for Artificial Internal Organs: Annual Meeting - Keynote Address, "The FDA Modernization Act", New York, NY, 2000
- ASAI0 - ISAO Annual Meeting, "How to Become More Involved in the Regulatory Process", Washington, DC, 2003
- ASCO American Society for Clinical Oncology Research Methods on Clinical Trials, "Design of Trials for Rapid Drug Development", Vail, CO, 1997
- ASCPT American Society for Clinical Pharmacology and Therapeutics: Annual Meeting, "Safety Assessment of High Risk Drugs: The FIAU experience", Orlando, FL, 1996
- Annual Meeting: "Clinical Trials and Modeling in Drug Development", 2007, 2009
- ASM American Society of Microbiology: An FDA perspective on the preclinical evaluation of activity for potential HIV therapeutics, "Introduction: The importance of preclinical activity studies in the development of HIV therapeutics", Anaheim, CA, 1992
- ASTRA American Society for Therapeutic Radiology and Oncology Annual Meeting, "CDRH's Role in Radiation Oncology", New Orleans, LA, 2002
- ATS American Thoracic Society Annual Meeting, "Statistics Course for Physicians: Trials with categorical and survival outcomes", Phoenix, AZ, 1989
- CFF Cystic Fibrosis Foundation: Workshop on Surrogate Markers for CF, "Use of Surrogate Markers in Accelerated Approval Process", Bethesda, MD, 1997
- CFF: Williamsburg Conference: Gene Therapy Section, "FDA Expedited Review Process", Williamsburg, VA, 1997
- CRT Cardiovascular Radiation Therapy III, "Vascular Brachytherapy - An FDA Perspective", Washington, DC, 2001
- Cardiovascular Radiation Therapy IV and Testenotic Forum, "Brachytherapy and Drug Eluting Stents: A regulatory perspective", Washington, DC, 2002
- CSS Canadian Statistical Society, Annual Meeting: Plenary Session, "Methodological Problems in AIDS Epidemiology", Victoria, Canada, 1988
- ECRI ECRI Annual Meeting, "Assessment of the Quality of Life Impact of Medical Devices", Plymouth Meeting, PA, 1999
- ECRI Annual Meeting, "Beyond Medical Error - FDA Last Hurdle or only the First?", Plymouth Meeting, PA, 2000
- ECRI Annual Meeting: From Populations to Persons: Putting EBM Research into Practice, "Medicine in the Information Age: From population to people", Plymouth Meeting, PA, 2003
- EUFEPS European Federation for Pharmaceutical Sciences Conference on Optimizing Drug Development, "The impact and use of biomarker-based diagnostic kits in drug development and clinical practice", Basel, Switzerland, 2001
- FDLI The Food and Drug Law Institute: Advanced Drug Law Workshop, "Improving the Drug Approval Process", Washington, DC, 1992
- FDLI Dispute Resolution Workshop, "Tutorial: Resolving disputes with the FDA", Washington, DC, 1998
- FDLI 42nd Annual Educational Conference, "Blood and Tissue Safety", Washington, DC, 1998

	FDLI Medical Technology Symposium 2000, "Device Regulation", Washington, DC, 2000
	FDLI Clinical Trials Workshop, "Evidence Based Medicine", Washington, DC, 2001
	FDLI Annual Educational Conference, "CDRH: Looking ahead", Washington, DC, 2001 - 2003
FHI	Family Health International: Opportunities for Industrial Collaboration in Contraceptive Research, "FDA Regulatory Issues: Anti-infective products", Durham, NC, 1996
IADR	International Association for Dental Research, "The Epidemiology of Oral Manifestations of HIV", Montreal, Canada, 1988
ICAAC	Interscience Conference on Antimicrobial Agents and Chemotherapy: Symposium - Prophylaxis in the HIV-infected patient, "Assessment of New Drugs and Combinations for OI Therapy Prior to Phase 3 Trials", Anaheim, CA, 1992
	ICAAC Annual Meeting, "Regulatory Requirements of Clinical Trials", "Acyclovir Forum", and Panel on AIDS Clinical Trials", Anaheim, CA,, Anaheim, CA, 1993
	ICAAC Annual Meeting, "New Modeling Methodologies: Influence on Clinical Trial Design", New Orleans, LA, 1994
ICP	9th International Conference on Pharmacoepidemiology: Use of Pharmacoepidemiology in Public Health, "Postmarketing surveillance and other uses of epidemiology in the development of anti-viral drugs", Washington, DC, 1993
IDSA	Infectious Disease Society of America Workshop on Clinical Trials in Anti-infective Drug Development, "FDA Regulations, and Guidance", San Francisco, CA, 1997
IICC	Second International Interdisciplinary Conference on Cardiovascular Medicine and Science, "Cardiovascular Devices, Medicine, Science and Society", Bethesda, MD, 2003
IPC	37th International Industrial Pharmacy Conference, "CBER's Vision for the Modernization of FDA", Austin TX, 1998
IRT	Intracoronary Radiation Therapy 2000, "Intracoronary Radiation: AN FDA Perspective", Washington, DC, 2000
ISCE	International Society of Computerized Electrocardiography, "Computers in Medical Product Development", Gaithersburg, MD, 2003; "Current Issues in the Regulation of Electrocardiography", Gaithersburg, MD, 2004.
ISACVB	International Society for Applied Cardiovascular Biology, Biennial Meeting, "Safe and Effective Tissue Engineering", Savannah, GA, 2004
ISNA	3rd International Symposium on Nutrition and HIV, "FDA Guidelines on Nutritional Claims and Products", Philadelphia, PA, 1994
ISTAHC	International Society for Technology Assessment in Health Care 2001, "Evaluating Breakthrough Technology", Philadelphia, PA, 2001
Keystone	UCLA Conference on Acquired Immunodeficiency Syndrome, "Modeling the impact of PCP prophylaxis on survival", Keystone, CO, 1990
	Keystone Symposia on Molecular & Cellular Biology: Discovery and Development of Therapeutic Compounds, "CD4 Counts and Clinical Outcomes: Follow-up of ddI and ddC trials", Snowmass, CO, 1993
	Keystone Dialog on Pharmacogenomics, "", Washington, DC, 2003
Lab Institute	21st Annual G2 Lab Summit, "Medical Diagnostics: Overcoming Regulatory Hurdles", Arlington, VA, 2003

NAMA	Nucleic Acid Medical Applications: International Conference on Nucleic Acid Medical Applications, "The Interaction among FDA, Industry and Research Institutions on Nucleic Acid Medical Applications", Cancun, Mexico, 1993
NFID	National Foundation for Infectious Diseases and American Society for Microbiology: First National Conference on Human Retroviruses and Related Infections, "Clinical Drug Trials, Surrogate Markers and Disease Progression", Washington, DC, 1993
PAF	Pediatric AIDS Foundation: Identification of Critical Areas for Research in Pediatric AIDS, Santa Barbara, CA, 1994
PCA	Patient Care Assessment Council (Professional Organization of Quality Assurance Coordinators): Annual Meeting, "Statistics and quantitative methods in quality assurance", Oakland, CA, 1986
Pop Council	Women's Health Action and Mobilization / Population Council Meeting, "Practical and Ethical Dilemmas in Testing of Microbicides", Airle, VA, 1997
PRSA	Public Relations Society of America, "Consumer Protection: Medical Devices and Radiation Emitting Products", Rockville, MD, 2003
SCI	Society for Clinical Immunology: Annual Meeting, "Surrogate Markers for Immune Based Therapies", Williamsburg, VA, 1993
SCT	Society for Clinical Trials and the International Society for Clinical Biostatistics: 2nd Joint Meeting, "Surrogate Markers", Boston, MA, 1997
STM	Society of Transplant Medicine: Annual Meeting, "Clinical Trial Design for Transplant Drugs", Houston, TX, 1993 STM Consensus Conference on Therapeutic Drug Monitoring in Transplantation Medicine, "Development of Drugs for Solid Organ Transplantation", Lake Louise, Alberta, Canada, 1995
SWHR	Society for Women's Health Research: Annual Corporate Advisory Council Meeting, "Development of Drugs and Medical Devices", Washington, DC, 2003
TCT	Transcatheter Cardiovascular Therapeutics 2002, "Cardiovascular Devices: What's New at CDRH", Washington, DC, 2002

Trade and Industry Associations

AdvaMed	Advanced Medical Technology Association (AdvaMed): Annual Device Submission Workshop, "CDRH Directions", Washington, DC, 1999 - 2003 AdvaMed Technical and Regulatory Board, "CDRH: The next 5 years", Washington, DC, 2000 AdvaMed Annual Meeting, "CDRH Looking Ahead", Palm Springs, CA, 2001; Carlsbad, CA, 2002; Aventura, FL, 2003 AdvaMed Annual Meeting, "CDRH Enforcement Priorities", Palm Springs, CA, 2001 Innovation for Preparedness: The Public-Private Partnership, "CDRH's Role in Counterterrorism", Washington, DC, 2003 AdvaMed Board of Directors Meeting, "MUDFMA Progress Report", Washington, DC, 2003 AdvaMed Annual Meeting, "Building CDRH of the Future", Phoenix, AZ, 2004 AdvaMed Audioconference: "Developing a Strategic Relationship with
---------	---

	FDA", Washington DC 2004
Biotech	Biotech Meeting, "CDRH Update", Laguna, CA, 2000 Biotech Meeting, "FDA Policy and Biotech", Laguna, CA, 2002
Blue Cross	Blue Cross of Northern California Technology Assessment Meeting, "Evidence Standards for Medical Device Approvals", San Francisco, CA, 2001
CMDMA	Colorado Medical Device Manufacturers Association Meeting, "Device Regulation - A look to the Future", Denver, CO, 1999, 2002
DDMA	Dallas Device Manufacturers Meeting, "Issues in Medical Device Regulation", Dallas, TX, 2002
DIA	Drug Information Association Annual Meeting, "Accelerated Review: Problems, Opportunities, and Experience to Date: A perspective from the Anti-Viral Division", Chicago, IL, 1993 Drug Information Association: Clinical Trials in Biotechnology: Planning to Prevent the Pitfalls, "Pivotal Trial Issues in HIV Disease", Newport Beach, CA, 1994 DIA Annual Meeting, "Effective FDA / Industry Meetings: FDA Perspectives", Washington, DC, 1994 DIA Annual Meeting, "Subgroup Analyses", Washington, DC, 1994 Drug Information Association: Regulatory aspects of Quality of Life Measurement in Drug approval, Safety Reporting and promotion, "Quality of Life Measurement and Drug Effects: Issues in AIDS Talks", Washington, DC, 1994 DIA Annual Meeting, "Expanded Access to Drugs for HIV Infection", Orlando, FL, 1995 DIA/CDER/CBER: Workshop on Proposed Interim Guidance for Electronic Submission of Case Report Forms and Tabulations, "An Office Level Perspective on Electronic Submissions", Washington, DC, 1996 DIA Meeting: Clinical Trials - Contemporary Design Solutions, "Clinical Endpoints and Surrogate Markers in High Mortality Diseases, AIDS as the Model Improving for Improving Drug Development", Philadelphia, PA, 1997 DIA Annual Meeting, "Clinical Research Training of Physicians: An Unmet Need - A Government Perspective", Boston, MA, 1998 DIA/FDA Project Management Workshop, "Project Management, CBER Perspectives", Bethesda, MD, 1998 DIA Annual Meeting, "CDRH Update", Chicago, IL, 2002
EUCOMED	European Medical Technology Industry Association Annual Meeting, "CDRH: Current Issues", Berlin, Germany, 2000 Annual Meeting: Workshop on Clinical Evidence in Medical Device Approvals, Brussels, Belgium 2010
EUROM	European Federation of Precision Mechanical and Optical Industries: EUROM VI Medical Device Technology General Assembly, "Global Markets through International Harmonization - A US Perspective", Brussels, Belgium, 2003
FDMA	Florida Device Manufacturers Meeting, "Current Issues for Medical Device Regulation", Orlando, FL, 1999
Guidant	Post-Approval Registries Summit, 2005
IDM	Irish Devices Manufacturers Delegation Visit, "US Regulation of Medical Devices", Gaithersburg, MD, 2003
IMDMC	Indiana Medical Device Manufacturers Consortium Annual Meeting, "One HHS: FDA/CMS Harmonization", Indianapolis, MN, 2002

InHealth	Institute for Health Technology Studies: Medical Technology: Breaking Barriers between the Bench and the Bedside, "Accelerating Solutions for Patients -- Regulatory Reform", Washington DC, 2006
Institute for Regulatory Science	CMR Conference: Regulating Personalized Medicine, "Utilizing Diagnostics: implications for Personalized Medicine (by videotape)", Surry, UK, 2003
JFMDA	Japanese Federation of Medical Device Associations, "Issues of Medical Device Regulation in the US Market", Tokyo, Japan, 2002
Marwood Group	Marwood Group Washington Investor's Meeting, "Regulation and Innovation: Recent Case Studies", Washington, DC, 2003
MassMedic	Massachusetts Medical Device Industry Council (MassMedic) Annual End-of-the-Year Regulatory Issues Forum, "CDRH Priorities", Boston, MA, 1999, 2001, 2003
MD&M	Medical Design and Manufacturing - West - Conference, "CDRH 2002: Current Objectives and New Initiatives", Anaheim, CA, 2002
MDMA	Medical Device Manufacturing Association - Annual Meeting, "CDRH Update", Alexandria, VA, 2000 - 2003
MDT	Medical Device Technology Annual Conference, "Device Regulation in an International Milieu", Paris, France, 2000 MDT Annual Conference, "Device Regulation: Global Standards - Global Quality", Ireland, 2001 MDT Annual Conference, "The Evolution of the Regulation of Medical Devices", Birmingham, UK, 2003
Medical Alley	Medical Alley Medical Device Meeting, "CDRH: Hot Topics", St. Louis Park, MN, 2000 Minneapolis Regulatory Reform Forum, "Regulation of Medical Devices", Minneapolis, MN, 2002
MTLF	Medical Technology Leadership Forum: Capital Forum, Rayburn House Office, Washington, DC, 2002, 2004 MTLF: Capital Forum, "Tissue Engineering: Where do we go from here?", Rayburn House Office, Washington, DC, 2003 "Innovative Approaches to the Regulation of Combination Products & New Science: Options for Policymakers", San Diego 2004
NCPDG	Northern California Pharmaceutical Discussion Group, "Speeding Up Drug Development - Lessons from the AIDS Drugs", Milbrae, CA, 1997
NEMA	NEMA Diagnostic Imaging and Therapy Systems, 24th Annual Meeting, "CDRH Update", Roslyn, VA, 1999
OCRA	Orange County Regulatory Associations Meeting, "CDRH's Strategic Plans", Irvine, CA, 2000
PhARMA	PhARMA: PMA AIDS Task Force, "Expanded Access, Parallel Track and Treatment IND's - The current status", Washington, DC, 1992 Pharmaceutical Manufacturers Association: PMA Medical Section: Fall Meeting, "Accelerated Approval: An FDA Perspective", Arlington, VA, 1992 PhARMA Spring Science Meeting, "More rapid approvals - lessons learned from the AIDS experience", Parsippany, NJ, 1994 PhARMA Biostatistics Annual Workshop, "The Interactive NDA Review Process", Baltimore, MD, 1997 Improving Clinical Trials: Contemporary Design Solutions, "Accelerated Biologicals Development, Philadelphia, PA", Philadelphia, PA, 1998 Biostatistics and Data Monitoring Conference Workshop, "The Road Ahead for Drug Development", Bethesda, MD, 2001

Piper Jaffrey	US Bancorp Piper Jaffray: Health Care Conference, "Medical Devices", New York, NY, 2001
RAPS	Regulatory Affairs Professional Society Annual Meeting: Changes, Challenges, Choices, "Fundamental Benefits and Failures of Early Patient Access Programs for Investigational Drugs", Washington, DC, 1992 RAPS Annual Meeting, "Drug Approvals 1962-1993: Future Directions for Drug Regulation in the United States", Washington, DC, 1994 RAPS Annual Meeting, "Rapid Drug Development: The HIV paradigm", Washington, DC, 1997 RAPS Annual Meeting, "CBER Executive Update, Washington, DC", Washington, DC, 1998 RAPS Annual Conference and Exhibition, "CDRH Executive Briefing", Washington, DC, 1999 - 2003
SDRAN	San Diego Regulatory Affairs Network Meeting, "CDRH: Current Goals and Objectives", La Jolla, CA, 2002
ULSA	Utah Life Sciences Association Meeting, "Device Regulation and Innovation", Salt Lake City, UT, 2003
WRG	The Washington Research Group's Seventh Annual Health Care Conference, "Device Regulation and New Technology", Washington, DC, 2002 The Washington Research Group's Eighth Annual Health Care Conference, "Medical Devices: Innovation and Regulation", Washington, DC, 2003
WAFDO	Annual Meeting, "The Role of FDA in the Future of Pharmacogenomics", Phoenix AZ 2005

Other Sponsored Workshops

ACI	4th National Conference on Managing Legal Risks in Conducting & Promoting Clinical Trials: "Compliance with the Regulatory Landscape" New York City, NY 2006
ACT	Applied Clinical Trials, "Designing and Managing Politically Charged Clinical Trials: AIDS and Expedited Drug Development", New Brunswick, NJ, 1994
Biocom Biologics Update Biomedical Focus	BIOCOM Meeting, "Medical Device Development", San Diego, CA, 2002 Biologics Update '98, "Safety issues for biological products: How safe is safe? Blood Safety", Washington, DC, 1998 Biomedical Focus 2000, "Medical Devices: Evidence of Benefit - From Performance Standards to Quality of Life", St. Paul, MN, 2000 50th Annual Minnesota Quality Conference & 17th Annual Biomedical Focus Conference, "Medical Device User Fee Legislation; Third Party Auditing", Minneapolis, MN, 2003
Cannan Partners	Cannan Partners CEO Meeting: Driving Innovation: "FDA Challenged", San Francisco, 2006
CHI	Cambridge Healthtech Institute: AIDS Drug Development, "FDA Perspective on Clinical Development of Treatment for HIV Infection", Alexandria, VA, 1994 CHI Workshop: HIV Surrogate Markers: Virological and Immunological Indicators, "Validation and Use of Viral Load Assays in Clinical Trials", McLean, VA, 1996

CPM	10th International Conference on Pharmaceutical Medicine, "Accelerating Drug Development and the Approval Process", Boston, MA, 1998
FDC Reports	"Trials and Tribulations: Randomized Trials vs. Practical Clinical Studies for Drugs and Devices", Teleconference 2004
GBF	Global Business Forum, "The FDA and the Development of AIDS Drugs", United Nations Building, New York, NY, 1993
IBC	IBC New Antiviral Therapeutics Workshop, "Accelerated Approval", Arlington, VA, 1993 IBC: Surrogate Markers in Drug Development Workshop, "Surrogate Markers", McLean, VA, 1994 IBC Conference on Surrogate Markers, "Standards of Evidence for Drug Approval -- An FDA Perspective", London, 1999
IIR	Institute for International Research: The 2nd Annual CANDIA/CAPLA Technology Conference, "The Rolling NDA: Computer-assisted applications for life-threatening diseases", Alexandria, VA, 1993
MF	Management Forum, "Development of Drugs for HIV Infection", London, England, 1994, 1995 Management Forum, "Drug/Device Combination Products – The US FDA Regulatory Approach, 2005
NeoPharma	Advances in Liposomes, "Regulation of New Medical Products – Innovation and Consumer Protection", Chicago, 2004
PERI	Pharmaceutical Education and Research Institute: Advanced GCP's, "Good Clinical Practice", Arlington, VA, 1998 PERI: Advanced Good Clinical Practices, "World-wide Regulatory Update on Drugs and Biologics", Roslyn, VA, 1999
Pharmillennium	Pharmillennium99: Accelerating the Pipeline: From Drug Discovery to Market, "Accelerated Approval and Fast Track Drug Development", Washington, DC, 1999
RAND	Rand Corporation Conference, "Assessment of the Quality of Care of Pneumocystis carinii Pneumonia", Los Angeles, CA, 1988
Texas AIDS Update	Texas AIDS Update, "Prevention of PCP Pneumonia", Houston, TX, 1990
US Oncology	US Oncology Annual Meeting, "What does the FDA Look for in Clinical Trials Monitoring", Dallas, 2004; "Post-marketing Surveillance – Recent changes in FDA's Requirements", 2008

PUBLISHED WORKS

ORIGINAL ARTICLES

1. Feigal DW, Blaisdell FW. The estimation of surgical risk. *Medical Clinics of North America* 63:1131-44, 1979.
2. Jakle C, Feigal DW, Robbins D, Shapiro R, Wiesner K. Serum IgG and IgM rheumatoid factors and complement activation in extra-articular rheumatoid disease. *J Rheumatology* 12:227-232, 1985.
3. Pollet S, White RH, Jang H, Yim CW, Feigal DW. Aspirin dosing using 15 grain enteric-coated tablets. *J Rheumatology* 12:337-342, 1985.
4. Feigal DW, Robbins D, Leek JC. Giant cell arteritis associated with mononeuritis multiplex and complement-activating 19S IgM rheumatoid factor. *American Journal of Medicine* 79:495-500, 1985.
5. Robbins D, Feigal DW, Leek JC, Shapiro R, Wiesner K. Complement Activation by 19S IgM Rheumatoid factor in Vitro: Relationship to Disease Activity in Rheumatoid Arthritis. *J Rheumatology* 13:33-38, 1986.
6. Hulley SB, Feigal DW, Ireland C. The systolic hypertension in the elderly program (SHEP): the first three months. *J Amer Geriatrics Society* 34:101-105, 1986.
7. Smith WM, Feigal DW, Furberg CD, Greenlick M, Kuller L, Perry HM, Schnaper HW, Schoenberger JA. Uses of diuretics in treatment of hypertension in the elderly. *Drugs* 31 (Suppl 4): 154-164, 1986.
8. Snyder NA, Feigal DW, Arieff AI. Hyponatremia in the elderly: A heterogeneous, morbid and iatrogenic entity. *Annals of Internal Medicine*. 107:309-319, 1987.
9. Siegel D, Kuller L, Lazarus NB, Black D, Feigal DW, Hughes G, Schoenberger JA, Hulley SB. Predictors of cardiovascular events and mortality in the Systolic Hypertension in the Elderly Program pilot project. *Amer J Epidemiol* 1987; 126:385-99.
10. Chaisson RE, Leuther MD, Allain J-P, Nusinoff-Lehrman S, Boone GS, Feigal DW, Volberding PA. Effect of zidovudine on serum HIV core antigen (HIV-Ag) levels: results from a placebo-controlled trial. *Archives of Internal Medicine* 1988; 148:2151-3.
11. Jacobson MA, O'Donnell JJ, Porteous D, Brodie HR, Feigal DW, Mills J. Retinal and gastrointestinal disease due to cytomegalovirus in patients with the acquired immune deficiency syndrome. *Quarterly Journal of Medicine*, 1988; 254:473-486.
12. Golden JA, Chernoff D, Hollander H, Feigal DW, Conte JE. Inhaled pentamidine prophylaxis for *Pneumocystis carinii* pneumonia in patients with acquired immunodeficiency syndrome and AIDS related complex. *Lancet*. 1:654-657, 1989.

13. Masur H., Allegra C., Armstrong D., DeGruttola V., Ellenberg S.S., Feigal D.W., et. al. Guidelines for prophylaxis against *Pneumocystis carinii* pneumonia for persons infected with Human Immunodeficiency virus. *MMWR* 38:S5 1-9, 1989.
14. Jacobson MA, Peiperl L, Volberding PA, Porteus D, Toy PTCY, Feigal DW. Packed red blood cell transfusion therapy for anemia in patients with AIDS and ARC: incidence, associated factors and outcome. *Transfusion*, 1990; 30:133-7.
15. Lemp GF, Payne SF, Rutherford GW, Hessol NA, Winkelstein W, Wiley JA, Moss AR, Chaisson RE, Chen RT, Feigal DW, Thomas PA, Werdegard D. Demographic projections of AIDS morbidity and mortality in San Francisco. *JAMA* 1990; 263:1497-1501.
16. Leoung GS, Montgomery AB, Abrams DI, Adams M, Corkery K, Wardlaw L, Busch D, Gordon S, Jacobson MA, Volberding PA, Feigal DW. Aerosolized pentamidine for prophylaxis against *Pneumocystis carinii* pneumonia: The San Francisco Community Prophylaxis Trial. *NEJM* 1990; 323:769-776.
17. The National-Institutes of Health - University of California Expert Panel for Corticosteroids as Adjunctive Therapy for *Pneumocystis pneumonia*. *NEJM* 1990; 323:1500-1504.
18. Greenspan D, Greenspan JS, Overby G, Hollander H, Abrams DI, MacPhail L, Borowsky C, Feigal DW Jr. Risk factors for rapid progression from hairy leukoplakia to AIDS: a nested case-control study. *J Acquir Immune Defic Syndr* 1991; 4:652-8.
19. MacPhail LA, Greenspan D, Feigal DW, Lennette ET, Greenspan JS. Recurrent aphthous ulcers in association with HIV infection. Description of ulcer types and analysis of T-lymphocyte subsets. *Oral Surg Oral Med Oral Pathol* 1991; 71:678-83.
20. Feigal DW, Katz MH, Greenspan D, Westenhouse J, Winkelstein W Jr, Lang W, Samuel M, Buchbinder SP, Hessol NA, Lifson AR, et al. The prevalence of oral lesions in HIV-infected homosexual and bisexual men: three San Francisco epidemiological cohorts. *AIDS* 1991; 5:519-25.
21. Jacobson MA, Hopewell PC, Yajko DM, Hadley WK, Lazarus E, Mohanty PK, Modin GW, Feigal DW, Cusick PS, Sande MA. Natural history of disseminated *Mycobacterium avium* complex infection in AIDS. *J Infect Dis* 1991; 164:994-8.
22. Dodd CL; Greenspan D; Katz MH; Westenhouse JL; Feigal DW; Greenspan JS. Oral candidiasis in HIV infection: pseudomembranous and erythematous candidiasis show similar rates of progression to AIDS. *AIDS* 1991; 5:1339-43.
23. Kemper CA, Meng TC, Nussbaum J, Chiu J, Feigal DW, Bartok AE, Leedom JM, Tilles JG, Deresinski SC, McCutchan JA. Treatment of *Mycobacterium avium* complex bacteremia in AIDS with a four-drug oral regimen. Rifampin, ethambutol, clofazimine, and ciprofloxacin. The California Collaborative Treatment Group. *Ann Intern Med* 1992; 116 :466-72.
24. Devor M, Barrett-Connor E, Renvall M, Feigal DW Jr, Ramsdell J. Estrogen replacement therapy and the risk of venous thrombosis. *Am J Med* 1992; 92:275-82.

25. Bozzette SA, Feigal D, Chiu J, Gluckstein D, Kemper C, Sattler F. Length of stay and survival after intensive care for severe *Pneumocystis carinii* pneumonia. A prospective study. California Collaborative Treatment Group. *Chest*. 1992 ; 101: 1404-6
26. Behrman RE, Kammerman LA, Feigal DW. Continued zidovudine or didanosine for human immunodeficiency virus infection. [letter] *N Engl J Med*. 1992; 327: 1598-9.
27. Tamayo SG, Rickman LS, Mathews WC, Fullerton SC, Bartok AE, Warner JT, Feigal DW Jr, Arnstein DG, Callandar NS, Lyche KD, et al. Examiner dependence on physical diagnostic tests for the detection of splenomegaly: a prospective study with multiple observers. *J Gen Intern Med*. 1993; 8: 69-75.
28. Broaddus VC, Feigal DW Jr. Starting an academic career. A survey of junior academic pulmonary physicians. *Chest*. 1994; 105: 1858-63.
29. Devor M, Wang A, Renvall M, Feigal D, Ramsdell J. Compliance with social and safety recommendations in an outpatient comprehensive geriatric assessment program. *J Gerontol*. 1994; 49: M168 -73.
30. Montgomery AB, Feigal DW Jr, Sattler F, Mason GR, Catanzaro A, Edison R, Markowitz N, Johnson E, Ogawa S, Rovzar M, et al. Pentamidine aerosol versus trimethoprim sulfamethoxazole for *Pneumocystis carinii* in acquired immune deficiency syndrome. *Am J Respir Crit Care Med*. 1995; 151: 1068 -- 74.
31. Perez Stable EJ, Coates TJ, Baron RB, Biro BS, Hauck WW, McHenry KS, Gardiner PS, Feigal D. Comparison of a lifestyle modification program with propranolol use in the management of diastolic hypertension. *J Gen Intern Med*. 1995; 10: 419--28.
32. Panel on Clinical Practices for Treatment of HIV Infection. Guidelines for the Use of Antiretroviral Agents in HIV Infected Adolescents. *Annals of Internal Medicine* 128:12(Part 2) 1079-1100.
33. Feigal D. FDA explores new antiretroviral trial designs: interview with David Feigal, M.D. Interview by John S. James. *AIDS Treat News* 1997:1-5.
34. Feigal DW, Jr. FDA public health advisory: risk of electromagnetic interference with medical telemetry systems. *Int J Trauma Nurs* 2000; 6:113-4.
35. Feigal DW, Jr. Recall of Clinipad sterile products used in prepackaged procedure kits and trays. *Int J Trauma Nurs* 2000; 6:101-2.
36. Feigal DW, Jr., Hughes JM. Public health advisory: infections from endoscopes inadequately reprocessed. *Int J Trauma Nurs* 2000; 6:1-3.
37. Feigal DW, Jr., Woodcock J. FDA public health advisory: potential for injury from medical gas misconnections of cryogenic vessels. *Int J Trauma Nurs* 2001; 7:121-2.
38. Feigal D. Who's on first? what's on second? *Control Clin Trials* 2001; 22:139-41.

39. Galluppi GR, Rogge MC, Roskos LK, Lesko LJ, Green MD, Feigal DW, Jr., Peck CC. Integration of pharmacokinetic and pharmacodynamic studies in the discovery, development, and review of protein therapeutic agents: a conference report. Clin Pharmacol Ther 2001; 69:387-99.
40. Feigal DW, Jr. FDA public health notification: reducing radiation risk from computed tomography for pediatric and small adult patients. Int J Trauma Nurs 2002; 8:1-2.
41. Petricoin EF, 3rd, Hackett JL, Lesko LJ, Puri RK, Gutman SI, Chumakov K, Woodcock J, Feigal DW, Jr., Zoon KC, Sistare FD. Medical applications of microarray technologies: a regulatory science perspective. Nat Genet 2002; 32 Suppl:474-9.
42. Feigal DW, Gardner SN, McClellan M. Ensuring safe and effective medical devices. N Engl J Med 2003; 348:191-2.
43. Feigal DW Jr. Public health notification: diathermy interactions with implanted leads and implanted systems with leads. J Ir Dent Assoc. 2003;49(1):26-7.
44. Gutman S, Feigal D. Decision making in pharmacogenomic diagnosis: is there anything new under the sun? Drug Discov Today. 2003 Sep 1;8(17):765-6.
45. Kaplan AV, Baim DS, Smith JJ, Feigal DA, Simons M, Jefferys D, Fogarty TJ, Kuntz RE, Leon MB. Medical device development: from prototype to regulatory approval. Circulation. 2004 Jun 29;109(25):3068-72
46. Mehran R, Leon MB, Feigal DA, Jefferys D, Simons M, Chronos N, Fogarty TJ, Kuntz RE, Baim DS, Kaplan AV. Post-market approval surveillance: a call for a more integrated and comprehensive approach. Circulation. 2004 Jun 29;109(25):3073-7.
47. Califf RM, Nissen SE, DeMaria AN, Ohman EM, Pitt B, Willerson JT, Bilheimer DW, Cohn JN, Feigal DW Jr, Hampson L, Lorell BH, Pepine CJ, Popp RL. Task force 2: Investigator participation in clinical research. J Am Coll Cardiol. 2004 Oct 19;44(8):1729-36.
48. Myerburg RJ, Feigal DW, Jr., Lindsay BD. Life-threatening malfunction of implantable cardiac devices. N Engl J Med 2006;354(22):2309-11.
49. Baim, D.S., et al., Medical device development: managing conflicts of interest encountered by physicians. Catheter Cardiovasc Interv, 2007. 69(5): p. 655-64.
50. Jacobson, J.D. and D. Feigal, Red sky in the morning: modifying prescription drug labels as a result of postmarket surveillance. Food Drug Law J, 2007. 62(3): p. 529-46.

II. INVITED ARTICLES, BOOK CHAPTERS, BOOKS

1. Feigal DW, Hulley SB. Mild hypertension: where should treatment begin? (Editorial)
Western J Med 141:515-7, 1984.
2. Feigal DW, Glasser R. Preoperative risk in the elderly. in Bolt RJ ed., *Medical evaluation of the surgical patient*. Futra Publishing, Mount Kisco, New York. pp 67-96, 1987.
3. Lo B, Feigal DW, Hulley SB. The study subjects: III. Ethical considerations. In: *Health research methods: An epidemiologic approach*, ed. Hulley SB, Cummings S. Williams & Wilkins, 1987.
4. Feigal DW. Data management & Analysis: In: *Health research methods: An epidemiologic approach*, ed. Hulley SB, Cummings S. Williams & Wilkins, 1987.
5. Feigal DW, Gutman S. Drug Development, Regulation and Genetically Guided Therapy
2002
6. Feigal, D.W., Chapter III.2.11 – Postmarket Considerations in Biomaterials and Medical Devices, in Biomaterials science: an introduction to Materials in Medicine, B.D. Ratner, Editor. Elsevier/Academic Press, Boston. 2013

Board Service

Renovo Ltd, Manchester, England

A biotech company developing anti-scarring biologicals and drugs

September 2004 - May 2006	Non-Executive Member, Board of Directors Privately Held Venture Funded Biotech
June 2006 – Feb 2009	Non-Executive Member, Board of Directors Traded on the London Stock RNVO Committees: Audit Committee

Aspect Medical Inc., Newton, Massachusetts

A medical device company developing anesthesia monitoring equipment

January 2005 - Sept - 2009	Non-Executive Member, Board of Directors Traded on the NASDAQ ASMP Committees: Audit Committee
-------------------------------	--

Alexza Inc., Palo Alto, California

A drug delivery company developing inhaled medications for acute care

September 2004 - May 2006	Scientific and Regulatory Advisory Board Member Traded on the NASDAQ ALXA
------------------------------	--

Baird Venture Partners, Chicago, Illinois

A venture fund managing investments in Medical Devices and IT

September 2004 - 2008	Scientific Advisory Board Member
--------------------------	----------------------------------

Panorama Capital, Palo Alto, California

A venture fund managing investments in Medical Innovation

June 2006 - May 2007	Scientific Advisor
-------------------------	--------------------

EJ Financial Services, Phoenix, AZ

A Medical Technology Investment Company

September 2006 - August 2007	Scientific Advisor
---------------------------------	--------------------

In Vivo Therapeutics

A Biotechnology Company

September 2006 - 2013	Scientific Advisory Board
-----------------------	---------------------------

EXHIBIT B

Prior Testimony

David W Feigal, Jr.

Trial or Arbitration Testimony in the Last 4 years:

5-23-2012 Phoenix, AZ	Rosemary Everett, Ray Everett, Et Al. vs. C. R. Bard, Inc. In the Superior Court of the State of Arizona, in and for the County of Maricopa No. CV 2009-019232.
6-18-2012 and 6-19-2012 Atlantic City, NJ	Rebecca Ree Wilkins Reynolds, (ATL-L-2644-03MT); Riley Wilkinson, (ATL-L-1311-08MT); Jason Young, (ATL-L-8349-05MT); Kathleen Rossitto, (ATL-L-7481-10MT); Plaintiffs, vs. Hoffmann-la Roche, INC. and Roche Laboratories, INC., Defendants in Superior Court of New Jersey, Atlantic County/Civil Division.
12-23-2012 New York, NY	Arbitration Hearing: Eagle Pharmaceuticals, Inc., Claimant, -against- The Medicine Company, Respondent. American Arbitration Association. Case No. 13 122 Y 02642 11
3-20-13 Cleveland, OH	In Re: Gadolinium Based Contrast Agents Products Liability Litigation (mdl No. 1909) Paul Decker and Karen Decker, Plaintiffs, vs. GE Healthcare, Inc., Et al., Defendants. In the United States District Court Northern District of Ohio Eastern Division. Case No. 1:12 GD 50004
4-3-13 Los Angeles, CA	Jack and Nancy Cooper, Plaintiff, v. Takeda Pharmaceuticals, et. al., Defendants, in the Superior Court, State of California, County of San Francisco. Case No. 12-518535.
5-3-13 Chicago, IL	Dolores and Milton Tietz, Plaintiff v. Abbott Laboratories, Defendant, in Circuit Court of Cook County, Illinois. Case No. 12L-002715
8-21-13 San Diego, CA	Kevin Fleischmann, Plaintiff v. DJO, Inc., Defendant, in Superior Court of the State of California in and for the County of San Diego, Case No. 37-2010-00093122-CU-PL-CTL
9-24-13 Baltimore, MD	Camhong An, et al. Plaintiffs, v. Takeda Pharmaceuticals America Inc., et al. Defendants, in the Circuit Court for Baltimore City, Baltimore, MD. Case No. 24-C-12-003565
12-6-13 Las Vegas, NV	Alsabaugh, Alen, Plaintiff, v. Takeda Pharmaceutical America Inc., et al, Defendant, in the Eight Circuit Court of Nevada, Las Vegas, NV. Eighth District Court, Nevada. case number A-12-655741-C
2-27-14 Atlantic City, NJ	Kamie S. Kendall, Plaintiff, v. Hoffmann-la Roche Inc.; Roche Laboratories Inc.; F. Hoffmann-la Roche Ltd.; and Roche Holding Ltd., Defendants, in Superior Court of New Jersey Law Division: Atlantic County, Docket No.: ATL-L-8213-05 MT

Trial Testimony in the Last 4 Years

3-27-14 and 3-28-14 Lafayette, LA	in Re: Actos (pioglitazone) Products Liability Litigation, MDL No. 6:11-Md-2299, Terrence and Susan Allen v. Takeda Pharmaceuticals International, Inc., et al, in the United States District Court for the Western District of Louisiana, Lafayette Division, No. 6:12-cv-00064-rfd-pjh
4-13-14 and 4-14-14 Chicago, IL	In Re: Actos Litigation, Diane Whitlatch, Individually and as Special Administrator for the Estate of William M. Whitlatch, Plaintiff, vs. Takeda Pharmaceuticals America, Inc.; Takeda Pharmaceuticals U.S.A., Inc., f/k/a Takeda Pharmaceuticals North America, Inc.; and Takeda Pharmaceutical Company Limited, Defendant, in the Circuit Court of Cook County, Illinois County Department Case No.: 201 L-I-010011 Case No.: 2012-L-006087
7-28-14 Boston, MA	Michael Tersigni v. Wyeth Pharmaceuticals, Inc., and Pfizer, Inc. in United States District Court for the District of Massachusetts Civil Action No. 1:11-CV-10466-JLT
10-01-14 Philadelphia, PA	Frances Wisniewski, Plaintiff, v. Takeda Pharmaceuticals North America, Inc., et al., Defendants, in the Court of Common Pleas First Judicial District of Pennsylvania Civil Trial Division, July Term, 2012, No. 02272 Philadelphia, Pennsylvania.
11-5-14 and 11-6-14 Martinsburg, WV	Richard P. Myers and Cynthia Myers v. Takeda Pharmaceuticals North America, Inc., et al., Defendants, in the Circuit Court of Berkeley County, West Virginia, Civil Actin 13-C-315.
11-12-14 and 11-13-14 Burlington, VT	Kevin Drake and Lori Drake, Individually and as Next Friend of J.D, Plaintiffs, v. Allergan, Inc., Defendant, In the United States District Court for the District of Vermont Case No. 2:13-CV-234
2-3-15, 2-4-15, and 2-9-15 Philadelphia, PA	John Kristufek v. Takeda Pharmaceuticals America, Inc., et al., in the Court of Common Pleas of Philadelphia County, First Judicial District of Pennsylvania, Civil Trial Division, July Term, 2012, No. 02275
2-5-15 Reno, NV	Kevin Phillips, Plaintiff, v. C. R. Bard, et al., Defendants, in the U. S. District Court for the District of Nevada, Civil Action Number 3:12-cv-00344-RCJ-WGC
5-12-15 New York, NY	Pericor Therapeutics, Inc., Claimant, v. Merck & Co., Inc., et.al., before the American Arbitration Association, Arb No. 13 122 Y 03052 11
9-29-15 to 10-01- 15, 10-06-15	George Decou and Mary Iorio v. Takeda Pharmaceuticals, Inc., et al., in District Court, Clark County, Nevada, Case No. A-13-683446-C

Deposition Testimony in the Last 4 Years

4-25-12 San Francisco, CA	In Re: Chantix (varenicline Products) Liability Litigation. United States District Court Northern District of Alabama Southern Division, No. 2:09-CY-2039-IPJ MDL No. 2092.
6-7-12 Encino, CA	Richard Hirschinger, D.D.S., on Behalf of Himself and All Others Similarly Situated Plaintiffs, vs. Anthem Blue Cross, A California Corporation and Does 1 to 50, Inclusive Defendants. Superior Court of the State of California for the County of Los Angeles, Central District. CASE No: BC 402739.
6-22-12 San Francisco, CA	Donna Treadwell, Plaintiff, Vs. Allergan, Inc., et al. Defendants. Superior Court for the District of Columbia Civil Division. Civil Action No. 2010 Ca 009087 M. Rockville, MD.
7-17-12 San Francisco, CA	In Re: Cold Therapy Cases. Coordination Proceeding Judicial Council Special Title (rule 3.550) Coordination Proceeding No. 4680. In the Superior Court of the State of California in and for the County of San Diego, Central Division.
8-30-12 San Francisco, CA	Ronna Dalton and John Dalton, Plaintiff(s), vs. Animas Corporation, Defendant(s), in the United States District Court Western District of Kentucky at Louisville Civil Action No.:3:09-CV-354-H.
8-31-12 San Francisco, CA	Maureen E. Calisi, Plaintiff, v. Abbott Laboratories, Defendant. In United States District Court District of Massachusetts, Civil Action No. 11-CV-10671
12-6-12 New York, NY	Eagle Pharmaceuticals, Inc., Claimant, -against- The Medicine Company, Respondent. American Arbitration Association. Case No. 13 122 Y 02642 11
12-30-12 San Francisco, CA	In Re: Gadolinium Based Contrast Agents Products Liability Litigation (MDL No. 1909) Paul Decker and Karen Decker, Plaintiffs, vs. GE Healthcare, Inc., Et al., Defendants. In the United States District Court Northern District of Ohio Eastern Division. Case No. 1:12 GD 50004
1-28-13 Washington, DC 6-12-13 New York, NY	Jack and Nancy Cooper, Plaintiff, v. Takeda Pharmaceuticals, et. al., Defendants, in the Superior Court, State of California, County of San Francisco. Case No. 12-518535; Camhong An, et al., Plaintiffs, v. Karl Nieberlein and Takeda Pharmaceuticals, et. al., in the Circuit Court of the City of Baltimore State of Maryland. Case No. 24-C12003565
1-30-13 San Francisco, CA	Jessica Wells, Individually and as Next Friend of Jackson Wells, v. Allergan Inc., Defendants, in the United States District Court for the Western District of Oklahoma. Case No. 5:12-CV-00973-C.
4-30-13 San Francisco, CA	In Re: C.R. Bard, Inc. Pelvic Repair System Products Liability Litigation (MDL No. 2187), in the United States District Court for the Southern District of West Virginia Charleston Division

Deposition Testimony in the Last 4 Years

6-12-13 New York, NY	Camhong An, et al. Plaintiffs, v. Takeda Pharmaceuticals America, Inc., et al. Defendants, in the Circuit Court for Baltimore City, Baltimore, MD. Case No. 24-C-12-003565
7-25-13 San Francisco, CA	In Re: Diet Drugs (phentermine / fenfluramine / dexfenfluramine) Products Liability Litigation (MDL No. 1203) in United States District Court for the Eastern District of Pennsylvania
8-14-13 San Francisco, CA	Heather Brown, Danny & Shauna Brown v. George W. DeMuth, MD, et al., in the Circuit Court of Montgomery County, Alabama. Case No. CV-2009-900734.00
10-9-13 San Francisco, CA	In Re: Actos (pioglitazone) Products Liability Litigation (MDL No. 6:11-md-2299), in the United States District Court for the Western District of Louisiana
11-6-13 San Francisco, CA	In Stephen Wendell & Lisa Wendell, Plaintiffs, V. Johnson & Johnson; Centocor, Inc.; Abbott Laboratories; Smithkline Beecham d/b/a Glaxosmithkline; Teva Pharmaceuticals USA; Gate Pharmaceuticals, A Division of Teva Pharmaceuticals USA; Par Pharmaceuticals; Mylan Laboratories, Inc., Defendants, in United States District Court, Northern District of California Oakland Division, Case No. CV09-4124 CW
11-21-13 San Francisco, CA	In Anthony Payne and Johnita Payne, His Wife, Plaintiffs, vs. C. R. Bard, Inc. and Bard Peripheral Vascular, Inc., Defendants, in United States District Court Middle District of Florida Orlando Division, Case No. 6:11-cv-01582-orl-37gjk
12-24-13 Redondo Beach, CA	Kamie S. Kendall, Plaintiff, vs. Hoffmann-la Roche Inc.; Roche Laboratories Inc.; F. Hoffmann-la Roche Ltd.; and Roche Holding Ltd., Defendants, in Superior Court of New Jersey Law Division: Atlantic County, Docket No.: ATL-L-8213-05 MT
2-19-14 San Francisco, CA	Diane Whitlatch, Individually and as Special Administrator for the Estate of William M. Whitlatch, Plaintiff, vs. Takeda Pharmaceuticals America, Inc.; Takeda Pharmaceuticals U.S.A., Inc., f/k/a Takeda Pharmaceuticals North America, Inc.; and Takeda Pharmaceutical Company Limited, Defendant, in the Circuit Court of Cook County, Illinois County Department Case No.: 201 L-I-010011 Case No.: 2012-I-006087
5-21-14 San Francisco, CA	Kevin Phillips, Plaintiff, v. C. R. Bard, et al., Defendants, in the U. S. District Court for the District of Nevada, Civil Action Number 3:12-cv-00344-RCJ-WGC; Melanie Rackliff, Plaintiff, v. CR Bard, Inc., Bard Peripheral Vascular, Inc., Defendants, Superior Court of Arizona, Maricopa County, Case No. CV2011-021206; and, Tina Barkley and Jeffery Barkley, Plaintiffs, v. CR Bard, Inc., Bard Peripheral Vascular, Inc., Defendants, Superior Court of Arizona, Maricopa County, Case No. CV2011-021250
7-17-14 San Francisco, CA	Donald Gates, Plaintiff, v. Sutter General Hospital, and Intuitive Surgical, in Superior Court, State of California or the County of Sacramento, Case No. 34-2011-00103436.

Deposition Testimony in the Last 4 Years

8-6-14 Cary, NC	Candie L. Willoughby and Jerome Willoughby, Plaintiffs, v. Johnston Memorial Hospital Authority, Defendant and Third-party Plaintiff, v. Steris Corporation and General Electric Company, Third-party Defendants, in the State of North Carolina in the General Court of Justice, Superior Court Division, County of Johnston, File No. 11-CVS-3008
8-19-14 San Francisco, CA	Kevin Drake and Lori Drake Individually and as Next Friend of J.D., Plaintiffs, vs. Allergan, Inc., Defendant, in the United States District Court for the District of Vermont Case No. 2:13-CV-234
9-16-14 San Francisco, CA	Jennifer Campbell, vs. Plaintiff, C.R. Bard, D/b/a Bard Peripheral Vascular, Inc., Bard Peripheral Vascular, Inc.; Georgetown Community Hospital, LLC, A/k/a the Bariatric Center Georgetown Community Hospital; St. Joseph Healthcare, Inc., Central Kentucky Radiology, PLLC; Dale Absher, MD, Individually; and Jason Alexander Harper, MD, Individually, Defendants. In, Commonwealth of Kentucky, Scott Circuit Court, Division I, Civil Action No. 08-CI-541
9-25-14 Baltimore, MD	Kevin Brunston and Roshanda Guy, Plaintiffs, vs. Bayer Healthcare Pharmaceuticals, Inc, et al., Defendants, in the Superior Court of California, for the County of San Bernardino, Case No. CIVDS 1310687
10-20-14 New York, NY	Mary K. Jones, Individually and on Behalf of All Others Similarly Situated, Plaintiff, vs. Pfizer Inc., et al., Defendants, in the United States District Court, Southern District of New York, No. 10-CV-03864(AKH)
11-18-14 Phoenix, AZ	In Re: Zimmer Nexgen Knee Implant Products Liability Litigation, In the United States District Court Northern District of Illinois Eastern Division, Master Docket Case MDL No. 2272 All Cases No. 1:11-CV-05468
12-2-14 Phoenix, AZ	Karen Larson, Plaintiff, vs. Abbott Laboratories, et al., Defendants, in the Circuit Court for Baltimore City, Maryland Case No.24-C-13-000002
6-9-15 San Francisco, CA	In Re: AlloDerm Litigation, Superior Court of the State of New Jersey Law Division: Middlesex County, Case Code 295.
6-17-15 Los Angeles, CA	Theresa Enoch, et al., Plaintiffs, vs. Forest Research Institute, Inc., et al, Defendants, In Re: Forest Research Institute, United States District Court District of New Jersey Camden Vicinage, Master Docket No.13-cv-1832-RBK/AMD.
8-11-15 San Diego, CA	Anna A. Good, and Dennis W. Good, Plaintiffs, vs. Pfizer Inc.; Wyeth Pharmaceuticals, Inc.; Wyeth LLC F/K/A, American Home Products Corporation; McKesson Corporation; and Does 1 through 10, in Superior Court for the State of California, County of Los Angeles, JCCP No.: 4032, [San Diego Superior Court Case No.: 37-2012-00084244-CU-PL-CTL]

Deposition Testimony in the Last 4 Years

10-20-15 Los Angeles, CA	In Re: Mirena IUD Products Liability Litigation MDL No. 2434, in the U.S. District Court Southern District of New York, Case No. 7:13-md-02434-cs-lms, and the Superior Court of New Jersey, Law Division, Bergen County, Case No. 297.
11-13-15 Boston, MA	United States of America, States of California, Colorado, et al., ex rel. Alex Booker and Edmund Hebron, Plaintiffs, Vs. Pfizer, Inc., Defendant, in the U.S. District Court, District of Massachusetts, Case No. 110-cv-11166-dpw
11-19-15 San Francisco, CA	Eve Sherrer, Plaintiff, vs. Truman Medical Center, Inc., Boston Scientific Inc., C.R. Bard, et al., Defendants, in the Circuit Court of Jackson County, Missouri at Kansas City, Case No. 1216-cv27879
5-4-16 Los Angeles, CA	Copley, Plaintiff v. Bayer HealthCare Pharmaceuticals, Inc., et al., Defendants, U.S. District Court, Middle District of Tennessee, Nashville Division, Civil Action No. 3:14-cv-00406

EXHIBIT C

David Feigal, M.D.
Materials Reviewed

Academic Literature

ACOG. Practice Bulletin 73: Use of hormonal contraception in women with coexisting medical conditions. *Obstetrics & Gynecology* 2006; 107(6):1453-1472.

ACOG. Committee Opinion 450: Increasing use of contraceptive implants and intrauterine devices to reduce unintended pregnancy. *Obstet Gynecol* 2009; 114(6):1434-1438.

ACOG. Practice Bulletin 121: long-acting reversible contraception: implants and intrauterine devices. *Obstetrics & Gynecology* 2011; 118:184-196.

American Association of Pediatricians. Committee on Adolescence. Policy Statement - Contraception for Adolescents. *Pediatrics* 2014. 134(4): e1244-56.

Alder JB et al. Levonorgestrel implants and intracranial hypertension. *N Engl J Med*. 1995; 332(25):1720-1721.

Almenoff, J., et al., Perspectives on the use of data mining in pharmaco-vigilance. *Drug Saf* 2005. 28(11):981-1007.

Bahemuka M. Benign intracranial hypertension associated with the use of depo-provera (depot medroxyprogesterone): a case report. *East Afr Med J*. 1981; 58(2):140-141.

Ball AK & Clarke CE. Idiopathic intracranial hypertension. *Lancet Neurol*. 2006; 5(5):433-442

Barnum AM and Jones J. National Center for Health Statistics. Data Brief No. 188. Trends in Long-acting Reversible Contraception Use Among U.S. Women Aged 15-44, 2015.

Biousse V et al. Update on the pathophysiology and management of idiopathic intracranial hypertension. *J Neurol Neurosurg Psychiatry*. 2012; 83(5):488-494.

Boresntein M et al. A basic introduction to fixed-effect and random-effects models for meta-analysis. *Res Syn Meth* 2010; 1:97-111)

Bradburn MJ et al. Much ado about nothing: a comparison of the performance of meta-analytical methods with rare events. *Stat Med* 2007; 26:53-77.

Centers for Disease Control and Prevention (CDC). US Medical Eligibility Center for Contraceptive Use. *Morbidity and Mortality Weekly Report* 2010; 59(RR-4).

Centers for Disease Control and Prevention (CDC). Update to CDC's U.S. Medical Eligibility Criteria for Contraceptive Use, 2010: Revised Recommendations for the Use of Contraceptive Methods During the Postpartum Period. 2011. 60(26):878-883.

Center for Disease Control and Prevention (CDC). Reproductive Health: Pregnancy Mortality Surveillance System, 2014. Available from:
<http://www.cdc.gov/reproductivehealth/MaternalInfantHealth/PMSS.html>.

Center for Disease Control. Fact Sheet: Contraception 2015. Available from:
<http://www.cdc.gov/nchs/fastats/contraceptive.htm>.

Chan JW. Idiopathic intracranial hypertension associated with depot medroxyprogesterone. Eye (Lond) 2006. 20(12):1396-7.

Committee on Contraceptive Research and Development, D.o.H.S.P., Insitute of Medicine, Contraceptive Research, Introduction, and Use: Lessons From Norplant. 1998. 128 pages.

Contraceptive Research, Introduction and Use: Lessons from Norplant (1998), Historical Background, at <http://www.nap.edu/read/5946/chapter/6>.

Costa-Bouzas J et al. HEpiMA: software for the identification of heterogeneity in meta-analysis. Comp Methods and Prog Biomed 2001; 64:101-107.

Dandy, W.E. Intracranial Pressure without Brain Tumor: Diagnosis and Treatment. Ann Surg, 1937. 106(4): 492-513.

Daniels AB et al. Profiles of Obesity, Weight Gain and Quality of Life in Idiopathic Intracranial Hypertension (Pseudotumor Cerebri). American Journal of Ophthalmology 2007; 143,4:635-641.

Deangelis LM. Tumors of the Central Nervous System and Intracranial Hypertension and Hypotension. Cecil Textbook of Medicine, L. Goldman and A.I. Schafer, Editors. 2011.

Department of Health and Human Services. Proposed Rule: Labeling for Prescription Drugs used in Man. Federal Register 1975. 40(67): 15392-15399.

Department of Health and Human Services and Food and Drug Administration. Labeling and Prescription Drug Advertising; Content and format for labeling human prescription drugs. June 26. Federal Register, 1979. 44 (124): pp. 37434 – 37467.

Digre KB et al. Pseudotumor cerebri and pregnancy. Neurology 1984. 34(6): 721-9.

Duggirala HJ et al. Use of data mining at the food and drug administration. J Am Med Inform Assoc 2015.

DuMouchel, W. and D. Pregibon, Empirical bayes screening for multi-item associations. Proceedings of the conference on knowledge discovery and data. Aug 26-29, 2001. ACM Press. 67-76.

Durcan P et al. The Incidence of Pseudotumor Cerebri: Population Studies in Iowa and Louisiana. Arch Neurol. 1988; 45:875-877.

Etminan M et al. Risk of Intracranial Hypertension with Intrauterine Levonorgestrel, Therapeutic Advances in Drug Safety. 2015; 6(3):110-113.

Etminan M. Risk of intracranial hypertension with intrauterine levonorgestrel: reply. Ther Adv Drug Saf. 2016; 7(1):25-26.

Evans SJ et al. Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiol Drug Saf 2001. 10(6):483-6.

Food and Drug Administration. Center for Drug Evaluation and Research. Manual of Policies & Procedures 6020.10. NDAs: "Dear Health Care Professional" Letters July 2, 2003.

Food and Drug Administration. Guidance for Industry. Good pharmacovigilance practices and phamacoepidemiologic assessment. March, 2005. 23 pages. Available from:
<http://www.fda.gov/downloads/RegulatoryInformation/Guidances/UCM126834.pdf>.

Food and Drug Administration. Guidance for Industry. Presenting Risk Information in Prescription Drug and Medical Device Promotion. May, 2009. 27 pages. Available from:
<http://www.fda.gov/downloads/RegulatoryInformation/Guidances/UCM155480.pdf>.

Food and Drug Administration. Guidance for Industry and FDA Staff. Dear Health Care Provider Letters: Improving Communication of Important Safety Information. November, 2010. 12 pages. Available from:
<http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM233769.pdf>.

Food and Drug Administration. What is Data Mining? 2006. Available from:
<http://www.fda.gov/ohrms/dockets/ac/06/briefing/2006-4266b1-02-06-FDA-appendix-f.pdf>

Food and Drug Administration. Adverse Event Reporting System (AERS). Updated April 27, 2012. Available from:
<http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Surveillance/AdverseDrugEffects/default.htm>.

Friedman D. Risk of intracranial hypertension with intrauterine levonorgestrel. *Ther Adv Drug Saf.* 2016; 7(1):23-24.

Friedman DI and Jacobson DM. Diagnostic criteria for idiopathic intracranial hypertension. *Neurology* 2002. 59(10):1492-5.

Furlong L. Division of Reproductive and Urological Drug Products. CDER. FDA. NDA 21-255 Mirena. Medical Review. December 5, 2000. 50 pages. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/21-225.pdf Mirena Medr.pdf

Galvin JA & Van Stavern GP. Clinical characterization of idiopathic intracranial hypertension at the Detroit Medical Center. *J Neurol Sci.* 2004; 223(2):157-160.

Giuseffi V et al. Symptoms and disease associations in idiopathic intracranial hypertension (pseudotumor cerebri): a case-control study. *Neurology* 1991. 41:239-44.

Glueck CJ et al. Idiopathic intracranial hypertension, polycystic-ovary syndrome, and thrombophilia. *J Lab Clin Med.* 2005; 145(2):72-82.

Harpaz R et al. A time-indexed reference standard of adverse drug reactions. *Sci Data* 2014. 1:140043.

Hazell L and Shakir SAW. Under-Reporting of Adverse Drug Reactions: A Systematic Review. *Drug Safety* 2006; 29(5): 389-396, 2006.

Hill AB. The Environment and Disease: Association or Causation? *Proc R Soc Med* 1965. 58: 295-300.

Ireland, B et al. The search for causes of idiopathic intracranial hypertension. A preliminary case-control study. *Arch Neurol* 1990. 47(3):315-20.

Kesler A et al. Idiopathic intracranial hypertension: risk of recurrences. *Neurology.* 2004;63(9):1737-1739.

Ko MW et al. Weight Gain and Recurrence in Idiopathic Intracranial Hypertension: A Case-Control Study. *Neurology.* 2011; 76:1564-1567.

Koerner JC and Friedman DI. Inpatient and emergency service utilization in patients with idiopathic intracranial hypertension. *J Neuroophthalmol* 2014. 34(3):229-32.

Lee AG and Wall M. Idiopathic intracranial hypertension (pseudotumor cerebri): Clinical features and diagnosis. In: UpToDate, Brazis PW (Ed), UpToDate, Waltham, MA. (Accessed February 25, 2016).

Lee AG and Wall M. Idiopathic intracranial hypertension (pseudotumor cerebri): Epidemiology and pathogenesis. In: UpToDate, Brazis PW (Ed), UpToDate, Waltham, MA. (Accessed February 25, 2016).

Lee AG and Wall M. Idiopathic intracranial hypertension (pseudotumor cerebri): Prognosis and treatment. In: UpToDate, Brazis PW (Ed), UpToDate, Waltham, MA. (Accessed February 25, 2016).

Lee AG and Wall M. Patient information: Idiopathic intracranial hypertension (pseudotumor cerebri) (The Basics). In: UpToDate, Brazis PW (Ed), UpToDate, Waltham, MA. (Accessed February 25, 2016).

Levine JG et al. Reply: The evaluation of data mining methods for the simultaneous and systematic detection of safety signals in large databases: lessons to be learned. Br J Clin Pharmacol 2006. 61(1):105-13; author reply 115-7.

Lippes Loop Intrauterine Device. Jacobs School of Medicine and Biomedical Sciences. University at Buffalo 2016.
https://medicine.buffalo.edu/research/research_highlights.host.html/content/shared/smb/research_highlights/lippes-loop.detail.html.

Ludbrook J and MJ Lew. Estimating the risk of rare complications: is the 'rule of three' good enough? ANZ J Surg 2009. 79(7-8):565-70.

Mantha S et al. Assessing the risk of venous thromboembolic events in women taking progestin-only contraception: a meta-analysis. BMJ 2012; 345: e4944.

Marnach ML et al. Current issues in contraception. Mayo Clin Proc. 2013; 88(3):295-299.

Martinez H, et al. Abstract: Atypical Pseudotumour Cerebri. Neuro-ophthalmology 2010; 34(3): 131-288.

McAdams M et al. Estimating the Extent of Reporting to FDA: A Case Study of Statin-Associated Rhabdomyolysis. Pharmacoepidemiology and Drug Safety. 2008.

MedSafe - New Zealand Medicines and Medical Devices Safety Authority. Minutes of the 106th Medicines Adverse Reactions Committee Meeting - 14 June 2001.
<http://www.medsafe.govt.nz/profs/adverse/Minutes106.htm>

MedSafe - New Zealand Medicines and Medical Devices Safety Authority. Minutes of the 105th Medicines Adverse Reactions Committee Meeting - 14 March 2001.
<http://medsafe.govt.nz/profs/adverse/minutes105.htm>.

NORDIC Idiopathic Intracranial Hypertension Study Group Writing Committee et al. Effect of acetazolamide on visual function in patients with idiopathic

intracranial hypertension and mild visual loss: the idiopathic intracranial hypertension treatment trial. *JAMA*. 2014; 311(16):1641-1651.

Population Council. Press Release: New Initiative Expands Access to Population Council-Developed Contraceptive Jadelle. September 26, 2012.

Radhakrishnan K et al. Epidemiology of idiopathic intracranial hypertension: a prospective and case-control study. *J Neurol Sci* 1993. 116(1):18-28.

Rai R, et al. The relationship between the levonorgestrel-releasing intrauterine system and idiopathic intracranial hypertension. Poster session presentation at ARVO 2015 Annual Meeting. May 4, 2015.

Rangel-Castillo L et al. Management of Intracranial Hypertension. *Neurol Clin*. 2008; 26(2): 521-541.

Raouf N et al. The incidence and prevalence of idiopathic intracranial hypertension in Sheffield, UK. *Eur J Neurol*. 2011; 18(10):1266-1268.

Shaw GY and Million SK. Benign intracranial hypertension: a diagnostic dilemma. *Case Rep Otolaryngol* 2012. 2012:814696.

Sivin I. Serious adverse events in Norplant users reported to the Food and Drug Administration's MedWatch Spontaneous Reporting System. *Obstet Gynecol*. 1995; 86(2):318-320.

Speidel JJ et al. Pregnancy: not a disease but still a health risk. *Contraception*. 2013; 88:481-484.

Sunku AJ et al. Benign intracranial hypertension associated with levonorgestrel implants. *Annals Neurol*. 1993; 34:299.

Szarfman A et al. Use of screening algorithms and computer systems to efficiently signal higher-than-expected combinations of drugs and events in the US FDA's spontaneous reports database. *Drug Saf* 2002. 25(6):381-92.

Szarfman A et al. Pharmacovigilance in the 21st century: new systematic tools for an old problem. *Pharmacotherapy* 2004. 24(9): 1099-104.

Takkouche B et al. Confidence intervals for heterogeneity measures in meta-analysis. *Am J Epidemiol* 2013; 178(6):993-1004.

Thierry M. Pioneers of the intrauterine device. *Eur J Contracept Reprod Health Care* 1997. 2(1):15-23.

Van Belle G. Statistical rules of thumb. 2nd ed. Wiley series in probability and statistics. 2008, Hoboken, N.J.: Wiley. xxi, 272.

Wall M & George D. Idiopathic intracranial hypertension. A prospective study of 50 patients. *Brain*. 1991; 114:155-180.

Watkins E. From Breakthrough to Bust: The Brief Life of Norplant, The Contraceptive Implant. *J Women's History* 2010; 22(3):88-111.

Weber ME. Levonorgestrel implants and intracranial hypertension. *N Engl J Med*. 1995; 332(25):1721.

World Health Organization. 19th WHO Model List of Essential Medicines. 2015. Available from:

http://www.who.int/medicines/publications/essentialmedicines/EML2015_8-May-15.pdf.

World Health Organization. Reproductive Health and Research. Medical eligibility criteria for contraceptive use. 4th ed. 2010, Geneva: Department of Reproductive Health and Research, World Health Organization. 125 pages.

Wyeth-Ayerst Laboratories, Physician's Desk Reference. Norplant Systems (levonorgestrel Implants) Prescribing Information Labeling. 1996: 2759-2764.

Wysowski DK & Green L. Serious Adverse Events in Norplant Users Reported to the Food and Drug Administration's MedWatch Spontaneous Reporting System. *Obstetrics & Gynecology*. 1995; 85(4):538-542.

Yeung EH et al. Adiposity and sex hormones across the menstrual cycle: the BioCycle Study. *Int J of Obesity*. 2013; 37:237-243.

Valenzuela RM et al. Poster 102: Exploratory study of the relationship between the levonorgestrel-releasing intrauterine system and idiopathic intracranial hypertension. North American Neuro-Ophthalmology Society 41st Annual Meeting Abstracts. 2015.

Vickery Z et al. Weight change at 12 months in users of three progestin-only contraceptive methods. *Contraception*. 2013; 88:503-508.

Statutes and Regulations

44 Fed. Reg. 37434

44 Fed. Reg. 37447

65 Fed. Reg. 81082

71 Fed. Reg. 15

71 Fed. Reg. 3922

71 Fed. Reg. 3946

73 Fed. Reg. 2848

21 CFR 201.57

21 CFR 201.80

21 CFR 202.1

FDCA 505(o)(4).

Labels and Other Materials Obtained from Drugs@FDA or Other Public Sources

1996 Norplant Label

2002 Jadelle Label

2002 Jadelle Supplement 003

2006 Mirena Label (Canada)

2014 Mirena Label

2011 FIMEA Jadelle (Finland) Approved Product Information

Jadelle NDA 20-544 Supplement Submission Letter

openFDA, About, FDA.gov (updated 3/10/16).

Deposition Testimony

Deposition of Julianne Schoendorf

Documents Received from Plaintiffs

“Response to Queries.pdf”

“Who Analysis.xls”

Documents from Bayer Productions

MIR_AC-R_00175589

MIR_CCDS_00000742

MIR_CCDS_00000755

MIR_INDNDA_00010441-00010516

MIR_INDNDA_00010719-00010752

MIR_INDNDA_00010880 at 890

MIR_INDNDA_00011072

MIR_INDNDA_00011157

MIR_INDNDA_00011509

MIR_INDNDA_00012119

MIR_INDNDA_00012697

MIR_INDNDA_00013409

MIR_INDNDA_00014291

MIR_INDNDA_00032125

MIR_INDNDA_00032132-322167

MIR_INDNDA_00033411

MIR_INDNDA_00035535

MIR_INDNDA_00035578

MIR_INDNDA_00035657-00035712

MIR_INDNDA_00036978

MIR_INDNDA_00037114

MIR_INDNDA_00037337

MIR_INDNDA_00037611
MIR_INDNDA_00044480
MIR_INDNDA_00053366
MIR_INDNDA_00127646
MIR_INDNDA_00202190-00202289
MIR_INDNDA_00213206-00213309
MIR_INDNDA_00246210-00246319
MIR_INDNDA_00246321
MIR_INDNDA_00253743
MIR_INDNDA_00254000
MIR_INDNDA_00270659
MIR_INDNDA_00279739-00279833
MIR_INDNDA_00289748-00289752
MIR_INDNDA_00290033-00290974
MIR_INDNDA_00309138-00309205
MIR_INDNDA_00316289-00316387
MIR_INDNDA_00322869-00322899
MIR_INDNDA_00340335-00340449
MIR_INDNDA-R_00324838-00324987
MIR_JR_00096234
MIR_JR_00177760
MIR_JR_00186051
MIR_JR_00186066
MIR_JR_00186491

MIR_JR_00186518

MIR_JR_00186596

MIR_JR_00209606

MIR_JR_00245552

MIR_JR_00245729

MIR_JR_00442929

MIR_JR_00855811-00855860

MIR_JSEU_00002108

MIR_JSEU_00571178

MIR_JSEU_00571180

MIR_JSEU_00780138

MIR_JSEU_01057343 at 01057384-01057385

MIR_JSEU_01426785

MIR_JSEU_01445975 at 01446069-01446071

MIR_JSEU_01446177

MIR_JSEU_01449677

MIR_JSEU-R_01345533

MIR_KCOPLEY_JSEU_00000046

MIR_KJEU_00000923

MIR_PIEU_00826230 at 00826232

MIR_PIEU_00157045

MIR_PKEU_00699321

MIR_PSEU_00053057

Expert Reports

1. Expert Report and reliance materials of David B. Ross, M.D.
2. Expert Report and reliance materials of Frederick W. Fraunfelder, M.D.
3. Expert Report of Mahyar Etminan, M.D.

